In	O
vivo	O
function	O
of	O
an	O
interleukin	B-protein
2	I-protein
receptor	I-protein
beta	I-protein
chain	I-protein
(	B-protein
IL-2Rbeta	I-protein
)	I-protein
/IL-4Ralpha	I-protein
cytokine	I-protein
receptor	I-protein
chimera	I-protein
potentiates	O
allergic	O
airway	O
disease	O
.	O

Strength	O
of	O
T	B-protein
cell	I-protein
receptor	I-protein
(	O
TCR	B-protein
)	O
signaling	O
,	O
coreceptors	B-protein
,	O
costimulation	O
,	O
antigen-presenting	B-cell_type
cell	I-cell_type
type	I-cell_type
,	O
and	O
cytokines	O
all	O
play	O
crucial	O
roles	O
in	O
determining	O
the	O
efficiency	O
with	O
which	O
type	B-cell_type
2	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
(	O
Th2	B-cell_type
,	O
Tc2	B-cell_type
)	O
develop	O
from	O
uncommitted	B-protein
precursors	I-protein
.	O

To	O
investigate	O
in	O
vivo	O
regulatory	O
mechanisms	O
that	O
control	O
the	O
population	O
of	O
type	B-cell_type
2	I-cell_type
T	I-cell_type
cells	I-cell_type
and	O
disease	O
susceptibility	O
,	O
we	O
have	O
created	O
lines	O
of	O
transgenic	O
mice	O
in	O
which	O
expression	O
of	O
a	O
chimeric	B-protein
cytokine	I-protein
receptor	I-protein
(	O
the	O
mouse	B-protein
interleukin	I-protein
2	I-protein
receptor	I-protein
beta	I-protein
chain	I-protein
[	I-protein
IL-2Rbeta	I-protein
]	I-protein
extracellular	I-protein
domain	I-protein
fused	O
to	O
the	O
cytoplasmic	B-protein
tail	I-protein
of	O
IL-4Ralpha	B-protein
)	O
is	O
targeted	O
to	O
the	O
T	B-cell_type
lymphoid	I-cell_type
lineage	I-cell_type
using	O
the	O
proximal	B-DNA
lck	I-DNA
promoter	I-DNA
.	O

This	O
chimera	O
transduced	O
IL-4	B-protein
-specific	O
signals	O
in	O
response	O
to	O
IL-2	B-protein
binding	O
and	O
dramatically	O
enhanced	O
type	O
2	O
responses	O
(	O
IL-4	B-protein
,	O
IL-5	B-protein
,	O
and	O
immunoglobulin	B-protein
E	I-protein
production	O
)	O
upon	O
in	O
vitro	O
TCR	B-protein
stimulation	O
or	O
in	O
vivo	O
antigen	O
challenge	O
.	O

Thus	O
,	O
type	O
2	O
effector	O
function	O
was	O
augmented	O
by	O
IL-4	B-protein
signals	O
transduced	O
through	O
a	O
chimeric	B-protein
receptor	I-protein
expressed	O
in	O
a	O
T	O
cell-specific	O
manner	O
.	O

This	O
influence	O
was	O
sufficient	O
for	O
establishment	O
of	O
antigen-induced	O
allergic	O
airway	O
hyperresponsiveness	O
on	O
a	O
disease-resistant	O
background	O

In	NULL
Vivo	NULL
Function	NULL
of	NULL
an	NULL
Interleukin	NULL
2	NULL
Receptor	NULL
B	NULL
Chain	NULL
(	NULL
IL-2RB	NULL
)	NULL
/	NULL
IL-4Ra	NULL
Cytokine	NULL
Receptor	NULL
Chimera	NULL
Potentiates	NULL
Allergic	NULL
Airway	NULL
Disease	NULL
By	NULL
Jeehee	NULL
Youn	NULL
,	NULL
*	NULL
Jin	NULL
Chen	NULL
,	NULL
#	NULL
$	NULL
Shreevrat	NULL
Goenka	NULL
,	NULL
*	NULL
Mark	NULL
A.	NULL
Aronica	NULL
,	NULL
*	NULL
!	NULL

Ana	NULL
L.	NULL
Mora	NULL
,	NULL
*	NULL
Victor	NULL
Correa	NULL
,	NULL
*	NULL
James	NULL
R	NULL
.	NULL

Sheller	NULL
,	NULL
!	NULL

and	NULL
Mark	NULL
Boothby*	NULL
From	NULL
the	NULL
*Department	NULL
of	NULL
Micubiology	NULL
and	NULL
Immunology	NULL
,	NULL
the	NULL
*Department	NULL
of	NULL
Cell	NULL
Biology	NULL
,	NULL
and	NULL
the	NULL
SR	NULL
heurnatology	NULL
Division	NULL
and	NULL
Pulmonary	NULL
Division	NULL
,	NULL
Department	NULL
of	NULL
Medicine	NULL
Vanderbilt	NULL
University	NULL
Medial	NULL
School	NULL
,	NULL
N	NULL
ashville	NULL
Tennessee	NULL
37232	NULL
Sum	NULL
m	NULL
ary	NULL
Strength	NULL
of	NULL
T	NULL
cell	NULL
receptor	NULL
(	NULL
TCR	NULL
)	NULL
signaling	NULL
,	NULL
coreceptors	NULL
,	NULL
costimulation	NULL
,	NULL
antigen-presenting	NULL
cell	NULL
type	NULL
,	NULL
and	NULL
cytokines	NULL
all	NULL
play	NULL
crucial	NULL
roles	NULL
in	NULL
determining	NULL
the	NULL
efficiency	NULL
with	NULL
which	NULL
type	NULL
2	NULL
T	NULL
lymphocytes	NULL
(	NULL
Th2	NULL
,	NULL
Tc2	NULL
)	NULL
develop	NULL
from	NULL
uncommitted	NULL
precursors	NULL
.	NULL

To	NULL
investigate	NULL
in	NULL
vivo	NULL
regulatory	NULL
mechanisms	NULL
that	NULL
control	NULL
the	NULL
population	NULL
of	NULL
type	NULL
2	NULL
T	NULL
cells	NULL
and	NULL
disease	NULL
susceptibility	NULL
,	NULL
we	NULL
have	NULL
created	NULL
lines	NULL
of	NULL
transgenic	NULL
mice	NULL
in	NULL
which	NULL
expression	NULL
of	NULL
a	NULL
chimeric	NULL
cytokine	NULL
receptor	NULL
(	NULL
the	NULL
mouse	NULL
interleukin	NULL
2	NULL
receptor	NULL
B	NULL
chain	NULL
[	NULL
IL-2R	NULL
BJ	NULL
]	NULL
extracellular	NULL
domain	NULL
fused	NULL
to	NULL
the	NULL
cytoplasmic	NULL
tail	NULL
of	NULL
IL-4R	NULL
a	NULL
)	NULL
is	NULL
targeted	NULL
to	NULL
the	NULL
T	NULL
lymphoid	NULL
lineage	NULL
using	NULL
the	NULL
proximal	NULL
Ick	NULL
promoter	NULL
.	NULL

This	NULL
chimera	NULL
transduced	NULL
IL-4-specific	NULL
signals	NULL
in	NULL
response	NULL
to	NULL
IL-2	NULL
binding	NULL
and	NULL
dramatically	NULL
enhanced	NULL
type	NULL
2	NULL
responses	NULL
(	NULL
IL-4	NULL
,	NULL
IL-5	NULL
,	NULL
and	NULL
immunoglobulin	NULL
E	NULL
production	NULL
)	NULL
upon	NULL
in	NULL
vitro	NULL
TCR	NULL
stimulation	NULL
or	NULL
in	NULL
vivo	NULL
antigen	NULL
challenge	NULL
.	NULL

Thus	NULL
,	NULL
type	NULL
2	NULL
effector	NULL
function	NULL
was	NULL
augmented	NULL
by	NULL
IL-4	NULL
signals	NULL
transduced	NULL
through	NULL
a	NULL
chimeric	NULL
receptor	NULL
expressed	NULL
in	NULL
a	NULL
T	NULL
cell-specific	NULL
manner	NULL
.	NULL

This	NULL
influence	NULL
was	NULL
sufficient	NULL
for	NULL
establishment	NULL
of	NULL
antigen-induced	NULL
allergic	NULL
airway	NULL
hyperresponsiveness	NULL
on	NULL
a	NULL
disease-resistant	NULL
background	NULL
(	NULL
C57BL/	NULL
6	NULL
)	NULL
.	NULL

Key	NULL
words	NULL
:	NULL
Interleukin	NULL
(	NULL
IL	NULL
)	NULL
-4	NULL
is	NULL
a	NULL
pleiotropic	NULL
cytokine	NULL
that	NULL
plays	NULL
an	NULL
important	NULL
role	NULL
in	NULL
the	NULL
growth	NULL
,	NULL
differentiation	NULL
,	NULL
and	NULL
survival	NULL
of	NULL
lymphocytes	NULL
(	NULL
1-4	NULL
)	NULL
,	NULL
as	NULL
well	NULL
as	NULL
regulating	NULL
other	NULL
key	NULL
hematopoietic	NULL
cells	NULL
such	NULL
as	NULL
monocytes	NULL
,	NULL
macrophages	NULL
,	NULL
and	NULL
dendritic	NULL
cells	NULL
(	NULL
5	NULL
)	NULL
.	NULL

One	NULL
of	NULL
the	NULL
most	NULL
important	NULL
roles	NULL
of	NULL
IL-4	NULL
in	NULL
immune	NULL
regulation	NULL
is	NULL
its	NULL
ability	NULL
to	NULL
influence	NULL
the	NULL
phenotype	NULL
of	NULL
effector	NULL
T	NULL
cells	NULL
as	NULL
they	NULL
differentiate	NULL
from	NULL
naive	NULL
precursors	NULL
(	NULL
1	NULL
,	NULL
6-8	NULL
)	NULL
.	NULL

For	NULL
instance	NULL
,	NULL
helper	NULL
and	NULL
cytolytic	NULL
T	NULL
lymphocytes	NULL
can	NULL
be	NULL
divided	NULL
into	NULL
distinct	NULL
subsets	NULL
of	NULL
effector	NULL
cells	NULL
based	NULL
on	NULL
their	NULL
functional	NULL
capabilities	NULL
and	NULL
the	NULL
profile	NULL
of	NULL
cytokines	NULL
they	NULL
produce	NULL
(	NULL
9	NULL
,	NULL
10	NULL
)	NULL
.	NULL

The	NULL
Th1	NULL
subset	NULL
of	NULL
CD4¢*	NULL
T	NULL
cells	NULL
secretes	NULL
IFN-y	NULL
and	NULL
TNF-B	NULL
,	NULL
which	NULL
activate	NULL
cell-mediated	NULL
immune	NULL
responses	NULL
optimally	NULL
suited	NULL
for	NULL
immunity	NULL
to	NULL
intracellular	NULL
pathogens	NULL
(	NULL
11-13	NULL
)	NULL
;	NULL
the	NULL
Tcl	NULL
subset	NULL
of	NULL
CD8*	NULL
cells	NULL
secretes	NULL
similar	NULL
cytokines	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
the	NULL
Th2	NULL
subset	NULL
produces	NULL
IL-5	NULL
,	NULL
-6	NULL
,	NULL
-10	NULL
,	NULL
and	NULL
-13	NULL
,	NULL
in	NULL
addition	NULL
to	NULL
IL-4	NULL
,	NULL
and	NULL
is	NULL
associated	NULL
with	NULL
immune	NULL
responses	NULL
that	NULL
combat	NULL
extracellular	NULL
mi-crobes	NULL
,	NULL
in	NULL
part	NULL
through	NULL
help	NULL
to	NULL
antibody	NULL
responses	NULL
(	NULL
12	NULL
,	NULL
13	NULL
)	NULL
.	NULL

The	NULL
mechanisms	NULL
by	NULL
which	NULL
naive	NULL
T	NULL
precursor	NULL
cells	NULL
differentiate	NULL
into	NULL
discrete	NULL
effector	NULL
cells	NULL
remain	NULL
a	NULL
subject	NULL
of	NULL
intensive	NULL
investigation	NULL
.	NULL

Factors	NULL
that	NULL
control	NULL
differentiation	NULL
into	NULL
Th1	NULL
or	NULL
Th2	NULL
cells	NULL
include	NULL
strength	NULL
of	NULL
signaling	NULL
through	NULL
the	NULL
TCR	NULL
,	NULL
antigen	NULL
presentation	NULL
(	NULL
including	NULL
antigen	NULL
dose	NULL
,	NULL
route	NULL
of	NULL
antigen	NULL
administration	NULL
,	NULL
and	NULL
type	NULL
of	NULL
APCs	NULL
)	NULL
,	NULL
involvement	NULL
1803	NULL
interleukin	NULL
4	NULL
«	NULL
T	NULL
cell	NULL
help	NULL
«	NULL
signal	NULL
transduction	NULL
*	NULL
allergic	NULL
diseases	NULL
of	NULL
costimulatory	NULL
pathways	NULL
such	NULL
as	NULL
those	NULL
activated	NULL
by	NULL
CD28	NULL
ligation	NULL
,	NULL
and	NULL
engagement	NULL
of	NULL
CD4	NULL
coreceptor	NULL
molecule	NULL
(	NULL
14-17	NULL
,	NULL
reviewed	NULL
in	NULL
18	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
to	NULL
these	NULL
regulatory	NULL
in-fluences	NULL
,	NULL
the	NULL
cytokines	NULL
to	NULL
which	NULL
APCs	NULL
and	NULL
T	NULL
cells	NULL
are	NULL
exposed	NULL
during	NULL
differentiation	NULL
of	NULL
the	NULL
naive	NULL
T	NULL
cell	NULL
are	NULL
also	NULL
a	NULL
potent	NULL
influence	NULL
.	NULL

Thus	NULL
,	NULL
IL-	NULL
12	NULL
and	NULL
IFN-y	NULL
favor	NULL
Th1	NULL
differentiation	NULL
and	NULL
inhibit	NULL
the	NULL
emergence	NULL
of	NULL
Th2	NULL
cells	NULL
(	NULL
11-13	NULL
,	NULL
19	NULL
,	NULL
20	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
the	NULL
presence	NULL
of	NULL
IL-4	NULL
early	NULL
during	NULL
priming	NULL
stimulates	NULL
Th2	NULL
development	NULL
and	NULL
represses	NULL
the	NULL
production	NULL
of	NULL
Th1	NULL
cells	NULL
and	NULL
their	NULL
characteristic	NULL
cytokine	NULL
products	NULL
(	NULL
21	NULL
,	NULL
22	NULL
)	NULL
.	NULL

Data	NULL
from	NULL
in	NULL
vitro	NULL
systems	NULL
indicate	NULL
that	NULL
there	NULL
are	NULL
conditions	NULL
under	NULL
which	NULL
IL-4	NULL
can	NULL
promote	NULL
the	NULL
differentiation	NULL
of	NULL
purified	NULL
small	NULL
,	NULL
resting	NULL
T	NULL
cells	NULL
into	NULL
Th2	NULL
cells	NULL
(	NULL
6	NULL
)	NULL
.	NULL

Importantly	NULL
,	NULL
however	NULL
,	NULL
the	NULL
ability	NULL
of	NULL
these	NULL
cytokines	NULL
to	NULL
influence	NULL
the	NULL
development	NULL
of	NULL
CD4*	NULL
T	NULL
cells	NULL
in	NULL
vivo	NULL
has	NULL
been	NULL
studied	NULL
almost	NULL
exclusively	NULL
in	NULL
systems	NULL
in	NULL
which	NULL
both	NULL
APCs	NULL
and	NULL
naive	NULL
precursor	NULL
T	NULL
cells	NULL
are	NULL
affected	NULL
(	NULL
23	NULL
,	NULL
24	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
the	NULL
relative	NULL
contributions	NULL
of	NULL
T	NULL
cell-autonomous	NULL
signaling	NULL
by	NULL
IL-4	NULL
and	NULL
its	NULL
effects	NULL
on	NULL
APCs	NULL
during	NULL
immune	NULL
responses	NULL
in	NULL
vivo	NULL
remain	NULL
to	NULL
be	NULL
established	NULL
.	NULL

In	NULL
this	NULL
regard	NULL
,	NULL
previous	NULL
work	NULL
has	NULL
established	NULL
that	NULL
,	NULL
although	NULL
IFN-y	NULL
may	NULL
have	NULL
some	NULL
direct	NULL
effects	NULL
on	NULL
T	NULL
cell	NULL
development	NULL
(	NULL
25	NULL
)	NULL
,	NULL
inhibition	NULL
of	NULL
IFN-y	NULL
receptor	NULL
signaling	NULL
in	NULL
the	NULL
T	NULL
lineage	NULL
had	NULL
little	NULL
effect	NULL
on	NULL
Th1	NULL
development	NULL
(	NULL
26	NULL
)	NULL
.	NULL

In	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

©	NULL
The	NULL
R	NULL
ockefeller	NULL
University	NULL
Press	NULL
»	NULL
0022-1007/98/	NULL
1	NULL
1/	NULL
1803/	NULL
14	NULL
$	NULL
2.00	NULL
Volume	NULL
188	NULL
,	NULL
Number	NULL
10	NULL
,	NULL
November	NULL
16	NULL
,	NULL
1998	NULL
1803-1816	NULL
http	NULL
:	NULL
//	NULL
www.jem.org	NULL
contrast	NULL
,	NULL
targeting	NULL
such	NULL
inhibition	NULL
to	NULL
macrophages	NULL
dramatically	NULL
decreased	NULL
Th1	NULL
development	NULL
(	NULL
26	NULL
)	NULL
.	NULL

Absence	NULL
of	NULL
interferon	NULL
regulatory	NULL
factor	NULL
1	NULL
(	NULL
IRF-1	NULL
)	NULL
'	NULL
from	NULL
APCs	NULL
led	NULL
to	NULL
a	NULL
similar	NULL
diminution	NULL
in	NULL
Th1	NULL
development	NULL
and	NULL
a	NULL
deficit	NULL
of	NULL
Thl1	NULL
function	NULL
in	NULL
vivo	NULL
(	NULL
27	NULL
,	NULL
28	NULL
)	NULL
.	NULL

However	NULL
,	NULL
it	NULL
is	NULL
unclear	NULL
to	NULL
what	NULL
extent	NULL
IL-4	NULL
acts	NULL
on	NULL
APCs	NULL
in	NULL
promoting	NULL
Th2	NULL
development	NULL
in	NULL
vivo	NULL
.	NULL

In	NULL
light	NULL
of	NULL
the	NULL
potent	NULL
ability	NULL
of	NULL
IL-4	NULL
directly	NULL
to	NULL
induce	NULL
the	NULL
CD28	NULL
ligands	NULL
B7-1	NULL
and	NULL
-2	NULL
(	NULL
29	NULL
)	NULL
and	NULL
to	NULL
increase	NULL
the	NULL
rate	NULL
of	NULL
synthesis	NULL
of	NULL
class	NULL
II	NULL
MHC	NULL
proteins	NULL
(	NULL
30	NULL
,	NULL
31	NULL
)	NULL
,	NULL
a	NULL
critical	NULL
role	NULL
of	NULL
IL-4	NULL
in	NULL
Th2	NULL
development	NULL
could	NULL
be	NULL
mediated	NULL
through	NULL
changes	NULL
in	NULL
the	NULL
strength	NULL
of	NULL
TCR	NULL
and	NULL
CD28	NULL
signaling	NULL
(	NULL
14	NULL
,	NULL
16	NULL
,	NULL
18	NULL
)	NULL
.	NULL

Moreover	NULL
,	NULL
under	NULL
some	NULL
circumstances	NULL
IL-4-deficient	NULL
T	NULL
cells	NULL
develop	NULL
cytokine	NULL
production	NULL
characteristics	NULL
consistent	NULL
with	NULL
the	NULL
Th2	NULL
phenotype	NULL
(	NULL
32	NULL
,	NULL
33	NULL
)	NULL
.	NULL

Taken	NULL
together	NULL
,	NULL
these	NULL
findings	NULL
raise	NULL
the	NULL
question	NULL
whether	NULL
the	NULL
role	NULL
of	NULL
IL-4	NULL
in	NULL
promoting	NULL
Th2	NULL
development	NULL
under	NULL
in	NULL
vivo	NULL
conditions	NULL
would	NULL
be	NULL
promoted	NULL
if	NULL
IL-4	NULL
signaling	NULL
were	NULL
initially	NULL
restricted	NULL
to	NULL
activated	NULL
naive	NULL
T	NULL
cells	NULL
and	NULL
did	NULL
not	NULL
affect	NULL
APCs	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
an	NULL
apparent	NULL
gain-of-function	NULL
mutation	NULL
in	NULL
the	NULL
human	NULL
IL-4R	NULL
«	NULL
chain	NULL
is	NULL
associated	NULL
with	NULL
atopic	NULL
diseases	NULL
(	NULL
34	NULL
)	NULL
,	NULL
thus	NULL
raising	NULL
the	NULL
question	NULL
whether	NULL
altered	NULL
patterns	NULL
of	NULL
IL-4R	NULL
signaling	NULL
in	NULL
T	NULL
cells	NULL
could	NULL
potentiate	NULL
allergic	NULL
disease	NULL
on	NULL
an	NULL
otherwise	NULL
resistant	NULL
genetic	NULL
background	NULL
.	NULL

To	NULL
investigate	NULL
such	NULL
questions	NULL
concerning	NULL
in	NULL
vivo	NULL
regulation	NULL
of	NULL
the	NULL
balance	NULL
of	NULL
types	NULL
1	NULL
and	NULL
2	NULL
T	NULL
cells	NULL
,	NULL
we	NULL
have	NULL
created	NULL
lines	NULL
of	NULL
mice	NULL
in	NULL
which	NULL
the	NULL
T	NULL
lineage	NULL
expresses	NULL
a	NULL
chimeric	NULL
cytokine	NULL
receptor	NULL
.	NULL

Specific	NULL
portions	NULL
of	NULL
the	NULL
human	NULL
IL-4R	NULL
«	NULL
cytoplasmic	NULL
tail	NULL
are	NULL
competent	NULL
to	NULL
transduce	NULL
signals	NULL
characteristic	NULL
of	NULL
IL-4	NULL
when	NULL
fused	NULL
to	NULL
human	NULL
IL-2R	NULL
B	NULL
and	NULL
a	NULL
portion	NULL
of	NULL
its	NULL
intracellular	NULL
domain	NULL
(	NULL
35	NULL
)	NULL
.	NULL

To	NULL
permit	NULL
binding	NULL
of	NULL
mouse	NULL
IL-2	NULL
and	NULL
avoid	NULL
potential	NULL
confounding	NULL
influences	NULL
from	NULL
cytoplasmic	NULL
portions	NULL
of	NULL
IL-2R	NULL
B	NULL
,	NULL
we	NULL
have	NULL
generated	NULL
a	NULL
translational	NULL
fusion	NULL
between	NULL
the	NULL
extracellular	NULL
and	NULL
transmembrane	NULL
domain	NULL
of	NULL
the	NULL
mouse	NULL
IL-2R	NULL
B	NULL
chain	NULL
and	NULL
the	NULL
complete	NULL
intracellular	NULL
domain	NULL
of	NULL
mouse	NULL
IL-4R	NULL
«	NULL
.	NULL

This	NULL
chimeric	NULL
receptor	NULL
transduced	NULL
signals	NULL
characteristic	NULL
of	NULL
IL-4	NULL
(	NULL
signal	NULL
transducer	NULL
and	NULL
activator	NULL
of	NULL
transcription	NULL
[	NULL
Stat	NULL
]	NULL
6	NULL
activation	NULL
)	NULL
in	NULL
response	NULL
to	NULL
IL-2	NULL
binding	NULL
.	NULL

Such	NULL
signaling	NULL
was	NULL
enhanced	NULL
by	NULL
activation	NULL
of	NULL
thymocytes	NULL
or	NULL
T	NULL
cells	NULL
,	NULL
presumably	NULL
due	NULL
to	NULL
the	NULL
known	NULL
role	NULL
of	NULL
IL-2R	NULL
«	NULL
/	NULL
CD25	NULL
in	NULL
mouse	NULL
IL-2	NULL
binding	NULL
and	NULL
function	NULL
(	NULL
36-38	NULL
)	NULL
.	NULL

Cells	NULL
from	NULL
these	NULL
transgenic	NULL
(	NULL
Tg	NULL
)	NULL
mice	NULL
exhibited	NULL
enhanced	NULL
Th2	NULL
responses	NULL
(	NULL
IL-4	NULL
and	NULL
IL-5	NULL
production	NULL
as	NULL
well	NULL
as	NULL
help	NULL
for	NULL
IgE	NULL
production	NULL
)	NULL
.	NULL

This	NULL
influence	NULL
on	NULL
the	NULL
development	NULL
of	NULL
effector	NULL
T	NULL
cells	NULL
was	NULL
sufficient	NULL
to	NULL
overcome	NULL
the	NULL
resistance	NULL
of	NULL
C57BL/	NULL
6	NULL
mice	NULL
to	NULL
O	NULL
VA-induced	NULL
allergic	NULL
airway	NULL
disease	NULL
.	NULL

Thus	NULL
,	NULL
it	NULL
is	NULL
likely	NULL
that	NULL
in	NULL
mice	NULL
expressing	NULL
the	NULL
chimeric	NULL
receptor	NULL
transgene	NULL
,	NULL
the	NULL
presence	NULL
of	NULL
IL-2	NULL
upon	NULL
antigen	NULL
challenge	NULL
favors	NULL
differentiation	NULL
of	NULL
naive	NULL
T	NULL
cells	NULL
into	NULL
Th2	NULL
effector	NULL
cells	NULL
by	NULL
activation	NULL
,	NULL
and	NULL
that	NULL
this	NULL
initially	NULL
cell-autonomous	NULL
pathway	NULL
can	NULL
augment	NULL
Th2	NULL
effector	NULL
function	NULL
mediated	NULL
by	NULL
IL-4	NULL
signals	NULL
in	NULL
T	NULL
cells	NULL
.	NULL

Materials	NULL
and	NULL
Methods	NULL
Reagents	NULL
.	NULL

-	NULL
Cells	NULL
were	NULL
cultured	NULL
in	NULL
RPMI	NULL
1640	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
fetal	NULL
bovine	NULL
serum	NULL
,	NULL
sodium	NULL
bicarbonate	NULL
,	NULL
2	NULL
mM	NULL
1-glu-	NULL
'	NULL
A	NULL
bbreviations	NULL
used	NULL
in	NULL
this	NULL
paper	NULL
:	NULL
TRF	NULL
,	NULL
interferon	NULL
regulatory	NULL
factor	NULL
;	NULL
NT	NULL
g	NULL
,	NULL
non-transgenic	NULL
;	NULL
Stat	NULL
,	NULL
signal	NULL
transducer	NULL
and	NULL
activator	NULL
of	NULL
transcription	NULL
;	NULL
T	NULL
g	NULL
,	NULL
transgenic	NULL
.	NULL

1804	NULL
tamine	NULL
,	NULL
nonessential	NULL
amino	NULL
acids	NULL
,	NULL
penicillin/	NULL
streptomycin	NULL
(	NULL
all	NULL
from	NULL
GIBCO	NULL
BRL	NULL
,	NULL
Gaithersburg	NULL
,	NULL
MD	NULL
)	NULL
,	NULL
and	NULL
5	NULL
X	NULL
10~	NULL
M	NULL
2-mer-captoethanol	NULL
(	NULL
Sigma	NULL
Chemical	NULL
Co.	NULL
,	NULL
St.	NULL
Louis	NULL
,	NULL
MO	NULL
)	NULL
,	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
39	NULL
)	NULL
.	NULL

Unmodified	NULL
and	NULL
fluorochrome-	NULL
or	NULL
biotin-conjugated	NULL
antibodies	NULL
against	NULL
IL-2R	NULL
B/CD122	NULL
(	NULL
unconjugated	NULL
or	NULL
FITC-labeled	NULL
)	NULL
,	NULL
CD4	NULL
(	NULL
FITC	NULL
,	NULL
r-PE	NULL
,	NULL
and	NULL
biotin	NULL
)	NULL
,	NULL
B220	NULL
(	NULL
r-PE	NULL
)	NULL
,	NULL
CD3	NULL
(	NULL
unconjugated	NULL
and	NULL
r-PE	NULL
)	NULL
,	NULL
I-A	NULL
``	NULL
(	NULL
FITC	NULL
,	NULL
r-PE	NULL
,	NULL
and	NULL
biotin	NULL
)	NULL
,	NULL
CD11b	NULL
(	NULL
FITC	NULL
and	NULL
biotin	NULL
)	NULL
,	NULL
CD11¢c	NULL
(	NULL
r-PE	NULL
)	NULL
,	NULL
IL-4	NULL
(	NULL
r-PE	NULL
)	NULL
,	NULL
IFN-y	NULL
(	NULL
FITC	NULL
)	NULL
,	NULL
goat	NULL
anti-rat	NULL
Ig	NULL
(	NULL
biotin	NULL
)	NULL
,	NULL
and	NULL
CD28	NULL
(	NULL
unconjugated	NULL
)	NULL
were	NULL
obtained	NULL
from	NULL
PharMingen	NULL
(	NULL
San	NULL
Diego	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

Biotin-conjugated	NULL
anti-mouse	NULL
CD	NULL
122	NULL
was	NULL
generated	NULL
from	NULL
azide-	NULL
free	NULL
preparations	NULL
of	NULL
anti-CD122	NULL
(	NULL
PharMingen	NULL
)	NULL
using	NULL
biotin-amidocaproate	NULL
N-hydroxy-succinimide	NULL
ester	NULL
(	NULL
Sigma	NULL
Chemical	NULL
Co.	NULL
)	NULL
.	NULL

Streptavidin-PE	NULL
and	NULL
streptavidin-PerCP	NULL
were	NULL
obtained	NULL
from	NULL
BioSource	NULL
International	NULL
(	NULL
Camarillo	NULL
,	NULL
CA	NULL
)	NULL
and	NULL
Becton	NULL
Dickinson	NULL
&	NULL
Co.	NULL
(	NULL
Mountain	NULL
View	NULL
,	NULL
CA	NULL
)	NULL
,	NULL
respectively	NULL
.	NULL

Antibodies	NULL
against	NULL
Stat5	NULL
and	NULL
Stat6	NULL
for	NULL
electro-phoretic	NULL
mobility	NULL
supershift	NULL
assays	NULL
were	NULL
obtained	NULL
from	NULL
Santa	NULL
Cruz	NULL
Biotechnology	NULL
(	NULL
Santa	NULL
Cruz	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

Purified	NULL
or	NULL
biotinylated	NULL
monoclonal	NULL
antibodies	NULL
for	NULL
cytokine	NULL
ELISA	NULL
(	NULL
IL-4	NULL
,	NULL
IL-5	NULL
,	NULL
and	NULL
IFN-y	NULL
)	NULL
were	NULL
obtained	NULL
from	NULL
PharMingen	NULL
.	NULL

Plasmid	NULL
Constudtion	NULL
and	NULL
Generation	NULL
of	NULL
T	NULL
g	NULL
Mic	NULL
.	NULL

_	NULL
The	NULL
chimeric	NULL
IL-2R/4R	NULL
cDNA	NULL
was	NULL
constructed	NULL
by	NULL
reverse	NULL
transcriptase-PCR	NULL
.	NULL

In	NULL
brief	NULL
,	NULL
sequences	NULL
encoding	NULL
the	NULL
extracellular	NULL
and	NULL
transmembrane	NULL
regions	NULL
of	NULL
murine	NULL
IL-2R	NULL
cDNA	NULL
were	NULL
amplified	NULL
using	NULL
PFU	NULL
poly-merase	NULL
.	NULL

The	NULL
sense	NULL
oligonucleotide	NULL
primer	NULL
corresponded	NULL
to	NULL
the	NULL
-flanking	NULL
sequence	NULL
and	NULL
signal	NULL
peptide	NULL
(	NULL
86-113	NULL
bp	NULL
based	NULL
on	NULL
reference	NULL
40	NULL
:	NULL
5-CCTGAATTCCTCTCAGCTGTGATGGCTA-3	NULL
'	NULL
)	NULL
with	NULL
additional	NULL
nucleotides	NULL
encoding	NULL
an	NULL
EcoRI	NULL
site	NULL
.	NULL

The	NULL
antisense	NULL
oligonucleotide	NULL
primer	NULL
corresponded	NULL
to	NULL
908-927	NULL
bp	NULL
,	NULL
including	NULL
a	NULL
naturally	NULL
occurring	NULL
KpnI	NULL
site	NULL
at	NULL
the	NULL
downstream	NULL
end	NULL
(	NULL
5-CCAAGGTACCGGCACTTGAC-3	NULL
'	NULL
)	NULL
.	NULL

The	NULL
complete	NULL
intracytoplasmic	NULL
domain	NULL
of	NULL
IL-4R	NULL
cDNA	NULL
was	NULL
amplified	NULL
from	NULL
cDNAs	NULL
using	NULL
primers	NULL
based	NULL
on	NULL
a	NULL
published	NULL
mouse	NULL
IL-4Ra	NULL
cDNA	NULL
sequence	NULL
(	NULL
41	NULL
)	NULL
,	NULL
except	NULL
that	NULL
a	NULL
KpnI	NULL
site	NULL
was	NULL
introduced	NULL
at	NULL
the	NULL
upstream	NULL
end	NULL
to	NULL
permit	NULL
ligation	NULL
to	NULL
EcoRI	NULL
,	NULL
Kpnl-digested	NULL
IL-2R	NULL
B	NULL
amplicon	NULL
.	NULL

After	NULL
amplification	NULL
,	NULL
proteinase	NULL
K	NULL
digestion	NULL
,	NULL
and	NULL
cleavage	NULL
with	NULL
appropriate	NULL
restriction	NULL
endonucleases	NULL
,	NULL
these	NULL
two	NULL
PCR	NULL
products	NULL
were	NULL
cloned	NULL
by	NULL
three-way	NULL
ligation	NULL
into	NULL
the	NULL
mammalian	NULL
expression	NULL
vector	NULL
pcDNA3	NULL
.	NULL

After	NULL
verification	NULL
of	NULL
expression	NULL
and	NULL
function	NULL
in	NULL
the	NULL
M12	NULL
B	NULL
lymphoma	NULL
cell	NULL
line	NULL
,	NULL
the	NULL
cDNA	NULL
was	NULL
shuttled	NULL
into	NULL
a	NULL
BamHI-digested	NULL
,	NULL
5'-end-filled	NULL
transgene	NULL
vector	NULL
.	NULL

The	NULL
transgene	NULL
generated	NULL
by	NULL
subcloning	NULL
the	NULL
chimeric	NULL
receptor	NULL
cDNA	NULL
into	NULL
the	NULL
T	NULL
lineage-specific	NULL
vector	NULL
p1017	NULL
(	NULL
Ick	NULL
proximal	NULL
promoter	NULL
followed	NULL
by	NULL
exons	NULL
,	NULL
introns	NULL
,	NULL
and	NULL
polyadenylation	NULL
signal	NULL
derived	NULL
from	NULL
the	NULL
human	NULL
growth	NULL
hormone	NULL
gene	NULL
)	NULL
(	NULL
42	NULL
)	NULL
was	NULL
released	NULL
as	NULL
a	NULL
NotI	NULL
fragment	NULL
encompassing	NULL
the	NULL
tissue-specific	NULL
transcription	NULL
unit	NULL
,	NULL
purified	NULL
by	NULL
standard	NULL
protocols	NULL
,	NULL
and	NULL
microinjected	NULL
into	NULL
the	NULL
pronu-clei	NULL
of	NULL
C57BL/6	NULL
X	NULL
DBA/	NULL
2	NULL
zygotes	NULL
.	NULL

Mice	NULL
were	NULL
maintained	NULL
in	NULL
accordance	NULL
with	NULL
federal	NULL
and	NULL
state	NULL
government	NULL
regulations	NULL
after	NULL
institutional	NULL
approval	NULL
.	NULL

Founder	NULL
lines	NULL
were	NULL
propagated	NULL
by	NULL
sequential	NULL
backcrossing	NULL
to	NULL
C57BL/6	NULL
and	NULL
,	NULL
in	NULL
later	NULL
experiments	NULL
,	NULL
C57BL/	NULL
10.D2	NULL
mice	NULL
for	NULL
these	NULL
studies	NULL
.	NULL

Northem	NULL
Blot	NULL
Analyses	NULL
.	NULL

RNA	NULL
was	NULL
prepared	NULL
from	NULL
splenocyte	NULL
suspensions	NULL
stimulated	NULL
under	NULL
the	NULL
indicated	NULL
conditions	NULL
according	NULL
to	NULL
the	NULL
manufacturer	NULL
's	NULL
protocol	NULL
after	NULL
harvest	NULL
and	NULL
lysis	NULL
in	NULL
TriZ	NULL
ol	NULL
acid-phenol	NULL
reagent	NULL
(	NULL
GIBCO	NULL
BRL	NULL
)	NULL
.	NULL

These	NULL
total	NULL
cellular	NULL
RNAs	NULL
prepared	NULL
by	NULL
chloroform	NULL
extraction	NULL
and	NULL
isopropanol	NULL
precipitation	NULL
were	NULL
resolved	NULL
on	NULL
1.1	NULL
%	NULL
agarose	NULL
gels	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
formalde-hyde	NULL
,	NULL
transferred	NULL
to	NULL
HyBond-N	NULL
membranes	NULL
(	NULL
Amersham	NULL
Pharma-cia	NULL
Biotech	NULL
,	NULL
Inc.	NULL
,	NULL
Piscataway	NULL
,	NULL
NJ	NULL
)	NULL
and	NULL
subjected	NULL
to	NULL
hybridization	NULL
using	NULL
gel-purified	NULL
cDNA	NULL
probes	NULL
labeled	NULL
by	NULL
a	NULL
random-primer	NULL
technique	NULL
.	NULL

A	NULL
2.4-kb	NULL
EcoRI	NULL
,	NULL
BamHI	NULL
fragment	NULL
spanning	NULL
the	NULL
full	NULL
chimeric	NULL
cDNA	NULL
was	NULL
used	NULL
to	NULL
detect	NULL
the	NULL
chimeric	NULL
cytokine	NULL
recep-	NULL
In	NULL
Vivo	NULL
Function	NULL
of	NULL
an	NULL
IL-2R/IL-4R	NULL
Chimera	NULL
tor	NULL
(	NULL
as	NULL
well	NULL
as	NULL
endogenous	NULL
IL-4R	NULL
«	NULL
and	NULL
IL-2R	NULL
B	NULL
bands	NULL
)	NULL
,	NULL
whereas	NULL
a	NULL
255-bp	NULL
cDNA	NULL
fragment	NULL
generated	NULL
by	NULL
reverse	NULL
transcriptase	NULL
PCR	NULL
was	NULL
used	NULL
to	NULL
detect	NULL
GATA-3	NULL
.	NULL

The	NULL
GATA-3	NULL
cDNA	NULL
probe	NULL
was	NULL
purified	NULL
after	NULL
amplification	NULL
(	NULL
60	NULL
s	NULL
each	NULL
at	NULL
94	NULL
,	NULL
58	NULL
,	NULL
and	NULL
72°C	NULL
for	NULL
35	NULL
cycles	NULL
)	NULL
using	NULL
cDNAs	NULL
prepared	NULL
from	NULL
IL-4-stimulated	NULL
splenocytes	NULL
and	NULL
the	NULL
oligonucleotides	NULL
5-GAAGGCATCCAGACCCGAAAC	NULL
and	NULL
5-ACCCATGGCGGTGACCATGC	NULL
as	NULL
primers	NULL
.	NULL

Flow	NULL
Cytometry	NULL
and	NULL
Detection	NULL
of	NULL
Intracellular	NULL
Cytokines	NULL
.	NULL

To	NULL
ana	NULL
lyze	NULL
development	NULL
and	NULL
subsets	NULL
of	NULL
T	NULL
lymphoid	NULL
cells	NULL
,	NULL
suspensions	NULL
of	NULL
lymphoid	NULL
cells	NULL
were	NULL
counted	NULL
,	NULL
prepared	NULL
,	NULL
stained	NULL
with	NULL
fluorochrome-conjugated	NULL
mAbs	NULL
,	NULL
and	NULL
analyzed	NULL
as	NULL
described	NULL
(	NULL
39	NULL
)	NULL
.	NULL

Due	NULL
to	NULL
the	NULL
weak	NULL
staining	NULL
of	NULL
mouse	NULL
IL-2R	NULL
B	NULL
(	NULL
CD122	NULL
)	NULL
,	NULL
the	NULL
indicated	NULL
samples	NULL
were	NULL
analyzed	NULL
using	NULL
fluorochrome-conjugated	NULL
T	NULL
lineage	NULL
markers	NULL
and	NULL
indirect	NULL
immunofluorescent	NULL
staining	NULL
of	NULL
IL-2R	NULL
B	NULL
us	NULL
ing	NULL
unlabeled	NULL
anti-CD122	NULL
followed	NULL
by	NULL
biotinylated	NULL
goat	NULL
anti-rat	NULL
Ig	NULL
,	NULL
and	NULL
then	NULL
streptavidin-r-PE	NULL
.	NULL

To	NULL
enhance	NULL
CD122	NULL
staining	NULL
in	NULL
experiments	NULL
involving	NULL
APCs	NULL
,	NULL
indirect	NULL
immunofluorescence	NULL
was	NULL
performed	NULL
using	NULL
biotinylated	NULL
anti-CD122	NULL
followed	NULL
by	NULL
streptavidin-r-PE	NULL
or	NULL
PerCP	NULL
,	NULL
and	NULL
larger	NULL
cells	NULL
were	NULL
included	NULL
in	NULL
the	NULL
initial	NULL
forward	NULL
and	NULL
side	NULL
scatter	NULL
gate	NULL
.	NULL

For	NULL
detection	NULL
of	NULL
cytokine	NULL
production	NULL
by	NULL
staining	NULL
intracellular	NULL
pools	NULL
,	NULL
lymph	NULL
node	NULL
cells	NULL
were	NULL
stimulated	NULL
with	NULL
immobilized	NULL
anti-CD3	NULL
(	NULL
10	NULL
pg/ml	NULL
)	NULL
,	NULL
anti-CD28	NULL
(	NULL
2	NULL
g/	NULL
ml	NULL
)	NULL
,	NULL
and	NULL
recombinant	NULL
mouse	NULL
IL-2	NULL
(	NULL
20	NULL
ng/	NULL
ml	NULL
)	NULL
for	NULL
40	NULL
h.	NULL
Monensin	NULL
was	NULL
added	NULL
to	NULL
the	NULL
cell	NULL
culture	NULL
in	NULL
the	NULL
last	NULL
4	NULL
h.	NULL
Cells	NULL
were	NULL
then	NULL
stained	NULL
with	NULL
anti-CD4-biotin	NULL
(	NULL
PharMingen	NULL
)	NULL
and	NULL
streptavidin-PerCP	NULL
(	NULL
Becton	NULL
Dickinson	NULL
&	NULL
Co.	NULL
)	NULL
,	NULL
permeabilized	NULL
according	NULL
to	NULL
the	NULL
manufacturer	NULL
's	NULL
instructions	NULL
,	NULL
stained	NULL
with	NULL
both	NULL
anti-IL-4-PE	NULL
and	NULL
anti-IFN-y-FITC	NULL
(	NULL
PharMingen	NULL
)	NULL
,	NULL
and	NULL
analyzed	NULL
by	NULL
flow	NULL
cytometry	NULL
.	NULL

Gel	NULL
Mobility	NULL
Shift	NULL
Analyses	NULL
.	NULL

-	NULL
Whole	NULL
cell	NULL
extracts	NULL
were	NULL
prepared	NULL
from	NULL
splenocyte	NULL
suspensions	NULL
(	NULL
43	NULL
,	NULL
44	NULL
)	NULL
stimulated	NULL
under	NULL
the	NULL
indicated	NULL
conditions	NULL
using	NULL
concanavalin	NULL
A	NULL
(	NULL
Sigma	NULL
Chemical	NULL
Co.	NULL
)	NULL
,	NULL
purified	NULL
recombinant	NULL
mouse	NULL
IL-4	NULL
(	NULL
R	NULL
&	NULL
D	NULL
Systems	NULL
,	NULL
Inc.	NULL
,	NULL
Minne-apolis	NULL
,	NULL
MN	NULL
)	NULL
,	NULL
mouse	NULL
IL-2	NULL
(	NULL
R	NULL
&	NULL
D	NULL
Systems	NULL
and	NULL
PharMingen	NULL
)	NULL
,	NULL
and	NULL
human	NULL
IL-2	NULL
(	NULL
Cetus	NULL
Corp.	NULL
,	NULL
Emeryville	NULL
,	NULL
CA	NULL
,	NULL
courtesy	NULL
of	NULL
the	NULL
Biological	NULL
Response	NULL
Modifiers	NULL
Program	NULL
)	NULL
.	NULL

In	NULL
brief	NULL
,	NULL
cells	NULL
were	NULL
lysed	NULL
at	NULL
4°C	NULL
using	NULL
0.5	NULL
%	NULL
NP-40	NULL
supplemented	NULL
with	NULL
0.15	NULL
M	NULL
NaC1	NULL
,	NULL
50	NULL
mM	NULL
NaF	NULL
,	NULL
1	NULL
mM	NULL
dithiothreitol	NULL
,	NULL
0.1	NULL
mM	NULL
Na-vanadate	NULL
,	NULL
0.4	NULL
mM	NULL
phe-nylmethylsulfonyl	NULL
fluoride	NULL
,	NULL
5	NULL
jug/	NULL
ml	NULL
aprotinin	NULL
,	NULL
and	NULL
1	NULL
pg/ml	NULL
leu-peptin	NULL
,	NULL
followed	NULL
by	NULL
pelleting	NULL
insoluble	NULL
materials	NULL
DNA	NULL
binding	NULL
reactions	NULL
were	NULL
performed	NULL
using	NULL
5	NULL
ug	NULL
of	NULL
protein	NULL
in	NULL
20	NULL
pl	NULL
reactions	NULL
containing	NULL
1	NULL
pg	NULL
poly	NULL
dI-dC	NULL
competitor	NULL
and	NULL
the	NULL
indicated	NULL
P-labeled	NULL
oligonucleotide	NULL
,	NULL
essentially	NULL
as	NULL
described	NULL
(	NULL
43	NULL
,	NULL
44	NULL
)	NULL
.	NULL

Double-stranded	NULL
oligonucleotides	NULL
used	NULL
contained	NULL
the	NULL
``	NULL
N4	NULL
``	NULL
Stat6	NULL
binding	NULL
site	NULL
from	NULL
residues	NULL
-122	NULL
to	NULL
-104	NULL
of	NULL
the	NULL
germline	NULL
epsilon	NULL
promoter	NULL
in	NULL
the	NULL
immunoglobulin	NULL
heavy	NULL
chain	NULL
locus	NULL
,	NULL
5-AACTTC-CCAAGAACAGA	NULL
and	NULL
its	NULL
complement	NULL
(	NULL
44	NULL
)	NULL
,	NULL
or	NULL
the	NULL
``	NULL
N3	NULL
``	NULL
gamma-activated	NULL
sequence	NULL
from	NULL
the	NULL
IRF-1	NULL
promoter	NULL
,	NULL
5-CCT-GATTTCCCCGAAATGAT	NULL
and	NULL
its	NULL
complement	NULL
(	NULL
45	NULL
)	NULL
.	NULL

Identification	NULL
of	NULL
components	NULL
in	NULL
a	NULL
DN	NULL
A-protein	NULL
complex	NULL
was	NULL
performed	NULL
by	NULL
supershift	NULL
analyses	NULL
using	NULL
1	NULL
g	NULL
per	NULL
binding	NULL
reaction	NULL
of	NULL
antibodies	NULL
against	NULL
either	NULL
Stat5	NULL
or	NULL
Stat6	NULL
(	NULL
Santa	NULL
Cruz	NULL
Biotechnology	NULL
)	NULL
.	NULL

DNA-protein	NULL
complexes	NULL
were	NULL
resolved	NULL
on	NULL
a	NULL
4.5	NULL
%	NULL
nondenaturing	NULL
polyacrylamide	NULL
gel	NULL
in	NULL
Tris-	NULL
borate-EDT	NULL
A	NULL
buffer	NULL
as	NULL
described	NULL
(	NULL
44	NULL
)	NULL
.	NULL

Cytokine	NULL
Assays	NULL
by	NULL
ELISA	NULL
.	NULL

Lymph	NULL
node	NULL
cells	NULL
were	NULL
stimulated	NULL
with	NULL
immobilized	NULL
anti-CD3	NULL
(	NULL
10	NULL
g/ml	NULL
)	NULL
and	NULL
either	NULL
soluble	NULL
anti-CD28	NULL
(	NULL
5	NULL
ug/ml	NULL
)	NULL
or	NULL
recombinant	NULL
mouse	NULL
IL-2	NULL
(	NULL
20	NULL
ng/	NULL
ml	NULL
)	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
neutralizing	NULL
polyclonal	NULL
antibody	NULL
to	NULL
mouse	NULL
IL-4	NULL
(	NULL
10	NULL
pg/ml	NULL
;	NULL
R	NULL
&	NULL
D	NULL
Systems	NULL
)	NULL
as	NULL
indicated	NULL
.	NULL

Similar	NULL
results	NULL
were	NULL
obtained	NULL
using	NULL
a	NULL
mAb	NULL
against	NULL
IL-4	NULL
(	NULL
11B11	NULL
;	NULL
PharMin-gen	NULL
)	NULL
.	NULL

After	NULL
culture	NULL
for	NULL
6	NULL
d	NULL
,	NULL
cells	NULL
were	NULL
washed	NULL
and	NULL
restimulated	NULL
with	NULL
immobilized	NULL
anti-CD3	NULL
plus	NULL
anti-CD28	NULL
for	NULL
24	NULL
h	NULL
before	NULL
collection	NULL
of	NULL
culture	NULL
supernatants	NULL
for	NULL
determination	NULL
of	NULL
cytokine	NULL
pro	NULL
1805	NULL
Youn	NULL
et	NULL
al	NULL
.	NULL

duction	NULL
.	NULL

To	NULL
measure	NULL
primary	NULL
responses	NULL
of	NULL
T	NULL
cells	NULL
,	NULL
suspensions	NULL
of	NULL
lymph	NULL
node	NULL
cells	NULL
were	NULL
cultured	NULL
with	NULL
immobilized	NULL
anti-CD3	NULL
(	NULL
10	NULL
g/	NULL
ml	NULL
)	NULL
and	NULL
either	NULL
anti-CD28	NULL
(	NULL
2.5	NULL
g/	NULL
ml	NULL
)	NULL
or	NULL
recombinant	NULL
mouse	NULL
IL-2	NULL
(	NULL
20	NULL
ng/	NULL
ml	NULL
)	NULL
for	NULL
48	NULL
h.	NULL
Cytokine	NULL
(	NULL
IL-4	NULL
,	NULL
IL-5	NULL
,	NULL
and	NULL
IFN-y	NULL
)	NULL
levels	NULL
from	NULL
culture	NULL
supernatants	NULL
were	NULL
determined	NULL
by	NULL
standard	NULL
sandwich	NULL
ELISA	NULL
according	NULL
to	NULL
the	NULL
manufacturer	NULL
's	NULL
instructions	NULL
(	NULL
PharMingen	NULL
)	NULL
and	NULL
standardized	NULL
to	NULL
purified	NULL
recombinant	NULL
cytokines	NULL
(	NULL
Phar-Mingen	NULL
for	NULL
IL-4	NULL
and	NULL
IFN-y	NULL
;	NULL
purified	NULL
recombinant	NULL
mouse	NULL
IL-5	NULL
was	NULL
a	NULL
gift	NULL
from	NULL
DNAX	NULL
,	NULL
Palo	NULL
Alto	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

Immunization	NULL
of	NULL
Mic	NULL
with	NULL
OVA	NULL
and	NULL
Antibody	NULL
Measurement	NULL
.	NULL

After	NULL
obtaining	NULL
preimmune	NULL
sera	NULL
,	NULL
mice	NULL
were	NULL
injected	NULL
intraperito-neally	NULL
with	NULL
OVA	NULL
(	NULL
10	NULL
jg	NULL
adsorbed	NULL
on	NULL
20	NULL
mg	NULL
aluminum	NULL
hydrox-ide	NULL
;	NULL
Sigma	NULL
Chemical	NULL
Co.	NULL
)	NULL
.	NULL

After	NULL
7	NULL
d	NULL
,	NULL
sera	NULL
were	NULL
collected	NULL
from	NULL
immunized	NULL
mice	NULL
,	NULL
and	NULL
then	NULL
analyzed	NULL
by	NULL
isotype-specific	NULL
ELISA	NULL
to	NULL
determine	NULL
levels	NULL
of	NULL
OVA-specific	NULL
and	NULL
total	NULL
antibodies	NULL
.	NULL

In	NULL
brief	NULL
,	NULL
ELISA	NULL
plates	NULL
(	NULL
Corning	NULL
Glass	NULL
Works	NULL
,	NULL
Corning	NULL
,	NULL
NY	NULL
)	NULL
were	NULL
incubated	NULL
overnight	NULL
at	NULL
4°C	NULL
with	NULL
50	NULL
pl	NULL
of	NULL
capture	NULL
antigen	NULL
solution	NULL
(	NULL
20	NULL
g/ml	NULL
OVA	NULL
for	NULL
OVA-specific	NULL
antibody	NULL
measurements	NULL
;	NULL
sheep	NULL
anti-mouse	NULL
IgE	NULL
[	NULL
Serotec	NULL
Ltd.	NULL
,	NULL
Kidlington	NULL
,	NULL
Oxford	NULL
,	NULL
UK	NULL
]	NULL
or	NULL
anti-mouse	NULL
IgG2a	NULL
[	NULL
Southern	NULL
Biotechnology	NULL
Associates	NULL
,	NULL
Birmingham	NULL
,	NULL
AL	NULL
]	NULL
for	NULL
total	NULL
isotype	NULL
determinations	NULL
)	NULL
.	NULL

After	NULL
discarding	NULL
coating	NULL
so-lutions	NULL
,	NULL
the	NULL
plates	NULL
were	NULL
blocked	NULL
with	NULL
1	NULL
%	NULL
BSA	NULL
in	NULL
PBS	NULL
(	NULL
2	NULL
h	NULL
at	NULL
room	NULL
temperature	NULL
)	NULL
and	NULL
washed	NULL
.	NULL

Mouse	NULL
serum	NULL
or	NULL
standard	NULL
antibodies	NULL
diluted	NULL
in	NULL
PBS	NULL
containing	NULL
0.3	NULL
%	NULL
BSA	NULL
were	NULL
added	NULL
to	NULL
each	NULL
well	NULL
.	NULL

Antiserum	NULL
against	NULL
OVA	NULL
,	NULL
mouse	NULL
IgE	NULL
(	NULL
affinity	NULL
purified	NULL
from	NULL
mouse	NULL
serum	NULL
immunized	NULL
with	NULL
DNP	NULL
;	NULL
Sigma	NULL
Chemical	NULL
Co.	NULL
)	NULL
or	NULL
mouse	NULL
IgG2a	NULL
were	NULL
used	NULL
as	NULL
standards	NULL
for	NULL
OVA-specific	NULL
,	NULL
total	NULL
IgE	NULL
,	NULL
or	NULL
total	NULL
IgG2a	NULL
ELISA	NULL
,	NULL
respectively	NULL
.	NULL

Plates	NULL
were	NULL
then	NULL
incubated	NULL
for	NULL
2	NULL
h	NULL
at	NULL
room	NULL
temperature	NULL
,	NULL
washed	NULL
,	NULL
and	NULL
incubated	NULL
with	NULL
biotinylated	NULL
detection	NULL
antibodies	NULL
(	NULL
rat	NULL
monoclonal	NULL
anti-mouse	NULL
IgE-biotin	NULL
[	NULL
BioSource	NULL
International	NULL
]	NULL
or	NULL
anti-mouse	NULL
IgG2a-biotin	NULL
)	NULL
for	NULL
1	NULL
h	NULL
,	NULL
washed	NULL
and	NULL
incubated	NULL
with	NULL
avidin-alkaline	NULL
phosphatase	NULL
(	NULL
Sigma	NULL
Chemical	NULL
Co.	NULL
)	NULL
.	NULL

Alkaline	NULL
phosphatase	NULL
activity	NULL
was	NULL
determined	NULL
with	NULL
phosphatase	NULL
substrate	NULL
tablets	NULL
(	NULL
Sigma	NULL
Chemical	NULL
Co.	NULL
)	NULL
and	NULL
as	NULL
sessed	NULL
during	NULL
the	NULL
linear	NULL
phase	NULL
of	NULL
the	NULL
reaction	NULL
using	NULL
an	NULL
ELISA	NULL
reader	NULL
(	NULL
SLT	NULL
-Tecan	NULL
US	NULL
,	NULL
Inc.	NULL
,	NULL
Durham	NULL
,	NULL
NC	NULL
)	NULL
at	NULL
420	NULL
nm	NULL
and	NULL
Del-taSoft	NULL
3	NULL
analytical	NULL
software	NULL
.	NULL

Each	NULL
sample	NULL
was	NULL
tested	NULL
in	NULL
duplicate	NULL
and	NULL
the	NULL
mean	NULL
value	NULL
recorded	NULL
.	NULL

Allergic	NULL
Airway	NULL
Disease	NULL
.	NULL

-	NULL
Mice	NULL
(	NULL
chimR	NULL
Tg	NULL
or	NULL
nontransgenic	NULL
[	NULL
NT	NULL
g	NULL
]	NULL
,	NULL
as	NULL
indicated	NULL
;	NULL
4-wk-old	NULL
pups	NULL
from	NULL
the	NULL
third	NULL
backcross	NULL
to	NULL
C57BL/	NULL
6	NULL
)	NULL
received	NULL
a	NULL
priming	NULL
injection	NULL
of	NULL
OVA	NULL
(	NULL
10	NULL
pg	NULL
in	NULL
aluminum	NULL
hydroxide	NULL
,	NULL
intraperitoneally	NULL
)	NULL
on	NULL
day	NULL
0	NULL
.	NULL

These	NULL
mice	NULL
underwent	NULL
a	NULL
series	NULL
of	NULL
eight	NULL
daily	NULL
exposures	NULL
(	NULL
40	NULL
min	NULL
each	NULL
)	NULL
to	NULL
an	NULL
aerosol	NULL
generated	NULL
from	NULL
OVA	NULL
(	NULL
chicken	NULL
OVA	NULL
,	NULL
grade	NULL
V	NULL
,	NULL
Sigma	NULL
Chemical	NULL
Co.	NULL
;	NULL
1	NULL
%	NULL
in	NULL
low-endotoxin	NULL
,	NULL
sterile	NULL
PBS	NULL
)	NULL
,	NULL
starting	NULL
at	NULL
day	NULL
14	NULL
.	NULL

The	NULL
day	NULL
after	NULL
their	NULL
eighth	NULL
inhalation	NULL
treatment	NULL
,	NULL
lung	NULL
mechanics	NULL
were	NULL
measured	NULL
in	NULL
these	NULL
sensitized	NULL
mice	NULL
and	NULL
in	NULL
controls	NULL
that	NULL
were	NULL
not	NULL
exposed	NULL
to	NULL
OVA	NULL
using	NULL
mechanical	NULL
ventilation	NULL
in	NULL
a	NULL
body	NULL
plethys	NULL
mography	NULL
chamber	NULL
.	NULL

After	NULL
cannulation	NULL
of	NULL
the	NULL
internal	NULL
jugular	NULL
vein	NULL
,	NULL
intravenous	NULL
methacholine	NULL
(	NULL
a	NULL
bronchoconstrictor	NULL
)	NULL
was	NULL
administered	NULL
in	NULL
the	NULL
indicated	NULL
escalating	NULL
doses	NULL
(	NULL
46	NULL
,	NULL
47	NULL
)	NULL
,	NULL
with	NULL
intervals	NULL
between	NULL
doses	NULL
to	NULL
allow	NULL
return	NULL
of	NULL
pulmonary	NULL
parameters	NULL
to	NULL
baseline	NULL
.	NULL

Each	NULL
resistance	NULL
value	NULL
represents	NULL
the	NULL
average	NULL
of	NULL
10	NULL
measurements	NULL
obtained	NULL
during	NULL
the	NULL
peak	NULL
of	NULL
a	NULL
response	NULL
.	NULL

After	NULL
the	NULL
final	NULL
dose	NULL
,	NULL
cells	NULL
were	NULL
collected	NULL
by	NULL
bronchoalveolar	NULL
lavage	NULL
,	NULL
counted	NULL
,	NULL
and	NULL
analyzed	NULL
by	NULL
Wright	NULL
staining	NULL
.	NULL

Results	NULL
Targeted	NULL
Expression	NULL
of	NULL
a	NULL
Chimenic	NULL
Cytokine	NULL
Receptor	NULL
in	NULL
T	NULL
Lineage	NULL
Cells	NULL
of	NULL
Tg	NULL
Mice	NULL
.	NULL

Earlier	NULL
in	NULL
vivo	NULL
studies	NULL
have	NULL
shown	NULL
that	NULL
systemic	NULL
IL-4	NULL
has	NULL
the	NULL
capacity	NULL
to	NULL
inhibit	NULL
the	NULL
develop	NULL
ment	NULL
of	NULL
Thl1	NULL
cells	NULL
while	NULL
promoting	NULL
the	NULL
Th2	NULL
phenotype	NULL
(	NULL
23	NULL
,	NULL
24	NULL
)	NULL
.	NULL

However	NULL
,	NULL
it	NULL
is	NULL
not	NULL
clear	NULL
during	NULL
such	NULL
IL-4	NULL
exposure	NULL
in	NULL
vivo	NULL
what	NULL
are	NULL
the	NULL
relative	NULL
contributions	NULL
of	NULL
IL-4	NULL
signaling	NULL
within	NULL
the	NULL
T	NULL
cell	NULL
versus	NULL
those	NULL
in	NULL
APCs	NULL
.	NULL

Moreover	NULL
,	NULL
T	NULL
cells	NULL
differentiated	NULL
under	NULL
strong	NULL
polarizing	NULL
conditions	NULL
in	NULL
vitro	NULL
retained	NULL
their	NULL
characteristics	NULL
after	NULL
transfer	NULL
in	NULL
vivo	NULL
(	NULL
48	NULL
)	NULL
,	NULL
but	NULL
the	NULL
extent	NULL
to	NULL
which	NULL
different	NULL
levels	NULL
of	NULL
IL-4	NULL
signaling	NULL
within	NULL
T	NULL
cells	NULL
affect	NULL
Th1	NULL
or	NULL
Th2	NULL
development	NULL
before	NULL
exogenous	NULL
antigen	NULL
challenge	NULL
is	NULL
unknown	NULL
.	NULL

To	NULL
investigate	NULL
these	NULL
questions	NULL
,	NULL
and	NULL
to	NULL
determine	NULL
if	NULL
enhanced	NULL
IL-4	NULL
signaling	NULL
after	NULL
activation	NULL
of	NULL
naive	NULL
T	NULL
cells	NULL
could	NULL
create	NULL
susceptibility	NULL
to	NULL
allergic	NULL
diseases	NULL
in	NULL
vivo	NULL
(	NULL
34	NULL
)	NULL
,	NULL
we	NULL
created	NULL
a	NULL
chimeric	NULL
cytokine	NULL
receptor	NULL
that	NULL
could	NULL
bypass	NULL
the	NULL
function	NULL
of	NULL
endogenous	NULL
IL-4	NULL
receptors	NULL
.	NULL
``	NULL

Because	NULL
mouse	NULL
IL-2	NULL
binds	NULL
poorly	NULL
to	NULL
human	NULL
IL-2	NULL
receptors	NULL
,	NULL
this	NULL
chimeric	NULL
receptor	NULL
was	NULL
designed	NULL
as	NULL
a	NULL
translational	NULL
fusion	NULL
of	NULL
the	NULL
ligand-binding	NULL
and	NULL
trans	NULL
membrane	NULL
domains	NULL
from	NULL
the	NULL
mouse	NULL
IL-2R	NULL
B	NULL
chain	NULL
and	NULL
the	NULL
intracellular	NULL
domain	NULL
of	NULL
the	NULL
mouse	NULL
IL-4R	NULL
«	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
A	NULL
)	NULL
.	NULL

The	NULL
IL-2	NULL
and	NULL
IL-4	NULL
receptors	NULL
share	NULL
a	NULL
number	NULL
of	NULL
architectural	NULL
principles	NULL
.	NULL

IL-2R	NULL
B	NULL
and	NULL
IL-4R	NULL
«	NULL
are	NULL
in	NULL
the	NULL
same	NULL
sub-family	NULL
of	NULL
hematopoietin	NULL
receptors	NULL
,	NULL
each	NULL
binds	NULL
to	NULL
the	NULL
Janus	NULL
kinase	NULL
Jak1	NULL
,	NULL
and	NULL
the	NULL
receptors	NULL
share	NULL
a	NULL
yc	NULL
chain	NULL
,	NULL
leading	NULL
to	NULL
Jak3	NULL
recruitment	NULL
(	NULL
49	NULL
)	NULL
.	NULL

Despite	NULL
these	NULL
features	NULL
,	NULL
they	NULL
activate	NULL
different	NULL
Stat	NULL
transcription	NULL
factors	NULL
and	NULL
appear	NULL
to	NULL
differ	NULL
in	NULL
their	NULL
respective	NULL
potency	NULL
for	NULL
activation	NULL
of	NULL
mitogen-activated	NULL
protein	NULL
kinase	NULL
and	NULL
insulin	NULL
receptor	NULL
substrate	NULL
pathways	NULL
(	NULL
49-51	NULL
)	NULL
.	NULL

Accordingly	NULL
,	NULL
transfer	NULL
of	NULL
specific	NULL
domains	NULL
of	NULL
human	NULL
IL-4R	NULL
«	NULL
onto	NULL
a	NULL
140-amino	NULL
acid	NULL
cytoplasmic	NULL
signaling	NULL
domain	NULL
from	NULL
human	NULL
IL-2R	NULL
B	NULL
was	NULL
sufficient	NULL
for	NULL
IL-2	NULL
induction	NULL
of	NULL
CD23	NULL
on	NULL
B	NULL
cells	NULL
,	NULL
a	NULL
response	NULL
characteristic	NULL
of	NULL
IL-4	NULL
but	NULL
not	NULL
IL-2	NULL
(	NULL
35	NULL
)	NULL
.	NULL

An	NULL
additional	NULL
important	NULL
consideration	NULL
is	NULL
that	NULL
,	NULL
unlike	NULL
the	NULL
human	NULL
IL-2/IL-2R	NULL
system	NULL
,	NULL
mouse	NULL
IL-2	NULL
is	NULL
reported	NULL
to	NULL
bind	NULL
mouse	NULL
IL-2R	NULL
B	NULL
and	NULL
activate	NULL
resting	NULL
T	NULL
cells	NULL
poorly	NULL
unless	NULL
IL-2Ra	NULL
«	NULL
is	NULL
expressed	NULL
(	NULL
36-38	NULL
)	NULL
.	NULL

Consistent	NULL
with	NULL
this	NULL
possibility	NULL
,	NULL
M12	NULL
B	NULL
lymphoma	NULL
cells	NULL
stably	NULL
trans-fected	NULL
with	NULL
our	NULL
chimeric	NULL
receptor	NULL
cDNA	NULL
demonstrated	NULL
that	NULL
this	NULL
receptor	NULL
transduced	NULL
IL-4-specific	NULL
signals	NULL
(	NULL
Stat6	NULL
activation	NULL
,	NULL
induction	NULL
of	NULL
CD23	NULL
and	NULL
the	NULL
Ig	NULL
germ	NULL
line	NULL
e	NULL
pro-moter	NULL
)	NULL
,	NULL
but	NULL
only	NULL
when	NULL
the	NULL
IL-2R	NULL
«	NULL
chain	NULL
,	NULL
a	NULL
protein	NULL
virtually	NULL
absent	NULL
from	NULL
resting	NULL
naive	NULL
T	NULL
cells	NULL
and	NULL
from	NULL
most	NULL
thy-mocytes	NULL
,	NULL
was	NULL
also	NULL
transfected	NULL
.	NULL

This	NULL
dependency	NULL
of	NULL
the	NULL
mouse	NULL
IL-2R	NULL
B	NULL
chain	NULL
on	NULL
IL-2R	NULL
«	NULL
expression	NULL
implied	NULL
that	NULL
the	NULL
chimeric	NULL
receptor	NULL
molecule	NULL
might	NULL
not	NULL
bind	NULL
IL-2	NULL
efficiently	NULL
until	NULL
a	NULL
cell	NULL
was	NULL
induced	NULL
to	NULL
express	NULL
IL-2R	NULL
a	NULL
chain	NULL
,	NULL
thus	NULL
providing	NULL
a	NULL
mechanism	NULL
to	NULL
protect	NULL
thymocyte	NULL
and	NULL
T	NULL
cell	NULL
development	NULL
from	NULL
abnormalities	NULL
induced	NULL
by	NULL
IL-4	NULL
(	NULL
42	NULL
)	NULL
.	NULL

Since	NULL
IL-2	NULL
is	NULL
a	NULL
ligand	NULL
that	NULL
will	NULL
be	NULL
present	NULL
at	NULL
high	NULL
concentration	NULL
early	NULL
after	NULL
activation	NULL
of	NULL
naive	NULL
T	NULL
cells	NULL
,	NULL
these	NULL
features	NULL
suggested	NULL
that	NULL
a	NULL
mIL-2R	NULL
B/	NULL
mIL-4R	NULL
«	NULL
chimera	NULL
might	NULL
activate	NULL
IL-4-specific	NULL
signals	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
IL-4	NULL
,	NULL
but	NULL
would	NULL
signal	NULL
inefficiently	NULL
before	NULL
T	NULL
cell	NULL
activation	NULL
.	NULL

In	NULL
light	NULL
of	NULL
these	NULL
findings	NULL
,	NULL
we	NULL
created	NULL
Tg	NULL
mice	NULL
in	NULL
which	NULL
expression	NULL
of	NULL
this	NULL
chimeric	NULL
receptor	NULL
was	NULL
targeted	NULL
to	NULL
the	NULL
T	NULL
lymphoid	NULL
lineage	NULL
using	NULL
the	NULL
T	NULL
lineage-specific	NULL
regulatory	NULL
sequences	NULL
of	NULL
the	NULL
Ick	NULL
proximal	NULL
promoter	NULL
,	NULL
thus	NULL
facilitating	NULL
an	NULL
Youn	NULL
,	NULL
J.	NULL
,	NULL
et	NULL
al	NULL
.	NULL

,	NULL
unpublished	NULL
observations	NULL
.	NULL

1806	NULL
A	NULL
|	NULL
IL-2RB	NULL
|	NULL
intracellular	NULL
|	NULL
O	NULL
-	NULL
>	NULL
Ligand	NULL
signal	NULL
Binding	NULL
transduction	NULL
B	NULL
spleen	NULL
thymus	NULL
M12	NULL
=~	NULL
oF	NULL
o-	NULL
+=	NULL
+	NULL
-	NULL
transgene	NULL
<	NULL
-C	NULL
thymus	NULL
T	NULL
cells	NULL
_	NULL
T	NULL
cells	NULL
B	NULL
cells	NULL
=	NULL
+	NULL
=o	NULL
40	NULL
o=	NULL
4+	NULL
=	NULL
+	NULL
transgene	NULL
endogenous	NULL
+	NULL
chimeric	NULL
chimeric	NULL
y	NULL
*	NULL
endogenous	NULL
/	NULL
+	NULL
chimeric	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
7	NULL
80	NULL
Figure	NULL
1	NULL
.	NULL

-	NULL
Targeted	NULL
expression	NULL
of	NULL
the	NULL
chimeric	NULL
IL-2R	NULL
B/IL-4R	NULL
«	NULL
transgene	NULL
to	NULL
T-lineage	NULL
cells	NULL
(	NULL
A	NULL
)	NULL
Structure	NULL
of	NULL
chimeric	NULL
cytokine	NULL
receptor	NULL
cDNA	NULL
.	NULL

The	NULL
chimeric	NULL
IL-2R/4R	NULL
receptor	NULL
was	NULL
composed	NULL
of	NULL
extracellular	NULL
domain	NULL
and	NULL
transmembrane	NULL
domain	NULL
of	NULL
mouse	NULL
IL-2R	NULL
B	NULL
,	NULL
linked	NULL
to	NULL
the	NULL
complete	NULL
intracellular	NULL
domain	NULL
of	NULL
IL-4R	NULL
«	NULL
.	NULL

Tyrosine	NULL
residues	NULL
and	NULL
two	NULL
acidic	NULL
domains	NULL
(	NULL
ID-1	NULL
and	NULL
I4R	NULL
)	NULL
in	NULL
the	NULL
IL-4R	NULL
«	NULL
intracytoplasmic	NULL
tail	NULL
are	NULL
indicated	NULL
.	NULL

(	NULL
B	NULL
and	NULL
C	NULL
)	NULL
Expression	NULL
of	NULL
chimeric	NULL
receptor	NULL
transcripts	NULL
in	NULL
T-lineage	NULL
cells	NULL
from	NULL
Tg	NULL
mice	NULL
.	NULL

RNA	NULL
was	NULL
prepared	NULL
from	NULL
NT	NULL
g	NULL
and	NULL
Tg	NULL
mice	NULL
(	NULL
right	NULL
)	NULL
(	NULL
second	NULL
backcross	NULL
generation	NULL
to	NULL
B6	NULL
)	NULL
using	NULL
the	NULL
indicated	NULL
lymphoid	NULL
organs	NULL
(	NULL
B	NULL
and	NULL
C	NULL
)	NULL
or	NULL
purified	NULL
T	NULL
or	NULL
B	NULL
cells	NULL
(	NULL
C	NULL
)	NULL
,	NULL
and	NULL
from	NULL
M12	NULL
B	NULL
lymphoma	NULL
cells	NULL
(	NULL
parental	NULL
,	NULL
-	NULL
,	NULL
or	NULL
transfected	NULL
,	NULL
+	NULL
,	NULL
with	NULL
the	NULL
chimeric	NULL
receptor	NULL
cDNA	NULL
)	NULL
as	NULL
indicated	NULL
.	NULL

Splenic	NULL
T	NULL
and	NULL
B	NULL
cells	NULL
were	NULL
separated	NULL
by	NULL
nylon	NULL
wool	NULL
column	NULL
,	NULL
and	NULL
B	NULL
cells	NULL
were	NULL
further	NULL
purified	NULL
by	NULL
magnetic	NULL
activated	NULL
cell	NULL
sorting	NULL
(	NULL
MACS	NULL
)	NULL
using	NULL
streptavidin-microbeads	NULL
after	NULL
labeling	NULL
with	NULL
a	NULL
biotinylated	NULL
anti-B220	NULL
mAb	NULL
.	NULL

Purity	NULL
determined	NULL
by	NULL
flow	NULL
cytometry	NULL
was	NULL
~80	NULL
%	NULL
CD3*	NULL
(	NULL
T	NULL
cells	NULL
)	NULL
or	NULL
95	NULL
%	NULL
B220+*	NULL
(	NULL
B	NULL
cells	NULL
)	NULL
.	NULL

RNA	NULL
was	NULL
resolved	NULL
on	NULL
a	NULL
formaldehyde-agarose	NULL
gel	NULL
,	NULL
transferred	NULL
to	NULL
HyBond	NULL
filters	NULL
,	NULL
and	NULL
probed	NULL
with	NULL
P-labeled	NULL
DNA	NULL
comprising	NULL
the	NULL
IL-2R	NULL
B	NULL
and	NULL
IL-4R	NULL
«	NULL
sequences	NULL
present	NULL
in	NULL
the	NULL
Tg	NULL
cDNA	NULL
.	NULL

(	NULL
C	NULL
)	NULL
Arrows	NULL
denote	NULL
the	NULL
position	NULL
of	NULL
RNAs	NULL
encoded	NULL
by	NULL
the	NULL
transgene	NULL
,	NULL
two	NULL
of	NULL
which	NULL
comigrated	NULL
with	NULL
endogenous	NULL
RNAs	NULL
hybridizing	NULL
to	NULL
the	NULL
IL-2R	NULL
B	NULL
+	NULL
IL-4R	NULL
«	NULL
probe	NULL
as	NULL
indicated	NULL
;	NULL
the	NULL
positions	NULL
of	NULL
these	NULL
RNAs	NULL
are	NULL
also	NULL
marked	NULL
by	NULL
open	NULL
circles	NULL
.	NULL

An	NULL
asterisk	NULL
marks	NULL
the	NULL
band	NULL
of	NULL
intermediate	NULL
mobility	NULL
unique	NULL
to	NULL
transgene-positive	NULL
animals	NULL
(	NULL
lane	NULL
2	NULL
)	NULL
.	NULL

investigation	NULL
of	NULL
the	NULL
regulatory	NULL
roles	NULL
of	NULL
IL-4	NULL
signaling	NULL
in	NULL
mouse	NULL
T	NULL
lineage	NULL
cells	NULL
Different	NULL
copy-number	NULL
integrations	NULL
on	NULL
the	NULL
X	NULL
chromosome	NULL
were	NULL
bred	NULL
from	NULL
founders	NULL
;	NULL
the	NULL
phenotype	NULL
in	NULL
each	NULL
of	NULL
these	NULL
lines	NULL
is	NULL
similar	NULL
to	NULL
the	NULL
others	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Transgene-positive	NULL
progeny	NULL
expressed	NULL
trans-gene-encoded	NULL
transcripts	NULL
in	NULL
thymocytes	NULL
and	NULL
unfractionated	NULL
splenocytes	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
B	NULL
)	NULL
.	NULL

When	NULL
peripheral	NULL
lymphoid	NULL
cells	NULL
In	NULL
Vivo	NULL
Function	NULL
of	NULL
an	NULL
IL-2R/IL-4R	NULL
Chimera	NULL
A	NULL
C	NULL
3-step	NULL
staining	NULL
Non-lymphoid	NULL
APCs	NULL
Thymocytes	NULL
CD4+	NULL
Cells	NULL
m	NULL
+	NULL
=	NULL
.	NULL

wts	NULL
population	NULL
I-A	NULL
``	NULL
-At	NULL
l-A*	NULL
CD11b	NULL
CD11b	NULL
gated	NULL
:	NULL
I	NULL
:	NULL
B220	NULL
B220~	NULL
CD1ict	NULL
CD11c*	NULL
CD1ic*	NULL
a	NULL
|	NULL
c.	NULL
e	NULL
g.	NULL
i	NULL
.	NULL

Cell	NULL
Number	NULL
wild-type	NULL
|	NULL
Tg	NULL
(	NULL
NTg	NULL
)	NULL
W	NULL
I	NULL
10°	NULL
TB	NULL
’	NULL
I	NULL
70	NULL
i0	NULL
%	NULL
aot	NULL
aot	NULL
ao	NULL
!	NULL

ast	NULL
ast	NULL
aot	NULL
no	NULL
``	NULL
ro	NULL
``	NULL
ao	NULL
``	NULL
as*	NULL
10°	NULL
10	NULL
``	NULL
102	NULL
10	NULL
%	NULL
aot	NULL
-	NULL
10°	NULL
so	NULL
``	NULL
102	NULL
aot	NULL
10+	NULL
corse	NULL
b	NULL
.	NULL

|	NULL
d.	NULL
f.	NULL
h.	NULL
]	NULL
.	NULL

transgenic	NULL
(	NULL
Tg	NULL
)	NULL
Direct	NULL
staining	NULL
GDa+	NULL
Cells	NULL
B220+	NULL
Cells	NULL
wi	NULL
Troms	NULL
erred	NULL
try	NULL
10	NULL
%	NULL
10°	NULL
10°	NULL
io	NULL
``	NULL
rot	NULL
10°	NULL
to	NULL
``	NULL
ace	NULL
as*	NULL
aot	NULL
ro	NULL
``	NULL
do	NULL
``	NULL
ao	NULL
``	NULL
10°	NULL
rot	NULL
10°	NULL
10	NULL
``	NULL
102	NULL
108	NULL
-	NULL
40°	NULL
ao	NULL
``	NULL
aot	NULL
10°	NULL
10	NULL
%	NULL
-nTg	NULL
-Tg	NULL
»	NULL
»	NULL
W	NULL
CD122	NULL
-	NULL
streptavidin-r-PE	NULL
r	NULL
»	NULL
Celt	NULL
Number	NULL
CD22	NULL
Figure	NULL
2	NULL
.	NULL

-	NULL
Cell	NULL
surface	NULL
expression	NULL
of	NULL
chimeric	NULL
receptor	NULL
molecules	NULL
on	NULL
thymocytes	NULL
and	NULL
peripheral	NULL
T	NULL
cells	NULL
from	NULL
Tg	NULL
mice	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Representative	NULL
fluorescence	NULL
histograms	NULL
from	NULL
thymocytes	NULL
and	NULL
lymph	NULL
node	NULL
cells	NULL
of	NULL
NT	NULL
g	NULL
or	NULL
Tg	NULL
mice	NULL
were	NULL
sequentially	NULL
stained	NULL
with	NULL
rat	NULL
anti-mouse	NULL
IL-2R	NULL
$	NULL
,	NULL
biotinylated	NULL
goat	NULL
anti-rat	NULL
Ig	NULL
,	NULL
and	NULL
then	NULL
streptavidin-PE	NULL
(	NULL
three-layer	NULL
staining	NULL
)	NULL
.	NULL

Lymph	NULL
node	NULL
cells	NULL
were	NULL
costained	NULL
with	NULL
anti-CD4	NULL
.	NULL

Heterozygous	NULL
females	NULL
exhibited	NULL
the	NULL
effects	NULL
of	NULL
Lyon-ization	NULL
,	NULL
with	NULL
high-level	NULL
expression	NULL
of	NULL
IL-2R	NULL
f	NULL
protein	NULL
on	NULL
only	NULL
50	NULL
%	NULL
of	NULL
thymocytes	NULL
.	NULL

However	NULL
,	NULL
the	NULL
alterations	NULL
(	NULL
cytokine	NULL
production	NULL
;	NULL
allergic	NULL
airway	NULL
disease	NULL
)	NULL
reported	NULL
below	NULL
were	NULL
observed	NULL
in	NULL
both	NULL
males	NULL
and	NULL
females	NULL
.	NULL

The	NULL
data	NULL
presented	NULL
were	NULL
from	NULL
second	NULL
backcross	NULL
generation	NULL
mice	NULL
;	NULL
similar	NULL
results	NULL
were	NULL
observed	NULL
using	NULL
N1-	NULL
and	NULL
N3-generation	NULL
mice	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Lymph	NULL
node	NULL
cells	NULL
were	NULL
costained	NULL
with	NULL
anti-mouse	NULL
IL-2R	NULL
B-FITC	NULL
and	NULL
either	NULL
anti-CD3-PE	NULL
or	NULL
anti-B220-PE	NULL
as	NULL
indicated	NULL
.	NULL

The	NULL
profiles	NULL
represent	NULL
the	NULL
fluorescence	NULL
intensity	NULL
of	NULL
cells	NULL
from	NULL
the	NULL
lymphocyte	NULL
gate	NULL
(	NULL
FSC	NULL
and	NULL
SSC	NULL
)	NULL
and	NULL
CD4+	NULL
,	NULL
CD3+	NULL
,	NULL
or	NULL
B220+	NULL
gate	NULL
,	NULL
as	NULL
indicated	NULL
.	NULL

(	NULL
C	NULL
)	NULL
Splenocytes	NULL
(	NULL
@	NULL
-f	NULL
)	NULL
,	NULL
or	NULL
metrizamide	NULL
gradient-enriched	NULL
APCs	NULL
(	NULL
g-7	NULL
)	NULL
,	NULL
from	NULL
wild-type	NULL
(	NULL
NT	NULL
g	NULL
)	NULL
and	NULL
chimeric	NULL
receptor	NULL
transgene-positive	NULL
(	NULL
Tg	NULL
)	NULL
mice	NULL
(	NULL
N3	NULL
generation	NULL
)	NULL
were	NULL
subjected	NULL
to	NULL
three-color	NULL
indirect	NULL
immunofluorescent	NULL
staining	NULL
as	NULL
indicated	NULL
,	NULL
and	NULL
then	NULL
analyzed	NULL
by	NULL
flow	NULL
cytometry	NULL
.	NULL

Uniform	NULL
compensations	NULL
and	NULL
a	NULL
uniform	NULL
forward	NULL
and	NULL
side-scatter	NULL
gate	NULL
were	NULL
applied	NULL
to	NULL
all	NULL
samples	NULL
.	NULL

CD122	NULL
staining	NULL
in	NULL
the	NULL
T	NULL
cell-enriched	NULL
gate	NULL
(	NULL
a	NULL
and	NULL
b	NULL
;	NULL
I-A	NULL
and	NULL
B220	NULL
nega-tive	NULL
)	NULL
demonstrated	NULL
expression	NULL
of	NULL
the	NULL
transgene	NULL
.	NULL

Higher	NULL
levels	NULL
of	NULL
autofluorescence	NULL
were	NULL
present	NULL
in	NULL
the	NULL
APC-enriched	NULL
populations	NULL
(	NULL
e	NULL
;	NULL
)	NULL
due	NULL
to	NULL
differences	NULL
between	NULL
the	NULL
larger	NULL
APCs	NULL
and	NULL
lymphoid	NULL
cells	NULL
,	NULL
thereby	NULL
leading	NULL
to	NULL
broader	NULL
CD122	NULL
histograms	NULL
.	NULL

In	NULL
all	NULL
APC-gated	NULL
samples	NULL
,	NULL
the	NULL
mean	NULL
fluorescence	NULL
intensity	NULL
(	NULL
MFT	NULL
)	NULL
for	NULL
CD122	NULL
in	NULL
Tg	NULL
samples	NULL
was	NULL
less	NULL
than	NULL
the	NULL
MFI	NULL
of	NULL
the	NULL
wild-type	NULL
controls	NULL
.	NULL

The	NULL
same	NULL
results	NULL
were	NULL
obtained	NULL
using	NULL
anti-CD122	NULL
directly	NULL
conjugated	NULL
with	NULL
fluorescein	NULL
and	NULL
appropriate	NULL
staining	NULL
combinations	NULL
for	NULL
APC	NULL
markers	NULL
.	NULL

were	NULL
fractionated	NULL
into	NULL
T	NULL
and	NULL
B	NULL
cells	NULL
and	NULL
subjected	NULL
to	NULL
Northern	NULL
blot	NULL
analyses	NULL
,	NULL
there	NULL
was	NULL
no	NULL
difference	NULL
in	NULL
intensity	NULL
of	NULL
a	NULL
band	NULL
representing	NULL
endogenous	NULL
RNA	NULL
in	NULL
Tg	NULL
and	NULL
NT	NULL
g	NULL
samples	NULL
and	NULL
no	NULL
band	NULL
at	NULL
the	NULL
position	NULL
of	NULL
the	NULL
chimeric	NULL
transcript	NULL
could	NULL
be	NULL
detected	NULL
in	NULL
the	NULL
B220*	NULL
cells	NULL
purified	NULL
from	NULL
Tg	NULL
mice	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
C	NULL
;	NULL
a	NULL
transgene-specific	NULL
RNA	NULL
species	NULL
migrates	NULL
at	NULL
a	NULL
position	NULL
[	NULL
*	NULL
]	NULL
between	NULL
two	NULL
bands	NULL
containing	NULL
endogenous	NULL
RNAs	NULL
[	NULL
o	NULL
]	NULL
)	NULL
.	NULL

In	NULL
FACS®	NULL
analyses	NULL
,	NULL
nearly	NULL
all	NULL
thymocytes	NULL
and	NULL
CD4*	NULL
cells	NULL
from	NULL
male	NULL
Tg	NULL
mice	NULL
expressed	NULL
the	NULL
IL-2R	NULL
B	NULL
epitope	NULL
(	NULL
CD122	NULL
)	NULL
at	NULL
their	NULL
cell	NULL
surface	NULL
,	NULL
whereas	NULL
expression	NULL
of	NULL
endogenous	NULL
IL-2R	NULL
B	NULL
chains	NULL
was	NULL
observed	NULL
only	NULL
on	NULL
a	NULL
smaller	NULL
fraction	NULL
of	NULL
those	NULL
cells	NULL
in	NULL
NT	NULL
g	NULL
littermates	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
A	NULL
)	NULL
.	NULL

Of	NULL
note	NULL
,	NULL
the	NULL
level	NULL
of	NULL
CD122	NULL
staining	NULL
on	NULL
Tg	NULL
thymocytes	NULL
and	NULL
T	NULL
cells	NULL
was	NULL
similar	NULL
to	NULL
the	NULL
staining	NULL
intensity	NULL
of	NULL
positive	NULL
cells	NULL
among	NULL
wild-type	NULL
samples	NULL
;	NULL
the	NULL
main	NULL
difference	NULL
was	NULL
in	NULL
the	NULL
frequency	NULL
of	NULL
positive	NULL
cells	NULL
.	NULL

Since	NULL
the	NULL
staining	NULL
intensity	NULL
of	NULL
CD122	NULL
on	NULL
Tg	NULL
T	NULL
cells	NULL
(	NULL
chimeric	NULL
receptors	NULL
plus	NULL
endogenous	NULL
IL-2R	NULL
B	NULL
)	NULL
appeared	NULL
at	NULL
most	NULL
fourfold	NULL
greater	NULL
than	NULL
on	NULL
wild-type	NULL
cells	NULL
(	NULL
endogenous	NULL
IL-2R	NULL
B	NULL
alone	NULL
)	NULL
,	NULL
these	NULL
findings	NULL
suggest	NULL
that	NULL
the	NULL
number	NULL
of	NULL
chimeric	NULL
receptors	NULL
is	NULL
only	NULL
a	NULL
few	NULL
times	NULL
higher	NULL
than	NULL
a	NULL
cytokine	NULL
receptor	NULL
such	NULL
as	NULL
endogenous	NULL
IL-	NULL
2R	NULL
B	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
B	NULL
)	NULL
.	NULL

Consistent	NULL
with	NULL
the	NULL
Northern	NULL
blot	NULL
data	NULL
,	NULL
direct	NULL
immunofluorescent	NULL
antibody	NULL
staining	NULL
indicated	NULL
that	NULL
among	NULL
cells	NULL
competent	NULL
to	NULL
express	NULL
the	NULL
IL-2R	NULL
«	NULL
chain	NULL
,	NULL
CD3*	NULL
cells	NULL
expressed	NULL
the	NULL
IL-2R	NULL
B	NULL
epitope	NULL
at	NULL
levels	NULL
higher	NULL
in	NULL
Tg	NULL
mice	NULL
than	NULL
in	NULL
their	NULL
NT	NULL
g	NULL
littermates	NULL
,	NULL
whereas	NULL
Tg	NULL
B220¢*	NULL
cells	NULL
did	NULL
not	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
B	NULL
)	NULL
.	NULL

Moreover	NULL
,	NULL
the	NULL
level	NULL
of	NULL
1807	NULL
Youn	NULL
et	NULL
al	NULL
.	NULL

CD122	NULL
on	NULL
I-A*B220~	NULL
cells	NULL
and	NULL
populations	NULL
labeled	NULL
with	NULL
cell-surface	NULL
epitopes	NULL
that	NULL
mark	NULL
macrophages	NULL
(	NULL
CD11bt	NULL
CD11c*	NULL
)	NULL
and	NULL
dendritic	NULL
cells	NULL
(	NULL
CD11b~-CD11c*	NULL
)	NULL
was	NULL
no	NULL
different	NULL
in	NULL
Tg	NULL
animals	NULL
and	NULL
wild-type	NULL
controls	NULL
,	NULL
whereas	NULL
increased	NULL
CD122	NULL
expression	NULL
was	NULL
readily	NULL
detected	NULL
in	NULL
the	NULL
T	NULL
cell-enriched	NULL
(	NULL
I-A~B2207-	NULL
)	NULL
gate	NULL
of	NULL
Tg	NULL
samples	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
C	NULL
)	NULL
.	NULL

We	NULL
conclude	NULL
that	NULL
expression	NULL
of	NULL
the	NULL
chimeric	NULL
cytokine	NULL
receptor	NULL
transgene	NULL
in	NULL
lymphoid	NULL
cells	NULL
is	NULL
restricted	NULL
to	NULL
the	NULL
T	NULL
lineage	NULL
.	NULL

Intact	NULL
Development	NULL
and	NULL
Deployment	NULL
of	NULL
the	NULL
T	NULL
Lineage	NULL
.	NULL

O	NULL
verexpression	NULL
of	NULL
IL-4	NULL
in	NULL
thymocytes	NULL
using	NULL
the	NULL
Ick	NULL
proximal	NULL
promoter	NULL
caused	NULL
a	NULL
dramatic	NULL
decrease	NULL
in	NULL
thymic	NULL
cellu-larity	NULL
and	NULL
led	NULL
to	NULL
a	NULL
failure	NULL
of	NULL
export	NULL
of	NULL
CD8	NULL
single	NULL
positive	NULL
cells	NULL
to	NULL
populate	NULL
peripheral	NULL
sites	NULL
(	NULL
42	NULL
)	NULL
.	NULL

Accordingly	NULL
,	NULL
it	NULL
was	NULL
possible	NULL
that	NULL
the	NULL
chimeric	NULL
cytokine	NULL
receptor	NULL
transgene	NULL
would	NULL
lead	NULL
to	NULL
similar	NULL
derangements	NULL
.	NULL

Alternatively	NULL
,	NULL
if	NULL
it	NULL
were	NULL
functionally	NULL
inert	NULL
in	NULL
resting	NULL
T	NULL
cells	NULL
and	NULL
most	NULL
thymocytes	NULL
(	NULL
which	NULL
do	NULL
not	NULL
express	NULL
IL-2R	NULL
«	NULL
protein/	NULL
CD25	NULL
)	NULL
,	NULL
T	NULL
lineage	NULL
development	NULL
and	NULL
deployment	NULL
should	NULL
be	NULL
normal	NULL
.	NULL

This	NULL
latter	NULL
possibility	NULL
would	NULL
be	NULL
consistent	NULL
with	NULL
reports	NULL
that	NULL
,	NULL
unlike	NULL
human	NULL
IL-2R	NULL
B	NULL
,	NULL
mouse	NULL
IL-2R	NULL
B	NULL
can	NULL
not	NULL
signal	NULL
proliferation	NULL
of	NULL
resting	NULL
thymocytes	NULL
or	NULL
CD4*	NULL
T	NULL
cells	NULL
(	NULL
36-38	NULL
)	NULL
.	NULL

Indeed	NULL
,	NULL
the	NULL
size	NULL
and	NULL
balance	NULL
of	NULL
thymic	NULL
populations	NULL
in	NULL
Tg	NULL
mice	NULL
were	NULL
no	NULL
different	NULL
from	NULL
thymic	NULL
profiles	NULL
of	NULL
their	NULL
NT	NULL
g	NULL
littermates	NULL
.	NULL

Moreover	NULL
,	NULL
although	NULL
there	NULL
was	NULL
a	NULL
subtle	NULL
variation	NULL
in	NULL
the	NULL
CD4/CDS8	NULL
ratio	NULL
(	NULL
Tg	NULL
,	NULL
2.5	NULL
+	NULL
0.4	NULL
vs.	NULL
NTg	NULL
,	NULL
1.7	NULL
+	NULL
#	NULL
0.1	NULL
)	NULL
,	NULL
CD4*	NULL
and	NULL
CD8*	NULL
T	NULL
cells	NULL
populated	NULL
the	NULL
spleen	NULL
and	NULL
lymph	NULL
eal	NULL
x2	NULL
Thymus	NULL
ho.3	NULL
%	NULL
]	NULL
Spleen	NULL
-/+	NULL
Q	NULL
0/+	NULL
of	NULL
CD8	NULL
Figure	NULL
3	NULL
.	NULL

Normal	NULL
development	NULL
in	NULL
the	NULL
T	NULL
lineage	NULL
.	NULL

Suspensions	NULL
of	NULL
(	NULL
A	NULL
)	NULL
thymocytes	NULL
and	NULL
(	NULL
B	NULL
)	NULL
splenocytes	NULL
were	NULL
subjected	NULL
to	NULL
staining	NULL
for	NULL
CD4	NULL
and	NULL
CD8	NULL
,	NULL
as	NULL
indicated	NULL
.	NULL

Fluorescence	NULL
histograms	NULL
from	NULL
a	NULL
representative	NULL
Tg	NULL
male	NULL
,	NULL
heterozygous	NULL
female	NULL
,	NULL
and	NULL
NT	NULL
g	NULL
littermate	NULL
are	NULL
shown	NULL
.	NULL

The	NULL
absolute	NULL
numbers	NULL
of	NULL
thymocytes	NULL
(	NULL
NT	NULL
g	NULL
,	NULL
176	NULL
X	NULL
10°	NULL
;	NULL
Tg	NULL
,	NULL
180	NULL
X	NULL
10°	NULL
)	NULL
,	NULL
splenocytes	NULL
(	NULL
NTg	NULL
,	NULL
74	NULL
X	NULL
10°	NULL
;	NULL
Tg	NULL
,	NULL
83	NULL
X	NULL
10°	NULL
)	NULL
,	NULL
T	NULL
cells	NULL
,	NULL
and	NULL
their	NULL
subsets	NULL
were	NULL
not	NULL
significantly	NULL
different	NULL
in	NULL
Tg	NULL
and	NULL
NT	NULL
g	NULL
animals	NULL
.	NULL

nodes	NULL
in	NULL
normal	NULL
numbers	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
)	NULL
.	NULL

Although	NULL
Ick	NULL
may	NULL
be	NULL
expressed	NULL
in	NULL
the	NULL
natural	NULL
T	NULL
cell	NULL
compartment	NULL
of	NULL
NKI1.1-positive	NULL
TCR	NULL
-	NULL
«	NULL
/B-bearing	NULL
T	NULL
cells	NULL
(	NULL
52	NULL
)	NULL
,	NULL
there	NULL
was	NULL
no	NULL
difference	NULL
between	NULL
Tg	NULL
mice	NULL
and	NULL
wild-type	NULL
(	NULL
NT	NULL
g	NULL
)	NULL
littermates	NULL
in	NULL
the	NULL
number	NULL
of	NULL
these	NULL
cells	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
T	NULL
cell	NULL
development	NULL
appears	NULL
normal	NULL
despite	NULL
the	NULL
potential	NULL
for	NULL
the	NULL
chimeric	NULL
cytokine	NULL
receptor	NULL
to	NULL
deliver	NULL
IL-4-like	NULL
signals	NULL
.	NULL

IL-4-independent	NULL
Induction	NULL
of	NULL
Statb	NULL
DNA	NULL
Binding	NULL
Adivity	NULL
in	NULL
Tg	NULL
T	NULL
Cells	NULL
The	NULL
finding	NULL
that	NULL
T	NULL
cell	NULL
development	NULL
was	NULL
normal	NULL
provided	NULL
evidence	NULL
,	NULL
albeit	NULL
indirect	NULL
,	NULL
that	NULL
signaling	NULL
by	NULL
the	NULL
chimeric	NULL
receptor	NULL
may	NULL
be	NULL
IL-2R	NULL
«	NULL
dependent	NULL
.	NULL

To	NULL
determine	NULL
directly	NULL
if	NULL
the	NULL
transgene	NULL
mediates	NULL
Stat6	NULL
activation	NULL
under	NULL
conditions	NULL
that	NULL
bypass	NULL
potential	NULL
influences	NULL
from	NULL
endogenous	NULL
IL-4	NULL
receptors	NULL
,	NULL
we	NULL
performed	NULL
mobility	NULL
shift	NULL
assays	NULL
using	NULL
thymocytes	NULL
and	NULL
spleen	NULL
cells	NULL
that	NULL
were	NULL
freshly	NULL
isolated	NULL
or	NULL
first	NULL
exposed	NULL
to	NULL
activating	NULL
stimuli	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
and	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

U	NULL
sing	NULL
an	NULL
oligonucleotide	NULL
probe	NULL
whose	NULL
spacing	NULL
of	NULL
the	NULL
consensus	NULL
repeat	NULL
TTC/GAA	NULL
permits	NULL
stable	NULL
binding	NULL
by	NULL
Stat6	NULL
but	NULL
not	NULL
Statl-Stat5	NULL
,	NULL
binding	NULL
activity	NULL
was	NULL
induced	NULL
in	NULL
resting	NULL
spleen	NULL
cells	NULL
with	NULL
addition	NULL
of	NULL
exogenous	NULL
IL-4	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
A	NULL
,	NULL
lanes	NULL
5	NULL
and	NULL
10	NULL
)	NULL
,	NULL
whereas	NULL
mouse	NULL
IL-2	NULL
at	NULL
10	NULL
ng/ml	NULL
(	NULL
~0.67	NULL
nM	NULL
,	NULL
near	NULL
the	NULL
K	NULL
,	NULL
of	NULL
an	NULL
IL-2R	NULL
By	NULL
dimer	NULL
,	NULL
1	NULL
nM	NULL
)	NULL
did	NULL
not	NULL
activate	NULL
Stato	NULL
in	NULL
resting	NULL
thymocytes	NULL
or	NULL
splenocytes	NULL
(	NULL
lanes	NULL
2	NULL
and	NULL
7	NULL
)	NULL
from	NULL
Tg	NULL
mice	NULL
or	NULL
controls	NULL
.	NULL

Higher	NULL
concentrations	NULL
of	NULL
mouse	NULL
IL-2	NULL
(	NULL
100	NULL
ng/m	NULL
!	NULL
)	NULL

or	NULL
human	NULL
IL-2	NULL
(	NULL
10°	NULL
Cetus	NULL
U/	NULL
ml	NULL
;	NULL
~300	NULL
ng/ml	NULL
)	NULL
were	NULL
sufficient	NULL
to	NULL
generate	NULL
nuclear	NULL
Stat6	NULL
binding	NULL
activity	NULL
(	NULL
lanes	NULL
3	NULL
,	NULL
4	NULL
,	NULL
8	NULL
,	NULL
and	NULL
9	NULL
)	NULL
,	NULL
whose	NULL
relatively	NULL
low	NULL
level	NULL
may	NULL
reflect	NULL
inefficient	NULL
activation	NULL
through	NULL
By	NULL
dimers	NULL
at	NULL
concentrations	NULL
well	NULL
above	NULL
their	NULL
K	NULL
,	NULL
,	NULL
as	NULL
well	NULL
as	NULL
the	NULL
presence	NULL
of	NULL
B	NULL
cells	NULL
,	NULL
which	NULL
lack	NULL
chimeric	NULL
receptor	NULL
expression	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
to	NULL
resting	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
B	NULL
,	NULL
lanes	NULL
1-6	NULL
)	NULL
,	NULL
activation	NULL
(	NULL
``	NULL
priming	NULL
``	NULL
)	NULL
and	NULL
production	NULL
of	NULL
IL-2	NULL
in	NULL
the	NULL
1808	NULL
cultures	NULL
triggered	NULL
efficient	NULL
Stat6	NULL
induction	NULL
in	NULL
Tg	NULL
(	NULL
lanes	NULL
10-12	NULL
)	NULL
but	NULL
not	NULL
NT	NULL
g	NULL
cells	NULL
(	NULL
lanes	NULL
7-9	NULL
)	NULL
.	NULL

Similar	NULL
results	NULL
were	NULL
obtained	NULL
when	NULL
neutralizing	NULL
antibodies	NULL
against	NULL
IL-4	NULL
were	NULL
included	NULL
during	NULL
the	NULL
activation	NULL
phase	NULL
of	NULL
the	NULL
culture	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
B	NULL
,	NULL
lanes	NULL
13-18	NULL
)	NULL
.	NULL

The	NULL
presence	NULL
of	NULL
Stat6	NULL
in	NULL
the	NULL
mobility	NULL
shift	NULL
complex	NULL
was	NULL
confirmed	NULL
by	NULL
supershifting	NULL
with	NULL
antiserum	NULL
specific	NULL
for	NULL
Stat6	NULL
,	NULL
whereas	NULL
anti-Stat5	NULL
failed	NULL
to	NULL
create	NULL
a	NULL
slower	NULL
mobility	NULL
complex	NULL
when	NULL
using	NULL
this	NULL
Stat6-	NULL
specific	NULL
oligonucleotide	NULL
probe	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
C	NULL
)	NULL
.	NULL

IL-2-dependent	NULL
Stat6	NULL
induction	NULL
in	NULL
Tg	NULL
cells	NULL
was	NULL
also	NULL
observed	NULL
for	NULL
activated	NULL
thy-mocytes	NULL
,	NULL
confirming	NULL
its	NULL
association	NULL
with	NULL
the	NULL
T	NULL
lineage	NULL
of	NULL
chimeric	NULL
receptor	NULL
Tg	NULL
mice	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
D	NULL
)	NULL
.	NULL

To	NULL
determine	NULL
the	NULL
effect	NULL
of	NULL
the	NULL
transgene	NULL
on	NULL
induction	NULL
of	NULL
an	NULL
IL-4	NULL
target	NULL
gene	NULL
in	NULL
T	NULL
cells	NULL
,	NULL
we	NULL
performed	NULL
Northern	NULL
blot	NULL
analyses	NULL
of	NULL
the	NULL
levels	NULL
of	NULL
GAT	NULL
A-3	NULL
mRNA	NULL
,	NULL
a	NULL
transcription	NULL
factor	NULL
whose	NULL
levels	NULL
increase	NULL
in	NULL
IL-4-treated	NULL
T	NULL
cells	NULL
and	NULL
during	NULL
Th2	NULL
differentiation	NULL
(	NULL
53	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
to	NULL
the	NULL
results	NULL
with	NULL
wild-type	NULL
mice	NULL
,	NULL
activation	NULL
of	NULL
lymphoid	NULL
cells	NULL
from	NULL
chimeric	NULL
receptor	NULL
Tg	NULL
mice	NULL
led	NULL
to	NULL
substantial	NULL
induction	NULL
of	NULL
GAT	NULL
A-3	NULL
without	NULL
the	NULL
addition	NULL
of	NULL
exogenous	NULL
IL-4	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
E	NULL
)	NULL
.	NULL

These	NULL
data	NULL
do	NULL
not	NULL
provide	NULL
quantitation	NULL
of	NULL
the	NULL
biochemical	NULL
efficiency	NULL
of	NULL
the	NULL
IL-2R	NULL
B/	NULL
IL-4R	NULL
«	NULL
chimera	NULL
.	NULL

Since	NULL
the	NULL
flow	NULL
cytometric	NULL
data	NULL
suggest	NULL
that	NULL
there	NULL
is	NULL
a	NULL
modest	NULL
(	NULL
less	NULL
than	NULL
fourfold	NULL
)	NULL
excess	NULL
of	NULL
chimeric	NULL
receptors	NULL
relative	NULL
to	NULL
wild-type	NULL
CD122	NULL
,	NULL
our	NULL
chimeric	NULL
receptor	NULL
may	NULL
induce	NULL
Stat6	NULL
less	NULL
efficiently	NULL
than	NULL
endogenous	NULL
IL-4R	NULL
«	NULL
chains	NULL
.	NULL

Notwithstanding	NULL
this	NULL
possibility	NULL
,	NULL
we	NULL
can	NULL
conclude	NULL
that	NULL
upon	NULL
activation	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
exogenous	NULL
IL-4	NULL
,	NULL
T	NULL
cells	NULL
from	NULL
Tg	NULL
mice	NULL
exhibit	NULL
increased	NULL
signaling	NULL
characteristic	NULL
of	NULL
IL-4	NULL
compared	NULL
with	NULL
their	NULL
NT	NULL
g	NULL
counterparts	NULL
.	NULL

Development	NULL
of	NULL
Type	NULL
2	NULL
T	NULL
Effector	NULL
Cells	NULL
from	NULL
Precursors	NULL
.	NULL

_	NULL
In	NULL
light	NULL
of	NULL
this	NULL
evidence	NULL
that	NULL
the	NULL
chimeric	NULL
receptor	NULL
is	NULL
functional	NULL
in	NULL
T	NULL
cells	NULL
,	NULL
we	NULL
tested	NULL
whether	NULL
the	NULL
transgene	NULL
could	NULL
influence	NULL
the	NULL
development	NULL
of	NULL
Thl	NULL
or	NULL
Th2	NULL
cells	NULL
during	NULL
in	NULL
vitro	NULL
stimulation	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
)	NULL
.	NULL

Cells	NULL
fom	NULL
Tg	NULL
mice	NULL
produced	NULL
over	NULL
10-fold	NULL
more	NULL
IL-4	NULL
than	NULL
those	NULL
from	NULL
their	NULL
NT	NULL
g	NULL
littermates	NULL
when	NULL
lymph	NULL
node	NULL
cells	NULL
were	NULL
stimulated	NULL
through	NULL
the	NULL
TCR	NULL
and	NULL
costimulatory	NULL
CD28	NULL
molecule	NULL
for	NULL
6	NULL
d	NULL
,	NULL
washed	NULL
,	NULL
and	NULL
restimulated	NULL
.	NULL

When	NULL
effector	NULL
cells	NULL
developed	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
neutralizing	NULL
antibodies	NULL
against	NULL
IL-4	NULL
during	NULL
the	NULL
primary	NULL
culture	NULL
,	NULL
this	NULL
difference	NULL
between	NULL
Tg	NULL
and	NULL
NT	NULL
g	NULL
mice	NULL
was	NULL
more	NULL
dramatic	NULL
fold	NULL
)	NULL
,	NULL
reflecting	NULL
a	NULL
greater	NULL
inhibitory	NULL
effect	NULL
of	NULL
anti-IL-4	NULL
on	NULL
the	NULL
NTg	NULL
samples	NULL
.	NULL

Consistent	NULL
with	NULL
reports	NULL
that	NULL
IL-4-deficient	NULL
mice	NULL
can	NULL
generate	NULL
Th2-like	NULL
cells	NULL
(	NULL
32	NULL
,	NULL
33	NULL
)	NULL
,	NULL
some	NULL
IL-4	NULL
production	NULL
was	NULL
still	NULL
observed	NULL
under	NULL
these	NULL
conditions	NULL
,	NULL
perhaps	NULL
reflecting	NULL
the	NULL
important	NULL
role	NULL
of	NULL
costimulation	NULL
through	NULL
CD28	NULL
.	NULL

Indeed	NULL
,	NULL
although	NULL
the	NULL
output	NULL
of	NULL
IL-4	NULL
was	NULL
diminished	NULL
if	NULL
anti-CD28	NULL
was	NULL
omitted	NULL
from	NULL
the	NULL
differentiation	NULL
phase	NULL
of	NULL
these	NULL
cultures	NULL
,	NULL
lymph	NULL
node	NULL
cells	NULL
from	NULL
chimeric	NULL
receptor	NULL
Tg	NULL
mice	NULL
exhibited	NULL
a	NULL
far	NULL
greater	NULL
competence	NULL
to	NULL
generate	NULL
IL-4-producing	NULL
effector	NULL
cells	NULL
when	NULL
compared	NULL
with	NULL
their	NULL
wild-type	NULL
littermates	NULL
.	NULL

Similar	NULL
,	NULL
albeit	NULL
less	NULL
dramatic	NULL
,	NULL
results	NULL
were	NULL
obtained	NULL
when	NULL
IL-5	NULL
production	NULL
by	NULL
these	NULL
cultures	NULL
was	NULL
used	NULL
as	NULL
an	NULL
indicator	NULL
of	NULL
effector	NULL
T	NULL
cell	NULL
development	NULL
.	NULL

Despite	NULL
the	NULL
potentiation	NULL
of	NULL
IL-4	NULL
production	NULL
conferred	NULL
by	NULL
this	NULL
diversion	NULL
of	NULL
IL-2	NULL
binding	NULL
into	NULL
signaling	NULL
pathways	NULL
characteristic	NULL
of	NULL
IL-4	NULL
,	NULL
IFN-y	NULL
production	NULL
was	NULL
not	NULL
suppressed	NULL
.	NULL

However	NULL
,	NULL
addition	NULL
of	NULL
exogenous	NULL
IL-4	NULL
to	NULL
similar	NULL
cultures	NULL
has	NULL
led	NULL
to	NULL
variable	NULL
inhibition	NULL
of	NULL
IFN-y	NULL
produc-	NULL
In	NULL
Vivo	NULL
Function	NULL
of	NULL
an	NULL
IL-2R/IL-4R	NULL
Chimera	NULL
A	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
7	NULL
8	NULL
9	NULL
10	NULL
<	NULL
#	NULL
4-	NULL
Stat6	NULL
{	NULL
3	NULL
£	NULL
BEEZ	NULL
£	NULL
i	NULL
-	NULL
®	NULL
-	NULL
-	NULL
a	NULL
-J	NULL
IL-2	NULL
IL-2	NULL
wild-type	NULL
transgenic	NULL
B	NULL
4	NULL
s	NULL
se	NULL
s	NULL
42	NULL
13	NULL
18	NULL
aw	NULL
--	NULL
--	NULL
-¢	NULL
--	NULL
ﬂg	NULL
«	NULL
~	NULL
on	NULL
fi	NULL
&	NULL
oo	NULL
#	NULL
(	NULL
E	NULL
“	NULL
a	NULL
“	NULL
a-	NULL
U=WB	NULL
|	NULL
-a-	NULL
stats	NULL
19	NULL
0000	NULL
00	NULL
as	NULL
bulls	NULL
shea	NULL
||	NULL
Re	NULL
]	NULL
=-	NULL
+=	NULL
-	NULL
#	NULL
4	NULL
ao	NULL
pom	NULL
m	NULL
pom	NULL
s	NULL
op	NULL
s	NULL
=o	NULL
4	NULL
=-	NULL
4	NULL
-	NULL
,	NULL
resting	NULL
primed	NULL
primed	NULL
(	NULL
conA	NULL
+	NULL
IL-2	NULL
)	NULL
(	NULL
conA	NULL
+	NULL
IL-2+anti-IL-4	NULL
)	NULL
C	NULL
123456789	NULL
D	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
ﬂ-P	NULL
”	NULL
.	NULL

”	NULL
“	NULL
ﬂ	NULL
«	NULL
a-	NULL
UUMU	NULL
UU	NULL
...	NULL
u	NULL
IL-2	NULL
]	NULL
(	NULL
t2	NULL
]	NULL
<	NULL
#	NULL
4-	NULL
Stato	NULL
--	NULL
+	NULL
--	NULL
+	NULL
--	NULL
+	NULL
_+._+	NULL
.	NULL

anti-	NULL
-	NULL
anti-	NULL
=o=	NULL
$	NULL
-	NULL
-	NULL
+	NULL
``	NULL
°	NULL
``	NULL
°	NULL
stat	NULL
Stat6	NULL
-o	NULL
+	NULL
E	NULL
123	NULL
4	NULL
56	NULL
Juf	NULL
-as	NULL
|	NULL
«	NULL
<	NULL
4	NULL
#	NULL
-	NULL
GATA-3	NULL
=+	NULL
-+	NULL
-+	NULL
-	NULL
transgene	NULL
=	NULL
-	NULL
++	NULL
4+	NULL
4	NULL
-	NULL
anti-CD3	NULL
+anti-CD28	NULL
=	NULL
=	NULL
off	NULL
-	NULL
-	NULL
-	NULL
IL-2	NULL
+	NULL
anti-lL-4	NULL
wow	NULL
sos	NULL
opp	NULL
0	NULL
IL-4	NULL
Figure	NULL
4	NULL
.	NULL

The	NULL
chimeric	NULL
receptor	NULL
induces	NULL
Stat6	NULL
in	NULL
activated	NULL
lymphoid	NULL
cells	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Induction	NULL
of	NULL
Stat6	NULL
by	NULL
IL-2	NULL
.	NULL

Single	NULL
cell	NULL
suspensions	NULL
of	NULL
resting	NULL
splenocytes	NULL
from	NULL
wild-type	NULL
(	NULL
NT	NULL
g	NULL
)	NULL
or	NULL
chimeric	NULL
receptor	NULL
transgene-positive	NULL
mice	NULL
(	NULL
N3	NULL
generation	NULL
)	NULL
were	NULL
cultured	NULL
in	NULL
complete	NULL
media	NULL
supplemented	NULL
(	NULL
30	NULL
min	NULL
at	NULL
37°C	NULL
)	NULL
with	NULL
the	NULL
indicated	NULL
concentration	NULL
of	NULL
purified	NULL
recombinant	NULL
IL-2	NULL
(	NULL
lanes	NULL
2-4	NULL
and	NULL
7-9	NULL
)	NULL
,	NULL
purified	NULL
recombinant	NULL
mouse	NULL
IL-4	NULL
(	NULL
lanes	NULL
5	NULL
and	NULL
10	NULL
)	NULL
,	NULL
or	NULL
without	NULL
added	NULL
lymphokine	NULL
(	NULL
lanes	NULL
/	NULL
and	NULL
6	NULL
)	NULL
.	NULL

Extracts	NULL
from	NULL
these	NULL
cells	NULL
were	NULL
then	NULL
subjected	NULL
to	NULL
mobility	NULL
shift	NULL
assays	NULL
using	NULL
an	NULL
oligonucleotide	NULL
from	NULL
the	NULL
mouse	NULL
Ig	NULL
germ	NULL
line	NULL
e	NULL
promoter	NULL
(	NULL
44	NULL
)	NULL
,	NULL
which	NULL
exhibits	NULL
specificity	NULL
for	NULL
Stat6	NULL
due	NULL
to	NULL
an	NULL
N4	NULL
spacing	NULL
between	NULL
the	NULL
TTC	NULL
and	NULL
GAA	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Activation-dependent	NULL
enhancement	NULL
of	NULL
IL-4-independent	NULL
induction	NULL
of	NULL
Stat6	NULL
binding	NULL
activity	NULL
.	NULL

Resting	NULL
or	NULL
activated	NULL
R	NULL
BC-depleted	NULL
splenocytes	NULL
(	NULL
N3	NULL
generation	NULL
)	NULL
were	NULL
stimulated	NULL
(	NULL
30	NULL
min	NULL
at	NULL
37°C	NULL
)	NULL
with	NULL
either	NULL
IL-2	NULL
or	NULL
IL-4	NULL
as	NULL
indicated	NULL
.	NULL

Where	NULL
indicated	NULL
,	NULL
cells	NULL
were	NULL
activated	NULL
during	NULL
a	NULL
15-h	NULL
culture	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
Con	NULL
A	NULL
(	NULL
2.5	NULL
g/ml	NULL
!	NULL
)	NULL

and	NULL
IL-2	NULL
(	NULL
10	NULL
ng/	NULL
ml	NULL
)	NULL
,	NULL
in	NULL
the	NULL
pres	NULL
ence	NULL
or	NULL
absence	NULL
of	NULL
neutralizing	NULL
anti-IL-4	NULL
antibodies	NULL
,	NULL
and	NULL
then	NULL
washed	NULL
before	NULL
stimulation	NULL
with	NULL
IL-2	NULL
or	NULL
-4	NULL
.	NULL

Whole	NULL
cell	NULL
extracts	NULL
were	NULL
subjected	NULL
to	NULL
mobility	NULL
shift	NULL
assays	NULL
as	NULL
in	NULL
A	NULL
.	NULL

(	NULL
C	NULL
)	NULL
Stat6	NULL
but	NULL
not	NULL
Stat5	NULL
present	NULL
in	NULL
the	NULL
IL-4-independent	NULL
mobility	NULL
shift	NULL
complexes	NULL
.	NULL

Extracts	NULL
from	NULL
activated	NULL
spleno-cytes	NULL
,	NULL
generated	NULL
as	NULL
in	NULL
A	NULL
,	NULL
and	NULL
then	NULL
treated	NULL
with	NULL
IL-2	NULL
(	NULL
lanes	NULL
2	NULL
,	NULL
5	NULL
and	NULL
8	NULL
)	NULL
or	NULL
1809	NULL
Youn	NULL
et	NULL
al	NULL
.	NULL

tion	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Taken	NULL
together	NULL
,	NULL
these	NULL
results	NULL
indicate	NULL
that	NULL
development	NULL
of	NULL
the	NULL
Th2	NULL
phenotype	NULL
in	NULL
T	NULL
cells	NULL
from	NULL
chimeric	NULL
receptor	NULL
Tg	NULL
mice	NULL
is	NULL
potentiated	NULL
,	NULL
and	NULL
indeed	NULL
can	NULL
be	NULL
largely	NULL
independent	NULL
of	NULL
endogenous	NULL
IL-4	NULL
.	NULL

Of	NULL
note	NULL
,	NULL
under	NULL
these	NULL
conditions	NULL
the	NULL
original	NULL
difference	NULL
between	NULL
Tg	NULL
and	NULL
NT	NULL
g	NULL
cells	NULL
in	NULL
levels	NULL
of	NULL
IL-4	NULL
signaling	NULL
is	NULL
confined	NULL
to	NULL
the	NULL
T	NULL
cells	NULL
.	NULL

Increased	NULL
Type	NULL
2	NULL
Cytokine	NULL
Response	NULL
and	NULL
Help	NULL
to	NULL
Antibody	NULL
Production	NULL
.	NULL

-	NULL
The	NULL
above	NULL
data	NULL
demonstrate	NULL
that	NULL
expression	NULL
of	NULL
the	NULL
transgene	NULL
is	NULL
able	NULL
to	NULL
influence	NULL
effector	NULL
T	NULL
cell	NULL
development	NULL
in	NULL
vitro	NULL
.	NULL

Given	NULL
that	NULL
the	NULL
transgene	NULL
amplified	NULL
IL-4-specific	NULL
outcomes	NULL
during	NULL
in	NULL
vitro	NULL
differentiation	NULL
of	NULL
T	NULL
cells	NULL
,	NULL
we	NULL
tested	NULL
its	NULL
effects	NULL
on	NULL
in	NULL
vivo	NULL
processes	NULL
.	NULL

First	NULL
,	NULL
we	NULL
investigated	NULL
this	NULL
issue	NULL
by	NULL
measuring	NULL
IL-4	NULL
and	NULL
IFN-y	NULL
production	NULL
after	NULL
short-term	NULL
polyclonal	NULL
stimulation	NULL
of	NULL
lymph	NULL
node	NULL
cells	NULL
in	NULL
vitro	NULL
,	NULL
since	NULL
the	NULL
cytokines	NULL
produced	NULL
under	NULL
these	NULL
conditions	NULL
are	NULL
derived	NULL
predominantly	NULL
from	NULL
CD4*	NULL
T	NULL
cells	NULL
expressing	NULL
an	NULL
antigen-experienced/memory	NULL
phenotype	NULL
(	NULL
13	NULL
,	NULL
54-56	NULL
)	NULL
.	NULL

Lymph	NULL
node	NULL
cells	NULL
were	NULL
stimulated	NULL
40	NULL
h	NULL
with	NULL
anti-CD3	NULL
and	NULL
either	NULL
anti-CD28	NULL
or	NULL
exogenous	NULL
IL-2	NULL
,	NULL
or	NULL
both	NULL
.	NULL

Culture	NULL
supernatants	NULL
were	NULL
then	NULL
subjected	NULL
to	NULL
cytokine	NULL
ELISA	NULL
(	NULL
Fig	NULL
.	NULL

6	NULL
A	NULL
)	NULL
,	NULL
and	NULL
cells	NULL
were	NULL
stained	NULL
with	NULL
fluorescein-conjugated	NULL
antibodies	NULL
to	NULL
determine	NULL
the	NULL
frequency	NULL
of	NULL
IL-4-	NULL
or	NULL
IFN-	NULL
y-pro-ducing	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

6	NULL
B	NULL
)	NULL
.	NULL

A	NULL
fourfold	NULL
increase	NULL
in	NULL
IL-4	NULL
produced	NULL
by	NULL
Tg	NULL
cells	NULL
was	NULL
observed	NULL
compared	NULL
with	NULL
those	NULL
from	NULL
NT	NULL
g	NULL
littermates	NULL
.	NULL

Consistent	NULL
with	NULL
the	NULL
in	NULL
vitro	NULL
differentiation	NULL
assays	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
)	NULL
,	NULL
Tg	NULL
cells	NULL
produced	NULL
similar	NULL
or	NULL
at	NULL
most	NULL
slightly	NULL
reduced	NULL
amounts	NULL
of	NULL
IFN-y	NULL
compared	NULL
with	NULL
NT	NULL
g	NULL
controls	NULL
(	NULL
Fig	NULL
.	NULL

6	NULL
A	NULL
)	NULL
.	NULL

In	NULL
concert	NULL
with	NULL
these	NULL
data	NULL
,	NULL
lymph	NULL
node	NULL
cells	NULL
from	NULL
chimeric	NULL
receptor	NULL
Tg	NULL
mice	NULL
included	NULL
3	NULL
%	NULL
IL-4-producing	NULL
CD4*	NULL
T	NULL
cells	NULL
,	NULL
whereas	NULL
at	NULL
most	NULL
0.3	NULL
%	NULL
of	NULL
CD4¢*	NULL
NTg	NULL
cells	NULL
exhibited	NULL
detectable	NULL
IL-4	NULL
(	NULL
Fig	NULL
.	NULL

6	NULL
B	NULL
;	NULL
the	NULL
background	NULL
of	NULL
nonspecific	NULL
staining	NULL
in	NULL
these	NULL
assays	NULL
was	NULL
~0.3	NULL
%	NULL
in	NULL
the	NULL
CD4+*	NULL
gate	NULL
)	NULL
.	NULL

Display	NULL
of	NULL
IFN-y-producing	NULL
cells	NULL
revealed	NULL
only	NULL
a	NULL
modest	NULL
difference	NULL
between	NULL
NT	NULL
g	NULL
and	NULL
Tg	NULL
mice	NULL
and	NULL
demonstrated	NULL
that	NULL
the	NULL
increase	NULL
in	NULL
IL-4	NULL
production	NULL
reflected	NULL
an	NULL
increase	NULL
in	NULL
the	NULL
frequency	NULL
of	NULL
cells	NULL
that	NULL
produce	NULL
IL-4	NULL
but	NULL
not	NULL
IFN-y	NULL
,	NULL
and	NULL
thus	NULL
correspond	NULL
to	NULL
a	NULL
Th2	NULL
rather	NULL
IL-4	NULL
(	NULL
lanes	NULL
3	NULL
,	NULL
6	NULL
,	NULL
and	NULL
9	NULL
)	NULL
as	NULL
indicated	NULL
,	NULL
were	NULL
incubated	NULL
with	NULL
antiserum	NULL
against	NULL
Stat5	NULL
(	NULL
lanes	NULL
4-6	NULL
)	NULL
or	NULL
Stat6	NULL
(	NULL
lanes	NULL
7-9	NULL
)	NULL
as	NULL
indicated	NULL
.	NULL

DNA-protein	NULL
complexes	NULL
were	NULL
then	NULL
resolved	NULL
by	NULL
nondenaturing	NULL
gel	NULL
electrophoresis	NULL
.	NULL

(	NULL
D	NULL
)	NULL
Induction	NULL
of	NULL
Stat6	NULL
in	NULL
activated	NULL
thymocytes	NULL
.	NULL

Thymocyte	NULL
suspensions	NULL
from	NULL
Tg	NULL
mice	NULL
and	NULL
wild-type	NULL
littermates	NULL
were	NULL
cultured	NULL
15	NULL
h	NULL
in	NULL
PMA	NULL
(	NULL
50	NULL
ng/	NULL
ml	NULL
)	NULL
and	NULL
ionomycin	NULL
(	NULL
1	NULL
g/	NULL
ml	NULL
)	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
mouse	NULL
IL-2	NULL
(	NULL
10	NULL
ng/	NULL
m1	NULL
)	NULL
and	NULL
neutralizing	NULL
antibodies	NULL
against	NULL
mouse	NULL
IL-4	NULL
(	NULL
10	NULL
pg/ml	NULL
)	NULL
.	NULL

These	NULL
activated	NULL
cells	NULL
were	NULL
then	NULL
washed	NULL
and	NULL
placed	NULL
in	NULL
culture	NULL
with	NULL
no	NULL
added	NULL
cytokine	NULL
(	NULL
lanes	NULL
I	NULL
and	NULL
4	NULL
)	NULL
,	NULL
mouse	NULL
IL-2	NULL
(	NULL
10	NULL
ng/	NULL
ml	NULL
;	NULL
lanes	NULL
2	NULL
and	NULL
5	NULL
)	NULL
,	NULL
or	NULL
mouse	NULL
IL-4	NULL
(	NULL
10	NULL
ng/	NULL
ml	NULL
;	NULL
lanes	NULL
3	NULL
and	NULL
6	NULL
)	NULL
.	NULL

(	NULL
£	NULL
)	NULL
Induction	NULL
of	NULL
GATA-3	NULL
mRNA	NULL
in	NULL
Tg	NULL
lympho-cytes	NULL
.	NULL

Portions	NULL
of	NULL
lymphoid	NULL
cell	NULL
suspensions	NULL
(	NULL
pooled	NULL
spleen	NULL
and	NULL
lymph	NULL
node	NULL
)	NULL
from	NULL
Tg	NULL
(	NULL
N2	NULL
generation	NULL
in	NULL
this	NULL
experiment	NULL
)	NULL
and	NULL
NT	NULL
g	NULL
mice	NULL
were	NULL
placed	NULL
in	NULL
culture	NULL
(	NULL
lanes	NULL
3-6	NULL
)	NULL
or	NULL
used	NULL
to	NULL
prepare	NULL
RNA	NULL
without	NULL
culture	NULL
(	NULL
lanes	NULL
/	NULL
and	NULL
2	NULL
)	NULL
.	NULL

RN	NULL
As	NULL
were	NULL
prepared	NULL
after	NULL
culturing	NULL
cells	NULL
48	NULL
h	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
immobilized	NULL
antibodies	NULL
against	NULL
CD3	NULL
(	NULL
10	NULL
ug/ml	NULL
)	NULL
,	NULL
soluble	NULL
anti-CD28	NULL
(	NULL
5	NULL
ug/ml	NULL
)	NULL
,	NULL
and	NULL
either	NULL
mouse	NULL
IL-4	NULL
(	NULL
10	NULL
ng/	NULL
ml	NULL
;	NULL
lanes	NULL
5	NULL
and	NULL
6	NULL
)	NULL
or	NULL
the	NULL
combination	NULL
of	NULL
human	NULL
IL-2	NULL
(	NULL
10	NULL
ng/m	NULL
!	NULL
)	NULL

and	NULL
neutralizing	NULL
antibodies	NULL
against	NULL
mouse	NULL
IL-4	NULL
(	NULL
10	NULL
pg/ml	NULL
!	NULL
)	NULL

(	NULL
lanes	NULL
3	NULL
and	NULL
4	NULL
)	NULL
,	NULL
as	NULL
indicated	NULL
.	NULL

Northern	NULL
blot	NULL
analyses	NULL
of	NULL
equally	NULL
loaded	NULL
lanes	NULL
of	NULL
RNA	NULL
(	NULL
as	NULL
assessed	NULL
by	NULL
hybridization	NULL
with	NULL
an	NULL
rR	NULL
NA	NULL
oligonucleotide	NULL
;	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
were	NULL
probed	NULL
for	NULL
GAT	NULL
A-3	NULL
as	NULL
described	NULL
in	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL

J	NULL
>	NULL
&	NULL
125-20	NULL
=	NULL
100-	NULL
5	NULL
€	NULL
O	NULL
NTg	NULL
_	NULL
£	NULL
a	NULL
9s	NULL
)	NULL
3	NULL
154	NULL
8	NULL
2	NULL
-	NULL
H	NULL
Tg	NULL
~	NULL
3	NULL
-	NULL
so-	NULL
30195	NULL
4	NULL
-	NULL
!	NULL

2s	NULL
-	NULL
57	NULL
o-	NULL
0	NULL
©-CD28	NULL
__	NULL
a-CD28	NULL
IL-2	NULL
IL-2	NULL
o-IL-4	NULL
a-IL-4	NULL
B	NULL
7500	NULL
-	NULL
2000	NULL
4	NULL
T	NULL
T	NULL
€	NULL
5000-	NULL
C	NULL
NTg	NULL
a	NULL
1500	NULL
]	NULL
CJ	NULL
3	NULL
M	NULL
Tg	NULL
_	NULL
=	NULL
>	NULL
1000	NULL
w	NULL
t	NULL
4	NULL
2500-	NULL
y	NULL
=	NULL
-~	NULL
_	NULL
5004	NULL
O-	NULL
o-o-CD28	NULL
_	NULL
o-CD28	NULL
IL-2	NULL
IL-2	NULL
o-IL-4	NULL
a-IL-4	NULL
C	NULL
400	NULL
-	NULL
400	NULL
350	NULL
-	NULL
350	NULL
2	NULL
soo	NULL
-	NULL
3	NULL
soo	NULL
&	NULL
aso	NULL
C	NULL
NTg	NULL
@	NULL
250-3	NULL
7	NULL
200	NULL
{	NULL
motg	NULL
OZ	NULL
2095	NULL
2	NULL
1507	NULL
z	NULL
1507	NULL
&	NULL
100-	NULL
t	NULL
100	NULL
50	NULL
-	NULL
507	NULL
o	NULL
-	NULL
0	NULL
~	NULL
o-CD28	NULL
_	NULL
c-CD28	NULL
IL-2	NULL
IL-2	NULL
a-IL4	NULL
a-IL-4	NULL
Figure	NULL
5	NULL
.	NULL

Enhanced	NULL
IL-4-independent	NULL
Th2	NULL
development	NULL
during	NULL
in	NULL
vitro	NULL
T	NULL
helper	NULL
cell	NULL
differentiation	NULL
.	NULL

Lymph	NULL
node	NULL
cells	NULL
from	NULL
a	NULL
pool	NULL
of	NULL
three	NULL
NT	NULL
g	NULL
or	NULL
Tg	NULL
littermates	NULL
(	NULL
N3	NULL
generation	NULL
)	NULL
were	NULL
stimulated	NULL
with	NULL
immobilized	NULL
anti-CD3	NULL
(	NULL
10	NULL
g/m	NULL
!	NULL
)	NULL

and	NULL
either	NULL
anti-CD28	NULL
(	NULL
2	NULL
pg/ml	NULL
)	NULL
or	NULL
recombinant	NULL
mouse	NULL
IL-2	NULL
(	NULL
20	NULL
ng/	NULL
m	NULL
!	NULL
)	NULL

in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
polyclonal	NULL
antibody	NULL
to	NULL
mouse	NULL
IL-4	NULL
(	NULL
10	NULL
pg/ml	NULL
)	NULL
,	NULL
as	NULL
indicated	NULL
.	NULL

After	NULL
6	NULL
d	NULL
of	NULL
culture	NULL
,	NULL
cells	NULL
were	NULL
washed	NULL
and	NULL
restimulated	NULL
with	NULL
immobilized	NULL
anti-CD3	NULL
plus	NULL
anti-CD28	NULL
for	NULL
24	NULL
h.	NULL
Supernatants	NULL
were	NULL
collected	NULL
and	NULL
analyzed	NULL
by	NULL
ELISA	NULL
as	NULL
described	NULL
in	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL

These	NULL
figures	NULL
are	NULL
representative	NULL
of	NULL
more	NULL
than	NULL
three	NULL
(	NULL
for	NULL
IL-4	NULL
and	NULL
IFN-y	NULL
)	NULL
or	NULL
two	NULL
(	NULL
for	NULL
IL-5	NULL
)	NULL
independent	NULL
experiments	NULL
.	NULL

Additional	NULL
experiments	NULL
using	NULL
lymph	NULL
node	NULL
cells	NULL
from	NULL
individual	NULL
mice	NULL
of	NULL
each	NULL
subline	NULL
showed	NULL
no	NULL
differences	NULL
in	NULL
the	NULL
penetrance	NULL
of	NULL
the	NULL
observed	NULL
effects	NULL
on	NULL
cytokine	NULL
(	NULL
IL-4	NULL
,	NULL
IFN-y	NULL
)	NULL
production	NULL
.	NULL

than	NULL
a	NULL
ThO	NULL
(	NULL
56	NULL
)	NULL
phenotype	NULL
.	NULL

Taken	NULL
together	NULL
,	NULL
these	NULL
data	NULL
suggest	NULL
that	NULL
the	NULL
T	NULL
cell-autonomous	NULL
signals	NULL
transduced	NULL
by	NULL
the	NULL
chimeric	NULL
cytokine	NULL
receptor	NULL
may	NULL
function	NULL
in	NULL
vivo	NULL
selectively	NULL
to	NULL
bias	NULL
effector	NULL
T	NULL
cell	NULL
development	NULL
in	NULL
favor	NULL
of	NULL
Th2	NULL
cells	NULL
.	NULL

To	NULL
measure	NULL
directly	NULL
the	NULL
effect	NULL
of	NULL
the	NULL
transgene	NULL
on	NULL
an	NULL
indicator	NULL
of	NULL
type	NULL
2	NULL
help	NULL
in	NULL
vivo	NULL
,	NULL
we	NULL
immunized	NULL
mice	NULL
with	NULL
OVA	NULL
in	NULL
aluminum	NULL
hydroxide	NULL
.	NULL

Generation	NULL
of	NULL
antigen-specific	NULL
IgE	NULL
requires	NULL
T	NULL
cell	NULL
help	NULL
and	NULL
IL-4	NULL
(	NULL
12	NULL
,	NULL
13	NULL
,	NULL
57	NULL
)	NULL
.	NULL

It	NULL
may	NULL
normally	NULL
require	NULL
days	NULL
to	NULL
generate	NULL
antigen-specific	NULL
effector	NULL
cells	NULL
that	NULL
are	NULL
efficient	NULL
producers	NULL
of	NULL
IL-4	NULL
,	NULL
and	NULL
for	NULL
the	NULL
IL-4	NULL
to	NULL
lead	NULL
to	NULL
antibody	NULL
class	NULL
switching	NULL
to	NULL
the	NULL
epsilon	NULL
heavy	NULL
chain	NULL
exons	NULL
so	NULL
as	NULL
to	NULL
secrete	NULL
IgE	NULL
(	NULL
58	NULL
,	NULL
59	NULL
)	NULL
.	NULL

Therefore	NULL
,	NULL
we	NULL
chose	NULL
day	NULL
7	NULL
after	NULL
immunization	NULL
as	NULL
a	NULL
time	NULL
point	NULL
for	NULL
comparison	NULL
of	NULL
total	NULL
and	NULL
antigen-specific	NULL
IgE	NULL
levels	NULL
in	NULL
chimeric	NULL
receptor	NULL
Tg	NULL
mice	NULL
to	NULL
those	NULL
in	NULL
their	NULL
wild-type	NULL
littermates	NULL
(	NULL
Fig	NULL
.	NULL

7	NULL
)	NULL
.	NULL

Both	NULL
antigen-specific	NULL
(	NULL
Fig	NULL
.	NULL

7	NULL
A	NULL
)	NULL
and	NULL
total	NULL
(	NULL
B	NULL
)	NULL
IgE	NULL
produc-	NULL
1810	NULL
s	NULL
2007	NULL
{	NULL
NTg	NULL
``	NULL
54	NULL
m	NULL
Tg	NULL
=	NULL
150	NULL
€	NULL
20-	NULL
€	NULL
&	NULL
&	NULL
£	NULL
154	NULL
£	NULL
1004	NULL
3	NULL
&	NULL
10104	NULL
~	NULL
-u—-	NULL
50-5—	NULL
O-	NULL
o~	NULL
CD3	NULL
CD3	NULL
«	NULL
CD3	NULL
«	NULL
-CD3	NULL
a-CD28	NULL
IL-2	NULL
o-CD28	NULL
IL-2	NULL
B	NULL
NTg	NULL
0.3	NULL
lu	NULL
&	NULL
e	NULL
$	NULL
0	NULL
j	NULL
+4	NULL
-	NULL
-=	NULL
!	NULL

E	NULL
E	NULL
IFN-	NULL
yFITC	NULL
IFN-	NULL
y-FITC	NULL
Figure	NULL
6	NULL
.	NULL

Enhanced	NULL
Th2	NULL
cytokines	NULL
in	NULL
early	NULL
primary	NULL
responses	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Lymph	NULL
node	NULL
cells	NULL
,	NULL
as	NULL
in	NULL
Fig	NULL
.	NULL

5	NULL
,	NULL
were	NULL
stimulated	NULL
48	NULL
h	NULL
as	NULL
indicated	NULL
and	NULL
supernatants	NULL
were	NULL
collected	NULL
.	NULL

IL-4	NULL
and	NULL
IFN-y	NULL
levels	NULL
in	NULL
supernatants	NULL
were	NULL
measured	NULL
by	NULL
ELISA	NULL
.	NULL

These	NULL
figures	NULL
are	NULL
representative	NULL
of	NULL
three	NULL
independent	NULL
experiments	NULL
;	NULL
additional	NULL
experiments	NULL
using	NULL
preparations	NULL
of	NULL
lymph	NULL
node	NULL
cells	NULL
from	NULL
individual	NULL
mice	NULL
of	NULL
each	NULL
subline	NULL
showed	NULL
no	NULL
differences	NULL
in	NULL
the	NULL
penetrance	NULL
of	NULL
the	NULL
observed	NULL
effects	NULL
on	NULL
cytokine	NULL
(	NULL
IL-4	NULL
,	NULL
IFN-y	NULL
)	NULL
production	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Lymph	NULL
node	NULL
cells	NULL
,	NULL
as	NULL
in	NULL
Fig	NULL
.	NULL

5	NULL
,	NULL
were	NULL
stimulated	NULL
with	NULL
immobilized	NULL
anti-CD3	NULL
(	NULL
10	NULL
pg/m	NULL
!	NULL
)	NULL

,	NULL
anti-CD28	NULL
(	NULL
2	NULL
pg/ml	NULL
)	NULL
,	NULL
and	NULL
recombinant	NULL
mouse	NULL
IL-2	NULL
(	NULL
20	NULL
ng/	NULL
ml	NULL
)	NULL
for	NULL
40	NULL
h.	NULL
Monensin	NULL
was	NULL
added	NULL
to	NULL
the	NULL
cell	NULL
culture	NULL
in	NULL
the	NULL
last	NULL
4	NULL
h.	NULL
Cells	NULL
were	NULL
stained	NULL
with	NULL
anti-CD4-biotin	NULL
and	NULL
streptavidin-PerCP	NULL
,	NULL
permeabilized	NULL
,	NULL
and	NULL
stained	NULL
with	NULL
both	NULL
anti-IL-4-PE	NULL
and	NULL
anti-IFN-y-FITC	NULL
,	NULL
followed	NULL
by	NULL
FACS®	NULL
analysis	NULL
.	NULL

These	NULL
figures	NULL
are	NULL
representative	NULL
of	NULL
histograms	NULL
in	NULL
two	NULL
independent	NULL
experiments	NULL
.	NULL

tion	NULL
were	NULL
elevated	NULL
in	NULL
the	NULL
Tg	NULL
mice	NULL
(	NULL
average	NULL
of	NULL
33-	NULL
and	NULL
11-fold	NULL
,	NULL
respectively	NULL
)	NULL
.	NULL

Moreover	NULL
,	NULL
total	NULL
IgE	NULL
levels	NULL
in	NULL
Tg	NULL
mice	NULL
were	NULL
elevated	NULL
even	NULL
before	NULL
immunization	NULL
,	NULL
suggesting	NULL
that	NULL
an	NULL
increase	NULL
in	NULL
type	NULL
2	NULL
help	NULL
may	NULL
be	NULL
engendered	NULL
by	NULL
the	NULL
chimeric	NULL
receptor	NULL
transgene	NULL
during	NULL
spontaneous	NULL
evolution	NULL
of	NULL
the	NULL
lymphoid	NULL
repertoire	NULL
in	NULL
vivo	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
levels	NULL
of	NULL
IgG2a	NULL
,	NULL
which	NULL
is	NULL
dependent	NULL
on	NULL
IFN-y	NULL
and	NULL
thus	NULL
favored	NULL
by	NULL
type	NULL
1	NULL
help	NULL
,	NULL
were	NULL
little	NULL
different	NULL
in	NULL
Tg	NULL
mice	NULL
from	NULL
NT	NULL
g	NULL
littermates	NULL
before	NULL
immunization	NULL
,	NULL
and	NULL
after	NULL
immunization	NULL
were	NULL
indistinguishable	NULL
from	NULL
NTg	NULL
controls	NULL
(	NULL
Fig	NULL
.	NULL

7	NULL
C	NULL
)	NULL
.	NULL

These	NULL
results	NULL
provide	NULL
in	NULL
vivo	NULL
evidence	NULL
that	NULL
T	NULL
cell-specific	NULL
expression	NULL
of	NULL
the	NULL
transgene	NULL
confers	NULL
a	NULL
selective	NULL
enhancement	NULL
of	NULL
type	NULL
2	NULL
help	NULL
,	NULL
and	NULL
suggest	NULL
the	NULL
possibility	NULL
that	NULL
this	NULL
effect	NULL
might	NULL
be	NULL
uncoupled	NULL
from	NULL
inhibition	NULL
of	NULL
type	NULL
1	NULL
help	NULL
in	NULL
vivo	NULL
.	NULL

Moreover	NULL
,	NULL
our	NULL
data	NULL
suggest	NULL
that	NULL
T	NULL
cell	NULL
activation	NULL
that	NULL
occurred	NULL
spontaneously	NULL
may	NULL
have	NULL
induced	NULL
a	NULL
bias	NULL
toward	NULL
provision	NULL
of	NULL
type	NULL
2	NULL
help	NULL
in	NULL
Tg	NULL
mice	NULL
before	NULL
antigen	NULL
challenge	NULL
.	NULL

Importantly	NULL
,	NULL
when	NULL
Tg	NULL
mice	NULL
were	NULL
rechallenged	NULL
with	NULL
OVA	NULL
5	NULL
wk	NULL
after	NULL
their	NULL
first	NULL
immunization	NULL
,	NULL
their	NULL
IgE	NULL
anti-O	NULL
VA	NULL
recall	NULL
response	NULL
remained	NULL
dramatically	NULL
greater	NULL
than	NULL
that	NULL
of	NULL
NT	NULL
g	NULL
controls	NULL
(	NULL
Fig	NULL
.	NULL

8	NULL
)	NULL
.	NULL

These	NULL
results	NULL
indicate	NULL
that	NULL
the	NULL
trans	NULL
gene-imposed	NULL
bias	NULL
in	NULL
the	NULL
helper	NULL
arm	NULL
of	NULL
a	NULL
response	NULL
to	NULL
a	NULL
specific	NULL
antigen	NULL
is	NULL
sustained	NULL
in	NULL
a	NULL
recall	NULL
response	NULL
.	NULL

In	NULL
Vivo	NULL
Function	NULL
of	NULL
an	NULL
IL-2R/IL-4R	NULL
Chimera	NULL
>	NULL
U	NULL
a	NULL
125	NULL
15000	NULL
€	NULL
v	NULL
A	NULL
P	NULL
1001	NULL
a	NULL
125001	NULL
-	NULL
E	NULL
m	NULL
1	NULL
)	NULL
ys	NULL
.	NULL

&	NULL
E	NULL
10000J	NULL
3	NULL
£	NULL
<	NULL
-	NULL
1	NULL
7500	NULL
``	NULL
o	NULL
501	NULL
bs	NULL
2	NULL
R	NULL
®	NULL
5000-	NULL
4	NULL
4	NULL
2s	NULL
,	NULL
a	NULL
£2	NULL
<	NULL
R	NULL
2500	NULL
-	NULL
a	NULL
L	NULL
°	NULL
-	NULL
0	NULL
4	NULL
+	NULL
*	NULL
NTg	NULL
Tg	NULL
NTg	NULL
Tg	NULL
NTg	NULL
Tg	NULL
NTg	NULL
Tg	NULL
pre	NULL
post	NULL
pre	NULL
post	NULL
C	NULL
100	NULL
§	NULL
°	NULL
s	NULL
3	NULL
A	NULL
a	NULL
#	NULL
§	NULL
-	NULL
50	NULL
{	NULL
o	NULL
#	NULL
~	NULL
&	NULL
+	NULL
fis	NULL
§	NULL
254	NULL
_	NULL
;	NULL
--	NULL
ov	NULL
e	NULL
0	NULL
al	NULL
``	NULL
¥	NULL
ol	NULL
L_£_	NULL
t	NULL
:	NULL
NTg	NULL
Tg	NULL
NTg	NULL
Tg	NULL
pre	NULL
post	NULL
Figure	NULL
7	NULL
.	NULL

-	NULL
Serum	NULL
levels	NULL
of	NULL
IgE	NULL
and	NULL
IgG2a	NULL
in	NULL
mice	NULL
immunized	NULL
with	NULL
OVA	NULL
.	NULL

Tg	NULL
(	NULL
n	NULL
=	NULL
6	NULL
)	NULL
and	NULL
NT	NULL
g	NULL
(	NULL
n	NULL
=	NULL
6	NULL
)	NULL
mice	NULL
(	NULL
N3	NULL
generation	NULL
)	NULL
in	NULL
two	NULL
independent	NULL
experiments	NULL
were	NULL
injected	NULL
intraperitoncally	NULL
with	NULL
10	NULL
g	NULL
OVA	NULL
adsorbed	NULL
in	NULL
aluminum	NULL
hydroxide	NULL
(	NULL
20	NULL
mg	NULL
)	NULL
.	NULL

7	NULL
d	NULL
after	NULL
injection	NULL
,	NULL
sera	NULL
were	NULL
collected	NULL
and	NULL
levels	NULL
of	NULL
OVA-specific	NULL
and	NULL
total	NULL
antibodies	NULL
were	NULL
measured	NULL
by	NULL
isotyping	NULL
ELISA	NULL
,	NULL
as	NULL
described	NULL
in	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL

(	NULL
4	NULL
)	NULL
OVA-specific	NULL
IgE	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Total	NULL
IgE	NULL
.	NULL

(	NULL
C	NULL
)	NULL
Total	NULL
IgG2a	NULL
.	NULL

Each	NULL
symbol	NULL
represents	NULL
each	NULL
individual	NULL
mouse	NULL
and	NULL
solid	NULL
lines	NULL
(	NULL
-	NULL
)	NULL
indicate	NULL
the	NULL
mean	NULL
value	NULL
for	NULL
each	NULL
group	NULL
.	NULL

Immunization	NULL
under	NULL
these	NULL
conditions	NULL
elicited	NULL
minimal	NULL
O	NULL
VA-spe-cific	NULL
IgG2a	NULL
responses	NULL
.	NULL

OVA	NULL
-induable	NULL
Airway	NULL
Hyperresponsiveness	NULL
Due	NULL
to	NULL
Chimenc	NULL
Cytokine	NULL
Receptor	NULL
Expression	NULL
.	NULL

-	NULL
In	NULL
light	NULL
of	NULL
the	NULL
findings	NULL
that	NULL
one	NULL
parameter	NULL
of	NULL
type	NULL
2	NULL
help	NULL
in	NULL
response	NULL
to	NULL
a	NULL
specific	NULL
antigen	NULL
was	NULL
increased	NULL
in	NULL
chimeric	NULL
cytokine	NULL
receptor	NULL
Tg	NULL
mice	NULL
,	NULL
we	NULL
tested	NULL
whether	NULL
this	NULL
effect	NULL
could	NULL
be	NULL
sufficient	NULL
to	NULL
enhance	NULL
an	NULL
allergic	NULL
response	NULL
(	NULL
Fig	NULL
.	NULL

9	NULL
)	NULL
.	NULL

After	NULL
intraperitoneal	NULL
sensitization	NULL
with	NULL
OVA	NULL
,	NULL
followed	NULL
by	NULL
daily	NULL
OVA	NULL
inhalations	NULL
,	NULL
BALB/c	NULL
mice	NULL
acquire	NULL
airway	NULL
hyperresponsiveness	NULL
to	NULL
methacholine	NULL
(	NULL
46	NULL
,	NULL
47	NULL
,	NULL
60	NULL
,	NULL
61	NULL
)	NULL
.	NULL

This	NULL
T	NULL
cell-dependent	NULL
hyperresponsiveness	NULL
is	NULL
accompanied	NULL
by	NULL
eosinophilic	NULL
airway	NULL
infiltration	NULL
and	NULL
evidence	NULL
of	NULL
type	NULL
2	NULL
help	NULL
(	NULL
60	NULL
,	NULL
61	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
to	NULL
the	NULL
BALB/c	NULL
background	NULL
,	NULL
C57BL/	NULL
6	NULL
mice	NULL
develop	NULL
an	NULL
eosinophilic	NULL
infiltrate	NULL
,	NULL
but	NULL
less	NULL
IL-4	NULL
production	NULL
and	NULL
minimal	NULL
airway	NULL
hyperresponsiveness	NULL
,	NULL
measurable	NULL
as	NULL
increased	NULL
lung	NULL
resistance	NULL
(	NULL
61	NULL
,	NULL
62	NULL
)	NULL
.	NULL

Consistent	NULL
with	NULL
previous	NULL
reports	NULL
,	NULL
the	NULL
lung	NULL
resistance	NULL
of	NULL
O	NULL
VA-sensitized	NULL
NT	NULL
g	NULL
littermates	NULL
was	NULL
no	NULL
different	NULL
than	NULL
that	NULL
of	NULL
unsensitized	NULL
mice	NULL
(	NULL
Fig	NULL
.	NULL

9	NULL
A	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
lung	NULL
resistance	NULL
after	NULL
bronchoconstrictor	NULL
challenge	NULL
(	NULL
Fig	NULL
.	NULL

9	NULL
A	NULL
)	NULL
and	NULL
airway	NULL
eosinophilia	NULL
(	NULL
B	NULL
)	NULL
were	NULL
increased	NULL
in	NULL
chimeric	NULL
receptor	NULL
Tg	NULL
mice	NULL
relative	NULL
to	NULL
littermate	NULL
controls	NULL
that	NULL
had	NULL
been	NULL
OVA	NULL
sensitized	NULL
at	NULL
the	NULL
same	NULL
time	NULL
.	NULL

We	NULL
conclude	NULL
that	NULL
the	NULL
chimeric	NULL
cytokine	NULL
receptor	NULL
served	NULL
as	NULL
a	NULL
dominant	NULL
monogenic	NULL
trait	NULL
capable	NULL
of	NULL
intensifying	NULL
an	NULL
allergic	NULL
disease	NULL
pro	NULL
1811	NULL
Youn	NULL
et	NULL
al	NULL
.	NULL

hd	NULL
d	NULL
E	NULL
so	NULL
£	NULL
P	NULL
=	NULL
I	NULL
£	NULL
so-5	NULL
C	NULL
NTg	NULL
E	NULL
I	NULL
ln	NULL
494	NULL
€	NULL
mote	NULL
0	NULL
g	NULL
,	NULL
1	NULL
s	NULL
2	NULL
$	NULL
ju	NULL
a	NULL
.	NULL

$	NULL
0	NULL
204	NULL
``	NULL
é	NULL
8	NULL
_	NULL
T	NULL
oo	NULL
pre	NULL
post	NULL
C	NULL
€	NULL
g	NULL
200-Q	NULL
NTg	NULL
=	NULL
§	NULL
so-M	NULL
Tg	NULL
<	NULL
3	NULL
)	NULL
®	NULL
'	NULL
;	NULL
T	NULL
8	NULL
1	NULL
®	NULL
.l	NULL
|	NULL
1	NULL
|	NULL
pre	NULL
post	NULL
Figure	NULL
8	NULL
.	NULL

-	NULL
Recall	NULL
responses	NULL
of	NULL
antibody	NULL
production	NULL
in	NULL
mice	NULL
after	NULL
second	NULL
immunization	NULL
.	NULL

Tg	NULL
(	NULL
n	NULL
=	NULL
6	NULL
)	NULL
and	NULL
NT	NULL
g	NULL
(	NULL
r	NULL
=	NULL
6	NULL
)	NULL
mice	NULL
in	NULL
two	NULL
independent	NULL
experiments	NULL
were	NULL
injected	NULL
intraperitoncally	NULL
with	NULL
100	NULL
g	NULL
OVA	NULL
adsorbed	NULL
to	NULL
20	NULL
mg	NULL
aluminum	NULL
hydroxide	NULL
.	NULL

Primary	NULL
responses	NULL
measured	NULL
at	NULL
7	NULL
d	NULL
were	NULL
similar	NULL
to	NULL
those	NULL
obtained	NULL
with	NULL
10	NULL
ug	NULL
OVA	NULL
(	NULL
Fig	NULL
.	NULL

7	NULL
)	NULL
.	NULL

The	NULL
indicated	NULL
antibody	NULL
levels	NULL
(	NULL
mean	NULL
+	NULL
SEM	NULL
)	NULL
were	NULL
quantified	NULL
by	NULL
ELISA	NULL
using	NULL
sera	NULL
obtained	NULL
before	NULL
,	NULL
and	NULL
7	NULL
d	NULL
after	NULL
,	NULL
reimmunization	NULL
with	NULL
OVA	NULL
(	NULL
100	NULL
pg	NULL
in	NULL
aluminum	NULL
hydroxide	NULL
)	NULL
.	NULL

(	NULL
4	NULL
)	NULL
OVA-specific	NULL
IgE	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Total	NULL
IgE	NULL
.	NULL

(	NULL
C	NULL
)	NULL
Total	NULL
IgG2a	NULL
.	NULL

cess	NULL
,	NULL
presumably	NULL
through	NULL
enhancement	NULL
of	NULL
the	NULL
development	NULL
of	NULL
type	NULL
2	NULL
T	NULL
cells	NULL
.	NULL

Discussion	NULL
In	NULL
vitro	NULL
findings	NULL
have	NULL
identified	NULL
conditions	NULL
under	NULL
which	NULL
IL-4	NULL
can	NULL
induce	NULL
Th2	NULL
differentiation	NULL
among	NULL
highly	NULL
purified	NULL
T	NULL
cells	NULL
.	NULL

In	NULL
vivo	NULL
experiments	NULL
investigating	NULL
the	NULL
contributions	NULL
of	NULL
cytokines	NULL
to	NULL
regulating	NULL
the	NULL
populations	NULL
of	NULL
type	NULL
1	NULL
(	NULL
IFN-y-producing	NULL
)	NULL
and	NULL
type	NULL
2	NULL
(	NULL
IL-4-producing	NULL
)	NULL
effector	NULL
T	NULL
cells	NULL
have	NULL
involved	NULL
perturbations	NULL
that	NULL
affect	NULL
APCs	NULL
as	NULL
well	NULL
as	NULL
activated	NULL
T	NULL
cells	NULL
.	NULL

In	NULL
light	NULL
of	NULL
the	NULL
influences	NULL
exerted	NULL
by	NULL
antigen	NULL
dose	NULL
,	NULL
APC	NULL
type	NULL
,	NULL
and	NULL
costimulation	NULL
intensity	NULL
(	NULL
13-18	NULL
)	NULL
,	NULL
it	NULL
is	NULL
not	NULL
clear	NULL
what	NULL
conditions	NULL
precisely	NULL
mimic	NULL
T	NULL
cell-APC	NULL
interactions	NULL
in	NULL
vivo	NULL
.	NULL

Thus	NULL
,	NULL
the	NULL
ability	NULL
of	NULL
IL-4	NULL
to	NULL
promote	NULL
Th2	NULL
development	NULL
when	NULL
the	NULL
initial	NULL
perturbation	NULL
is	NULL
confined	NULL
to	NULL
the	NULL
T	NULL
lineage	NULL
,	NULL
and	NULL
whether	NULL
this	NULL
would	NULL
be	NULL
sufficient	NULL
to	NULL
enhance	NULL
allergic	NULL
disease	NULL
susceptibility	NULL
,	NULL
have	NULL
not	NULL
been	NULL
established	NULL
.	NULL

We	NULL
have	NULL
employed	NULL
an	NULL
in	NULL
vivo	NULL
strategy	NULL
that	NULL
used	NULL
a	NULL
chimeric	NULL
cytokine	NULL
receptor	NULL
to	NULL
bypass	NULL
endogenous	NULL
IL-4	NULL
receptors	NULL
by	NULL
broadening	NULL
the	NULL
signaling	NULL
specificity	NULL
of	NULL
IL-2	NULL
.	NULL

This	NULL
approach	NULL
was	NULL
combined	NULL
with	NULL
the	NULL
use	NULL
of	NULL
a	NULL
T	NULL
lineage-specific	NULL
promoter	NULL
to	NULL
target	NULL
expression	NULL
of	NULL
this	NULL
receptor	NULL
as	NULL
a	NULL
T	NULL
cell-specific	NULL
transgene	NULL
,	NULL
so	NULL
that	NULL
the	NULL
initial	NULL
in	NULL
vivo	NULL
perturbations	NULL
of	NULL
signaling	NULL
are	NULL
segregated	NULL
from	NULL
APC	NULL
populations	NULL
(	NULL
26	NULL
,	NULL
42	NULL
,	NULL
and	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
.	NULL

This	NULL
diversion	NULL
of	NULL
IL-2	NULL
binding	NULL
into	NULL
IL-4	NULL
signaling	NULL
pathways	NULL
enhanced	NULL
type	NULL
2	NULL
responses	NULL
.	NULL

Although	NULL
a	NULL
precise	NULL
quantitation	NULL
of	NULL
the	NULL
magnitude	NULL
of	NULL
activation	NULL
of	NULL
IL-4	NULL
signaling	NULL
by	NULL
the	NULL
chimeric	NULL
receptor	NULL
in	NULL
comparison	NULL
to	NULL
endogenous	NULL
IL-4	NULL
receptors	NULL
can	NULL
not	NULL
be	NULL
performed	NULL
,	NULL
our	NULL
findings	NULL
indicate	NULL
that	NULL
T	NULL
cell-autonomous	NULL
IL-4	NULL
signaling	NULL
in	NULL
vivo	NULL
is	NULL
sufficient	NULL
to	NULL
potentiate	NULL
Th2	NULL
development	NULL
on	NULL
a	NULL
C57BL/6	NULL
A	NULL
10	NULL
p=0.01	NULL
_	NULL
p=0.015	NULL
8	NULL
O	NULL
A	NULL
%	NULL
wo	NULL
»	NULL
NO	NULL
OVA	NULL
I	NULL
g	NULL
«	NULL
-e-	NULL
NTg/OVA	NULL
RI	NULL
a	NULL
-o-	NULL
Tg	NULL
/	NULL
OVA	NULL
ut	NULL
6C	NULL
2	NULL
0	NULL
5	NULL
15	NULL
46	NULL
137	NULL
411	NULL
1233	NULL
3700	NULL
Methacholine	NULL
(	NULL
ug/gm	NULL
)	NULL
B	NULL
g	NULL
...	NULL
“	NULL
CI	NULL
NO	NULL
OVA	NULL
2	NULL
M	NULL
_	NULL
NTg/OVA	NULL
if	NULL
&	NULL
-	NULL
chimRTg/OVA	NULL
%	NULL
0	NULL
TOTAL	NULL
CELLS	NULL
MACROPHAGES	NULL
EOSINOPHILS	NULL
LYMPHOCYTES	NULL
Figure	NULL
9.	NULL
.	NULL

The	NULL
chimeric	NULL
cytokine	NULL
receptor	NULL
transgene	NULL
is	NULL
sufficient	NULL
to	NULL
create	NULL
sensitivity	NULL
to	NULL
allergic	NULL
airway	NULL
disease	NULL
on	NULL
a	NULL
disease-resistant	NULL
background	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Antigen	NULL
sensitization	NULL
of	NULL
Tg	NULL
,	NULL
but	NULL
not	NULL
wild-type	NULL
,	NULL
mice	NULL
leads	NULL
to	NULL
an	NULL
increased	NULL
bronchoconstrictor	NULL
response	NULL
.	NULL

Mice	NULL
backcrossed	NULL
to	NULL
C57BL/	NULL
6	NULL
(	NULL
N3	NULL
)	NULL
were	NULL
sensitized	NULL
to	NULL
OVA	NULL
by	NULL
a	NULL
single	NULL
intraperitoneal	NULL
injection	NULL
(	NULL
10	NULL
pg	NULL
in	NULL
aluminum	NULL
hydroxide	NULL
)	NULL
,	NULL
followed	NULL
by	NULL
a	NULL
series	NULL
of	NULL
antigen	NULL
inhalations	NULL
as	NULL
described	NULL
in	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL

Control	NULL
mice	NULL
were	NULL
sham	NULL
sensitized	NULL
using	NULL
PBS	NULL
.	NULL

These	NULL
mice	NULL
then	NULL
underwent	NULL
measurements	NULL
of	NULL
lung	NULL
resistance	NULL
to	NULL
airflow	NULL
after	NULL
each	NULL
of	NULL
a	NULL
series	NULL
of	NULL
methacholine	NULL
injections	NULL
at	NULL
standard	NULL
doses	NULL
(	NULL
47	NULL
)	NULL
.	NULL

The	NULL
data	NULL
represent	NULL
the	NULL
mean	NULL
(	NULL
+	NULL
SEM	NULL
)	NULL
values	NULL
derived	NULL
from	NULL
eight	NULL
sensitized	NULL
chimeric	NULL
receptor	NULL
Tg	NULL
mice	NULL
and	NULL
an	NULL
equal	NULL
number	NULL
of	NULL
littermates	NULL
in	NULL
independent	NULL
experiments	NULL
.	NULL

Significance	NULL
values	NULL
(	NULL
comparison	NULL
of	NULL
sensitized	NULL
Tg	NULL
and	NULL
NTg	NULL
animals	NULL
)	NULL
are	NULL
indicated	NULL
above	NULL
the	NULL
graph	NULL
at	NULL
those	NULL
methacholine	NULL
doses	NULL
for	NULL
which	NULL
differences	NULL
were	NULL
observed	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Mean	NULL
values	NULL
for	NULL
the	NULL
number	NULL
and	NULL
distribution	NULL
of	NULL
cells	NULL
recovered	NULL
after	NULL
bronchoalveolar	NULL
lavage	NULL
of	NULL
the	NULL
lungs	NULL
of	NULL
the	NULL
mice	NULL
described	NULL
in	NULL
A	NULL
.	NULL

(	NULL
Th1-oriented	NULL
)	NULL
background	NULL
.	NULL

Moreover	NULL
,	NULL
in	NULL
vitro	NULL
evidence	NULL
suggests	NULL
that	NULL
Stat6	NULL
induction	NULL
by	NULL
IL-2	NULL
treatment	NULL
of	NULL
activated	NULL
,	NULL
Tg	NULL
T	NULL
cells	NULL
is	NULL
no	NULL
greater	NULL
than	NULL
the	NULL
response	NULL
of	NULL
wild-type	NULL
cells	NULL
to	NULL
IL-4	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
)	NULL
.	NULL

As	NULL
such	NULL
,	NULL
these	NULL
findings	NULL
complement	NULL
and	NULL
extend	NULL
in	NULL
vitro	NULL
evidence	NULL
suggesting	NULL
that	NULL
the	NULL
genetic	NULL
background	NULL
of	NULL
a	NULL
T	NULL
cell	NULL
is	NULL
a	NULL
more	NULL
important	NULL
factor	NULL
in	NULL
the	NULL
polarization	NULL
of	NULL
effector	NULL
function	NULL
than	NULL
is	NULL
the	NULL
source	NULL
of	NULL
the	NULL
APCs	NULL
(	NULL
63	NULL
)	NULL
.	NULL

One	NULL
current	NULL
model	NULL
for	NULL
the	NULL
regulated	NULL
choice	NULL
of	NULL
polarized	NULL
effector	NULL
cytokine	NULL
production	NULL
divides	NULL
the	NULL
process	NULL
into	NULL
two	NULL
phases	NULL
.	NULL

In	NULL
the	NULL
first	NULL
phase	NULL
,	NULL
the	NULL
naive	NULL
uncommitted	NULL
precursor	NULL
is	NULL
induced	NULL
to	NULL
secrete	NULL
IL-2	NULL
and	NULL
to	NULL
activate	NULL
at	NULL
least	NULL
low-level	NULL
transcription	NULL
of	NULL
IL-4	NULL
and	NULL
IFN-y	NULL
(	NULL
64	NULL
)	NULL
.	NULL

The	NULL
magnitude	NULL
of	NULL
1812	NULL
IL-4	NULL
gene	NULL
activation	NULL
in	NULL
this	NULL
phase	NULL
would	NULL
depend	NULL
primarily	NULL
on	NULL
the	NULL
strength	NULL
of	NULL
TCR	NULL
signaling	NULL
,	NULL
costimulation	NULL
,	NULL
and	NULL
CD4	NULL
engagement	NULL
(	NULL
14-18	NULL
,	NULL
56	NULL
,	NULL
65	NULL
)	NULL
.	NULL

The	NULL
initial	NULL
release	NULL
of	NULL
IL-4	NULL
,	NULL
or	NULL
IFN-y	NULL
and	NULL
resultant	NULL
IL-	NULL
12	NULL
,	NULL
would	NULL
then	NULL
result	NULL
in	NULL
an	NULL
amplification	NULL
phase	NULL
during	NULL
which	NULL
Stat6	NULL
,	NULL
or	NULL
Statl	NULL
and	NULL
Stat4	NULL
,	NULL
would	NULL
potentiate	NULL
the	NULL
differentiation	NULL
process	NULL
.	NULL

In	NULL
contrast	NULL
to	NULL
their	NULL
wild-type	NULL
counterparts	NULL
,	NULL
T	NULL
cells	NULL
bearing	NULL
the	NULL
chimeric	NULL
receptor	NULL
transgene	NULL
could	NULL
transduce	NULL
IL-4-specific	NULL
signals	NULL
in	NULL
the	NULL
earlier	NULL
phase	NULL
due	NULL
to	NULL
the	NULL
presence	NULL
of	NULL
IL-2	NULL
,	NULL
leading	NULL
to	NULL
enhanced	NULL
Th2	NULL
development	NULL
.	NULL

The	NULL
observed	NULL
increase	NULL
in	NULL
IgE	NULL
levels	NULL
of	NULL
chimeric	NULL
receptor	NULL
mice	NULL
before	NULL
immunization	NULL
with	NULL
an	NULL
antigen	NULL
suggests	NULL
that	NULL
these	NULL
early-phase	NULL
IL-4	NULL
signals	NULL
may	NULL
be	NULL
sufficient	NULL
to	NULL
increase	NULL
the	NULL
development	NULL
of	NULL
effector	NULL
Th2	NULL
cells	NULL
as	NULL
the	NULL
antigen-experienced	NULL
T	NULL
cell	NULL
effector	NULL
and	NULL
memory	NULL
repertoires	NULL
evolve	NULL
in	NULL
vivo	NULL
.	NULL

Since	NULL
GAT	NULL
A-3	NULL
expression	NULL
in	NULL
Tg	NULL
T	NULL
cells	NULL
has	NULL
been	NULL
reported	NULL
to	NULL
be	NULL
sufficient	NULL
to	NULL
enhance	NULL
Th2	NULL
development	NULL
(	NULL
53	NULL
)	NULL
,	NULL
the	NULL
finding	NULL
that	NULL
GAT	NULL
A-3	NULL
expression	NULL
is	NULL
potentiated	NULL
after	NULL
activation	NULL
of	NULL
chimeric	NULL
cytokine	NULL
receptor-bearing	NULL
T	NULL
cells	NULL
may	NULL
provide	NULL
the	NULL
mechanistic	NULL
basis	NULL
for	NULL
the	NULL
T	NULL
cell-autonomous	NULL
increase	NULL
in	NULL
Th2	NULL
cells	NULL
However	NULL
,	NULL
other	NULL
transcription	NULL
factors	NULL
may	NULL
also	NULL
be	NULL
involved	NULL
in	NULL
this	NULL
effect	NULL
.	NULL

In	NULL
contrast	NULL
to	NULL
the	NULL
increase	NULL
in	NULL
IgE	NULL
,	NULL
the	NULL
finding	NULL
that	NULL
IgG2a	NULL
levels	NULL
in	NULL
our	NULL
Tg	NULL
mice	NULL
are	NULL
essentially	NULL
normal	NULL
suggests	NULL
that	NULL
the	NULL
alteration	NULL
in	NULL
signaling	NULL
caused	NULL
by	NULL
chimeric	NULL
receptor	NULL
expression	NULL
in	NULL
T	NULL
cells	NULL
may	NULL
not	NULL
be	NULL
sufficient	NULL
to	NULL
suppress	NULL
type	NULL
1	NULL
help	NULL
in	NULL
vivo	NULL
.	NULL

Moreover	NULL
,	NULL
no	NULL
significant	NULL
decrease	NULL
in	NULL
IFN-y	NULL
production	NULL
by	NULL
chimeric	NULL
receptor	NULL
transgene-positive	NULL
cells	NULL
was	NULL
observed	NULL
,	NULL
even	NULL
under	NULL
conditions	NULL
where	NULL
Th2	NULL
development	NULL
was	NULL
>	NULL
30-fold	NULL
more	NULL
potent	NULL
than	NULL
that	NULL
of	NULL
NT	NULL
g	NULL
counterparts	NULL
.	NULL

Although	NULL
these	NULL
data	NULL
were	NULL
less	NULL
conclusive	NULL
because	NULL
of	NULL
the	NULL
variable	NULL
ability	NULL
of	NULL
exogenous	NULL
IL-4	NULL
to	NULL
suppress	NULL
in	NULL
vitro	NULL
IFN-y	NULL
production	NULL
in	NULL
our	NULL
samples	NULL
,	NULL
they	NULL
suggest	NULL
that	NULL
when	NULL
IL-4	NULL
signaling	NULL
during	NULL
the	NULL
early	NULL
activation	NULL
phase	NULL
of	NULL
effector	NULL
T	NULL
cell	NULL
development	NULL
is	NULL
confined	NULL
to	NULL
the	NULL
T	NULL
cells	NULL
,	NULL
enhancement	NULL
of	NULL
type	NULL
2	NULL
help	NULL
may	NULL
be	NULL
uncoupled	NULL
from	NULL
inhibition	NULL
of	NULL
type	NULL
1	NULL
help	NULL
.	NULL

Consistent	NULL
with	NULL
this	NULL
possibility	NULL
,	NULL
transfer	NULL
experiments	NULL
suggest	NULL
that	NULL
exposure	NULL
of	NULL
APCs	NULL
to	NULL
IL-4	NULL
in	NULL
vivo	NULL
creates	NULL
an	NULL
APC	NULL
population	NULL
that	NULL
does	NULL
not	NULL
support	NULL
Th1	NULL
development	NULL
(	NULL
15	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
it	NULL
is	NULL
possible	NULL
that	NULL
IL-4	NULL
action	NULL
on	NULL
APCs	NULL
may	NULL
play	NULL
a	NULL
role	NULL
in	NULL
the	NULL
inhibition	NULL
of	NULL
Th1	NULL
development	NULL
,	NULL
a	NULL
mechanism	NULL
analogous	NULL
to	NULL
the	NULL
role	NULL
of	NULL
APCs	NULL
in	NULL
IFN-y-induced	NULL
Th1	NULL
development	NULL
but	NULL
in	NULL
contrast	NULL
to	NULL
the	NULL
T	NULL
cell-autonomous	NULL
promotion	NULL
of	NULL
Th2	NULL
development	NULL
by	NULL
IL-4	NULL
.	NULL

Gene	NULL
knockout	NULL
experiments	NULL
have	NULL
shown	NULL
that	NULL
the	NULL
IL-4-induced	NULL
transcription	NULL
factor	NULL
Stat6	NULL
is	NULL
involved	NULL
in	NULL
inhibition	NULL
of	NULL
the	NULL
emergence	NULL
of	NULL
Th1	NULL
cells	NULL
as	NULL
well	NULL
as	NULL
in	NULL
Th2	NULL
development	NULL
(	NULL
66	NULL
,	NULL
67	NULL
)	NULL
.	NULL

A	NULL
potential	NULL
explanation	NULL
of	NULL
the	NULL
normal	NULL
IFN-y	NULL
production	NULL
and	NULL
IgG2a	NULL
is	NULL
that	NULL
this	NULL
inhibitory	NULL
function	NULL
of	NULL
Stat6	NULL
is	NULL
mediated	NULL
by	NULL
its	NULL
activity	NULL
in	NULL
APCs	NULL
.	NULL

Since	NULL
IFN-y	NULL
acts	NULL
on	NULL
APCs	NULL
to	NULL
enhance	NULL
IL-	NULL
12	NULL
release	NULL
and	NULL
promote	NULL
Th1	NULL
development	NULL
(	NULL
11	NULL
,	NULL
68	NULL
)	NULL
,	NULL
one	NULL
possibility	NULL
for	NULL
target	NULL
gene	NULL
regulation	NULL
in	NULL
the	NULL
APCs	NULL
is	NULL
that	NULL
activated	NULL
Stat6	NULL
inhibits	NULL
induction	NULL
of	NULL
inter-feron-responsive	NULL
factors	NULL
such	NULL
as	NULL
the	NULL
transcription	NULL
factor	NULL
IRF-1	NULL
.	NULL

In	NULL
this	NULL
regard	NULL
,	NULL
an	NULL
intact	NULL
IRF-1	NULL
gene	NULL
in	NULL
the	NULL
APC	NULL
population	NULL
is	NULL
required	NULL
for	NULL
normal	NULL
Thl	NULL
development	NULL
(	NULL
27	NULL
,	NULL
28	NULL
)	NULL
.	NULL

Moreover	NULL
,	NULL
IL-4	NULL
can	NULL
inhibit	NULL
IRF-1	NULL
promoter	NULL
induction	NULL
(	NULL
69	NULL
)	NULL
by	NULL
a	NULL
Stat6-dependent	NULL
mechanism	NULL
(	NULL
Goenka	NULL
,	NULL
S.	NULL
,	NULL
J.	NULL
Youn	NULL
,	NULL
L.-y	NULL
.	NULL

Yu-Lee	NULL
,	NULL
U.	NULL
Schindler	NULL
,	NULL
and	NULL
M.	NULL
Boothby	NULL
,	NULL
manuscript	NULL
In	NULL
Vivo	NULL
Function	NULL
of	NULL
an	NULL
IL-2R/IL-4R	NULL
Chimera	NULL
submitted	NULL
for	NULL
publication	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
one	NULL
mechanism	NULL
that	NULL
could	NULL
mediate	NULL
a	NULL
role	NULL
for	NULL
APCs	NULL
in	NULL
IL-4-induced	NULL
repression	NULL
of	NULL
Th1	NULL
development	NULL
is	NULL
inhibition	NULL
of	NULL
IRF-1	NULL
.	NULL

A	NULL
mechanism	NULL
that	NULL
may	NULL
be	NULL
T	NULL
cell-autonomous	NULL
has	NULL
been	NULL
reported	NULL
to	NULL
reinforce	NULL
inhibition	NULL
of	NULL
Th1	NULL
development	NULL
by	NULL
IL-4	NULL
in	NULL
an	NULL
in	NULL
vitro	NULL
system	NULL
.	NULL

In	NULL
this	NULL
model	NULL
,	NULL
IL-4	NULL
inhibits	NULL
expression	NULL
on	NULL
T	NULL
cells	NULL
of	NULL
an	NULL
IL-12	NULL
receptor	NULL
chain	NULL
(	NULL
IL-12R	NULL
B2	NULL
)	NULL
needed	NULL
for	NULL
normal	NULL
signaling	NULL
(	NULL
70	NULL
)	NULL
.	NULL

These	NULL
results	NULL
were	NULL
obtained	NULL
using	NULL
cells	NULL
from	NULL
BALB/c-background	NULL
mice	NULL
,	NULL
and	NULL
the	NULL
extinction	NULL
of	NULL
IL-12R	NULL
B2	NULL
mRNA	NULL
required	NULL
~5	NULL
d	NULL
,	NULL
a	NULL
time	NULL
point	NULL
at	NULL
which	NULL
many	NULL
cells	NULL
may	NULL
already	NULL
have	NULL
become	NULL
committed	NULL
to	NULL
IFN-y	NULL
production	NULL
(	NULL
64	NULL
,	NULL
70	NULL
)	NULL
.	NULL

However	NULL
,	NULL
our	NULL
data	NULL
reflect	NULL
a	NULL
C57BL/	NULL
6	NULL
background	NULL
.	NULL

Thus	NULL
,	NULL
one	NULL
possible	NULL
explanation	NULL
is	NULL
that	NULL
Th1	NULL
regulation	NULL
used	NULL
different	NULL
mechanisms	NULL
in	NULL
cells	NULL
derived	NULL
from	NULL
a	NULL
BALB/c	NULL
(	NULL
Th2-oriented	NULL
)	NULL
background	NULL
as	NULL
compared	NULL
with	NULL
C57BL/6-derived	NULL
cells	NULL
.	NULL

Also	NULL
,	NULL
IL-4	NULL
signaling	NULL
by	NULL
the	NULL
chimeric	NULL
receptor	NULL
may	NULL
primarily	NULL
occur	NULL
early	NULL
during	NULL
effector	NULL
cell	NULL
differentiation	NULL
,	NULL
when	NULL
IL-2	NULL
levels	NULL
are	NULL
maximal	NULL
,	NULL
so	NULL
that	NULL
the	NULL
mechanism	NULL
inhibiting	NULL
Th1	NULL
development	NULL
upon	NULL
initial	NULL
T	NULL
cell	NULL
activation	NULL
may	NULL
differ	NULL
from	NULL
the	NULL
process	NULL
in	NULL
which	NULL
cells	NULL
committed	NULL
to	NULL
a	NULL
Th2	NULL
phenotype	NULL
are	NULL
rendered	NULL
unresponsive	NULL
to	NULL
IL-	NULL
12	NULL
.	NULL

An	NULL
important	NULL
question	NULL
underlying	NULL
these	NULL
studies	NULL
is	NULL
the	NULL
degree	NULL
to	NULL
which	NULL
genetic	NULL
influences	NULL
that	NULL
bias	NULL
the	NULL
effector	NULL
T	NULL
cell	NULL
repertoire	NULL
account	NULL
for	NULL
differences	NULL
in	NULL
susceptibility	NULL
to	NULL
allergic	NULL
diseases	NULL
(	NULL
34	NULL
,	NULL
71	NULL
)	NULL
.	NULL

Although	NULL
it	NULL
is	NULL
clear	NULL
that	NULL
the	NULL
efficiency	NULL
of	NULL
generating	NULL
type	NULL
2	NULL
help	NULL
can	NULL
be	NULL
correlated	NULL
with	NULL
susceptibility	NULL
of	NULL
C57BL	NULL
(	NULL
B6	NULL
or	NULL
B10.D2	NULL
)	NULL
and	NULL
BALB/c	NULL
mice	NULL
to	NULL
immunologic	NULL
diseases	NULL
(	NULL
61	NULL
,	NULL
72	NULL
,	NULL
73	NULL
)	NULL
,	NULL
it	NULL
also	NULL
is	NULL
clear	NULL
that	NULL
susceptibility	NULL
arises	NULL
from	NULL
complex	NULL
,	NULL
polygenic	NULL
characteristics	NULL
and	NULL
not	NULL
only	NULL
from	NULL
Thl/Th2	NULL
regulation	NULL
(	NULL
32	NULL
,	NULL
33	NULL
,	NULL
74-76	NULL
)	NULL
.	NULL

For	NULL
instance	NULL
,	NULL
in	NULL
certain	NULL
instances	NULL
BALB/c	NULL
mice	NULL
are	NULL
unable	NULL
to	NULL
heal	NULL
Leishmania	NULL
major	NULL
infection	NULL
despite	NULL
inactivation	NULL
of	NULL
the	NULL
IL-4	NULL
gene	NULL
(	NULL
32	NULL
)	NULL
.	NULL

A	NULL
reciprocal	NULL
question	NULL
relates	NULL
to	NULL
the	NULL
resistance	NULL
of	NULL
C57BL/6	NULL
mice	NULL
to	NULL
airway	NULL
hyperresponsiveness	NULL
in	NULL
allergic	NULL
airway	NULL
disease	NULL
(	NULL
61	NULL
)	NULL
.	NULL

In	NULL
particular	NULL
,	NULL
it	NULL
is	NULL
not	NULL
clear	NULL
if	NULL
the	NULL
T	NULL
cell	NULL
contribution	NULL
to	NULL
allergic	NULL
disease	NULL
is	NULL
exclusively	NULL
a	NULL
re	NULL
flection	NULL
of	NULL
Th2	NULL
development	NULL
,	NULL
or	NULL
if	NULL
other	NULL
T	NULL
cells	NULL
may	NULL
be	NULL
important	NULL
(	NULL
for	NULL
a	NULL
review	NULL
,	NULL
see	NULL
reference	NULL
77	NULL
)	NULL
.	NULL

While	NULL
previous	NULL
studies	NULL
have	NULL
shown	NULL
that	NULL
transfer	NULL
of	NULL
5	NULL
X	NULL
10°	NULL
activated	NULL
,	NULL
antigen-specific	NULL
Th2	NULL
cells	NULL
is	NULL
sufficient	NULL
to	NULL
create	NULL
susceptibility	NULL
in	NULL
BALB/c	NULL
mice	NULL
(	NULL
78	NULL
)	NULL
,	NULL
other	NULL
data	NULL
indicate	NULL
that	NULL
far	NULL
fewer	NULL
antigen-specific	NULL
T	NULL
cells	NULL
normally	NULL
arise	NULL
after	NULL
immune	NULL
challenge	NULL
(	NULL
79	NULL
)	NULL
.	NULL

Moreover	NULL
,	NULL
data	NULL
from	NULL
other	NULL
disease	NULL
models	NULL
show	NULL
that	NULL
normal	NULL
resistance	NULL
is	NULL
overcome	NULL
when	NULL
such	NULL
large	NULL
numbers	NULL
of	NULL
cells	NULL
are	NULL
used	NULL
in	NULL
transfers	NULL
(	NULL
80	NULL
)	NULL
.	NULL

The	NULL
present	NULL
data	NULL
indicate	NULL
that	NULL
the	NULL
introduction	NULL
of	NULL
a	NULL
bias	NULL
toward	NULL
Th2	NULL
development	NULL
on	NULL
a	NULL
C57BL/	NULL
6	NULL
background	NULL
is	NULL
sufficient	NULL
to	NULL
potentiate	NULL
a	NULL
bronchoconstrictor	NULL
response	NULL
when	NULL
normal	NULL
numbers	NULL
of	NULL
T	NULL
cells	NULL
are	NULL
present	NULL
,	NULL
the	NULL
response	NULL
evolves	NULL
exclusively	NULL
from	NULL
antigen	NULL
challenge	NULL
,	NULL
and	NULL
effector	NULL
cytokines	NULL
are	NULL
produced	NULL
only	NULL
by	NULL
their	NULL
natural	NULL
promoters	NULL
in	NULL
physiologically	NULL
appropriate	NULL
cell	NULL
types	NULL
.	NULL

Moreover	NULL
,	NULL
our	NULL
findings	NULL
are	NULL
consistent	NULL
with	NULL
the	NULL
possibility	NULL
that	NULL
a	NULL
sufficient	NULL
enhancement	NULL
of	NULL
IL-4R	NULL
«	NULL
signaling	NULL
in	NULL
T	NULL
cells	NULL
could	NULL
promote	NULL
allergic	NULL
disease	NULL
susceptibility	NULL
in	NULL
humans	NULL
(	NULL
34	NULL
)	NULL
.	NULL

These	NULL
data	NULL
suggest	NULL
that	NULL
one	NULL
useful	NULL
application	NULL
of	NULL
the	NULL
chimeric	NULL
cytokine	NULL
receptor	NULL
transgene	NULL
will	NULL
be	NULL
in	NULL
simplifying	NULL
the	NULL
analysis	NULL
of	NULL
disease	NULL
susceptibility	NULL
traits	NULL
.	NULL

It	NULL
can	NULL
be	NULL
predicted	NULL
that	NULL
of	NULL
the	NULL
many	NULL
loci	NULL
that	NULL
contribute	NULL
to	NULL
differences	NULL
between	NULL
C57BL	NULL
(	NULL
B6	NULL
or	NULL
B10.D2	NULL
)	NULL
and	NULL
BALB/c	NULL
mice	NULL
in	NULL
disease	NULL
susceptibility	NULL
,	NULL
only	NULL
some	NULL
will	NULL
be	NULL
involved	NULL
in	NULL
regulation	NULL
of	NULL
the	NULL
balance	NULL
between	NULL
Th1	NULL
and	NULL
Th2	NULL
cells	NULL
Use	NULL
of	NULL
this	NULL
dominant	NULL
monogenic	NULL
trait	NULL
(	NULL
the	NULL
transgene	NULL
)	NULL
could	NULL
facilitate	NULL
identification	NULL
of	NULL
those	NULL
loci	NULL
that	NULL
regulate	NULL
functions	NULL
other	NULL
than	NULL
effector	NULL
T	NULL
cell	NULL
phenotype	NULL
.	NULL

However	NULL
,	NULL
it	NULL
should	NULL
be	NULL
noted	NULL
that	NULL
the	NULL
magnitude	NULL
of	NULL
such	NULL
airway	NULL
hyperresponsiveness	NULL
was	NULL
still	NULL
considerably	NULL
less	NULL
than	NULL
that	NULL
typically	NULL
obtained	NULL
in	NULL
BALB/c	NULL
mice	NULL
(	NULL
Aronica	NULL
,	NULL
M.A	NULL
.	NULL

,	NULL
and	NULL
J.R	NULL
.	NULL

Sheller	NULL
,	NULL
unpublished	NULL
observations	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
the	NULL
susceptibility	NULL
of	NULL
the	NULL
BALB/c	NULL
strain	NULL
to	NULL
allergic	NULL
airway	NULL
disease	NULL
probably	NULL
reflects	NULL
genetic	NULL
contributions	NULL
in	NULL
addition	NULL
to	NULL
its	NULL
tendency	NULL
to	NULL
develop	NULL
robust	NULL
Th2	NULL
responses	NULL
.	NULL

We	NULL
gratefully	NULL
acknowledge	NULL
technical	NULL
assistance	NULL
from	NULL
W.	NULL
Armistead	NULL
and	NULL
D.	NULL
Mitchell	NULL
,	NULL
helpful	NULL
discussions	NULL
and	NULL
a	NULL
critical	NULL
reading	NULL
of	NULL
the	NULL
manuscript	NULL
by	NULL
M.	NULL
Rincon	NULL
,	NULL
G.	NULL
Miller	NULL
,	NULL
T.	NULL
Aune	NULL
,	NULL
and	NULL
L.	NULL
Van	NULL
Kaer	NULL
,	NULL
invaluable	NULL
advice	NULL
from	NULL
and	NULL
discussions	NULL
with	NULL
D.	NULL
Gabrilovich	NULL
,	NULL
and	NULL
assistance	NULL
with	NULL
flow	NULL
cytometry	NULL
from	NULL
J	NULL
.	NULL

Price	NULL
(	NULL
VA	NULL
Medical	NULL
Center	NULL
and	NULL
Vanderbilt	NULL
University	NULL
Cancer	NULL
Center	NULL
Flow	NULL
Cytometry	NULL
Core	NULL
)	NULL
,	NULL
and	NULL
D.	NULL
MacFarland	NULL
(	NULL
Howard	NULL
Hughes	NULL
Medical	NULL
Institute	NULL
Flow	NULL
Cytometry	NULL
Core	NULL
)	NULL
.	NULL

This	NULL
study	NULL
was	NULL
supported	NULL
by	NULL
the	NULL
National	NULL
Institutes	NULL
of	NULL
Health	NULL
(	NULL
NIH	NULL
)	NULL
Cancer	NULL
Center	NULL
grant	NULL
CA-68485	NULL
,	NULL
core	NULL
facilities	NULL
of	NULL
the	NULL
Vanderbilt	NULL
Cancer	NULL
Center	NULL
and	NULL
Diabetes	NULL
Research	NULL
and	NULL
Training	NULL
Center	NULL
(	NULL
DRTC	NULL
;	NULL
P60	NULL
DK20593	NULL
)	NULL
,	NULL
an	NULL
American	NULL
Heart	NULL
Association	NULL
Scientist	NULL
Development	NULL
Award	NULL
(	NULL
J.	NULL
Chen	NULL
)	NULL
,	NULL
a	NULL
Glaxo-Wellcome	NULL
Pulmonary	NULL
Fellowship	NULL
(	NULL
M.A	NULL
.	NULL

Aronica	NULL
)	NULL
,	NULL
NIH	NULL
grant	NULL
GM-15431	NULL
(	NULL
J.	NULL
Sheller	NULL
)	NULL
,	NULL
a	NULL
Leukemia	NULL
Society	NULL
of	NULL
America	NULL
Scholar	NULL
's	NULL
Award	NULL
(	NULL
M.	NULL
Boothby	NULL
)	NULL
,	NULL
NIH	NULL
grant	NULL
R	NULL
01	NULL
GM-42550	NULL
,	NULL
and	NULL
the	NULL
Mark	NULL
Collie	NULL
Pilot	NULL
Project	NULL
Fund	NULL
of	NULL
the	NULL
DRTC	NULL
(	NULL
M.	NULL
Boothby	NULL
)	NULL
.	NULL

Address	NULL
correspondence	NULL
to	NULL
Mark	NULL
Boothby	NULL
,	NULL
Department	NULL
of	NULL
Microbiology	NULL
&	NULL
Immunology	NULL
,	NULL
AA-4214B	NULL
Medical	NULL
Center	NULL
North	NULL
,	NULL
Vanderbilt	NULL
University	NULL
Medical	NULL
School	NULL
,	NULL
Nashville	NULL
,	NULL
TN	NULL
37232-2363	NULL
.	NULL

Phone	NULL
:	NULL
615-343-1699	NULL
;	NULL
Fax	NULL
:	NULL
615-343-9443	NULL
;	NULL
E-mail	NULL
:	NULL
mark.boothby	NULL
@	NULL
memail.vanderbilt.edu	NULL
Received	NULL
for	NULL
publication	NULL
8	NULL
May	NULL
1998	NULL
and	NULL
in	NULL
revised	NULL
form	NULL
24	NULL
August	NULL
1998	NULL
.	NULL

1813	NULL
Youn	NULL
et	NULL
al	NULL
.	NULL

References	NULL
1	NULL
.	NULL

2	NULL
.	NULL

10	NULL
.	NULL

11	NULL
.	NULL

12	NULL
.	NULL

13	NULL
.	NULL

14	NULL
.	NULL

15	NULL
.	NULL

16	NULL
.	NULL

17	NULL
.	NULL

Paul	NULL
,	NULL
W.E	NULL
.	NULL

1991	NULL
.	NULL

Interleukin-4	NULL
:	NULL
a	NULL
prototypic	NULL
immunoregula-tory	NULL
lymphokine	NULL
.	NULL

Blood	NULL
.	NULL

77:1859-1870	NULL
.	NULL

Jansen	NULL
,	NULL
J.H	NULL
.	NULL

,	NULL
W.E	NULL
.	NULL

Fibbe	NULL
,	NULL
R.	NULL
Willemze	NULL
,	NULL
and	NULL
J.C.	NULL
Kluin-Nele-mans	NULL
.	NULL

1990	NULL
.	NULL

Interleukin-4	NULL
:	NULL
a	NULL
regulatory	NULL
protein	NULL
.	NULL

Blut	NULL
.	NULL

60	NULL
:	NULL
269-274.	NULL
.	NULL

Foote	NULL
,	NULL
LC	NULL
.	NULL

,	NULL
R.G	NULL
.	NULL

Howard	NULL
,	NULL
A.	NULL
Marshak-R	NULL
othstein	NULL
,	NULL
and	NULL
TL	NULL
.	NULL

Rothstein	NULL
.	NULL

1996	NULL
.	NULL

IL-4	NULL
induces	NULL
Fas	NULL
resistance	NULL
in	NULL
B	NULL
cells	NULL
.	NULL

J	NULL
Immunol	NULL
.	NULL

157:2749-2753.	NULL
.	NULL

Vella	NULL
,	NULL
A.	NULL
,	NULL
TK	NULL
.	NULL

Teague	NULL
,	NULL
J.	NULL
Ihle	NULL
,	NULL
J.	NULL
Kappler	NULL
,	NULL
and	NULL
P.	NULL
Marrack	NULL
.	NULL

1997	NULL
.	NULL

Interleukin	NULL
4	NULL
(	NULL
IL-4	NULL
)	NULL
or	NULL
IL-7	NULL
prevents	NULL
the	NULL
death	NULL
of	NULL
resting	NULL
T	NULL
cells	NULL
:	NULL
Stat6	NULL
is	NULL
probably	NULL
not	NULL
required	NULL
for	NULL
the	NULL
effect	NULL
of	NULL
IL-4	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

186:325-330.	NULL
.	NULL

Rennick	NULL
,	NULL
D.	NULL
,	NULL
G.	NULL
Yang	NULL
,	NULL
C.	NULL
Muller-Sieburg	NULL
,	NULL
C.	NULL
Smith	NULL
,	NULL
N.	NULL
Arai	NULL
,	NULL
Y.	NULL
Takabe	NULL
,	NULL
and	NULL
L.	NULL
Gemmell	NULL
.	NULL

1987	NULL
.	NULL

Interleukin	NULL
4	NULL
(	NULL
B-cell	NULL
stimulatory	NULL
factor	NULL
1	NULL
)	NULL
can	NULL
enhance	NULL
or	NULL
antagonize	NULL
the	NULL
factor-dependent	NULL
growth	NULL
of	NULL
hemopoietic	NULL
progenitor	NULL
cells	NULL
Proc	NULL
Natl	NULL
.	NULL

Aad	NULL
.	NULL

Sa	NULL
.	NULL

USA	NULL
.	NULL

84:6889-6893.	NULL
.	NULL

Le	NULL
Gros	NULL
,	NULL
G.	NULL
,	NULL
S.Z	NULL
.	NULL

Ben-Sasson	NULL
,	NULL
R	NULL
.	NULL

Seder	NULL
,	NULL
F.D	NULL
.	NULL

Finkleman	NULL
,	NULL
and	NULL
W.E	NULL
.	NULL

Paul	NULL
.	NULL

1990	NULL
.	NULL

Generation	NULL
of	NULL
interleukin	NULL
(	NULL
IL	NULL
)	NULL
-4-producing	NULL
cells	NULL
in	NULL
vivo	NULL
and	NULL
in	NULL
vitro	NULL
:	NULL
IL-2	NULL
and	NULL
IL-4	NULL
are	NULL
required	NULL
for	NULL
in	NULL
vitro	NULL
generation	NULL
of	NULL
IL-4-producing	NULL
cells	NULL
J	NULL
Exp	NULL
.	NULL

Med	NULL
172	NULL
;	NULL
921-929.	NULL
.	NULL

Swain	NULL
,	NULL
S.L	NULL
.	NULL

,	NULL
A.D.	NULL
Weinberg	NULL
,	NULL
M.	NULL
English	NULL
,	NULL
and	NULL
G.	NULL
Huston	NULL
.	NULL

1990	NULL
.	NULL

IL-4	NULL
directs	NULL
the	NULL
development	NULL
of	NULL
Th2	NULL
like	NULL
helper	NULL
effec-tors	NULL
.	NULL

J	NULL
Immunol	NULL
.	NULL

145:3796-3806.	NULL
.	NULL

Abehsira-	NULL
Amar	NULL
,	NULL
O.	NULL
,	NULL
M.	NULL
Gibert	NULL
,	NULL
M.	NULL
Joliy	NULL
,	NULL
J.	NULL
Theze	NULL
,	NULL
and	NULL
D.	NULL
Jankovic	NULL
.	NULL

1992	NULL
.	NULL

IL-4	NULL
plays	NULL
a	NULL
dominant	NULL
role	NULL
in	NULL
the	NULL
differential	NULL
development	NULL
of	NULL
ThO	NULL
into	NULL
Th1	NULL
and	NULL
Th2	NULL
cells	NULL
.	NULL

J	NULL
Immunol	NULL
.	NULL

148	NULL
:	NULL
3820-3829.	NULL
.	NULL

Kim	NULL
,	NULL
J.	NULL
,	NULL
A	NULL
.	NULL

Woods	NULL
,	NULL
E.	NULL
Becker-Dunn	NULL
,	NULL
and	NULL
K.	NULL
Bottomly	NULL
.	NULL

1985	NULL
.	NULL

Distinct	NULL
functional	NULL
phenotypes	NULL
of	NULL
clones	NULL
Ia-restricted	NULL
helper	NULL
T	NULL
cells	NULL
.	NULL

J	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

162:188-201	NULL
.	NULL

Mosmann	NULL
,	NULL
T.R	NULL
.	NULL

,	NULL
H.	NULL
Cherwinski	NULL
,	NULL
M.W	NULL
.	NULL

Bond	NULL
,	NULL
M.A	NULL
.	NULL

Giedlin	NULL
,	NULL
and	NULL
R	NULL
.L	NULL
.	NULL

Coffman	NULL
.	NULL

1986	NULL
.	NULL

Two	NULL
types	NULL
of	NULL
murine	NULL
helper	NULL
T	NULL
cell	NULL
clone	NULL
.	NULL

I	NULL
.	NULL

Definition	NULL
according	NULL
to	NULL
profiles	NULL
of	NULL
lymphokine	NULL
activities	NULL
and	NULL
secreted	NULL
proteins	NULL
.	NULL

J	NULL
Immunol	NULL
.	NULL

136:2348-2357	NULL
.	NULL

Hsich	NULL
,	NULL
C.-S.	NULL
,	NULL
SE	NULL
.	NULL

Macatonia	NULL
,	NULL
C.S.Tripp	NULL
,	NULL
S.F	NULL
.	NULL

Wolf	NULL
,	NULL
A.	NULL
O'Garra	NULL
,	NULL
and	NULL
K.M	NULL
.	NULL

Murphy	NULL
.	NULL

1993	NULL
.	NULL

Development	NULL
of	NULL
Tyl	NULL
CD4*	NULL
T	NULL
cells	NULL
through	NULL
IL-12	NULL
produced	NULL
by	NULL
Listeria-induced	NULL
macrophages	NULL
.	NULL

Saenee	NULL
.	NULL

260:547-549	NULL
.	NULL

Mosmann	NULL
,	NULL
TR	NULL
.	NULL

,	NULL
and	NULL
RL	NULL
.	NULL

Coffman	NULL
.	NULL

1989	NULL
.	NULL

Th1	NULL
and	NULL
Th2	NULL
cells	NULL
:	NULL
different	NULL
patterns	NULL
of	NULL
lymphokine	NULL
secretion	NULL
lead	NULL
to	NULL
different	NULL
functional	NULL
properties	NULL
.	NULL

Annu	NULL
.	NULL

Rev	NULL
.	NULL

Immunol	NULL
.	NULL

7:145-173	NULL
.	NULL

Swain	NULL
,	NULL
S.L	NULL
.	NULL

,	NULL
LM	NULL
.	NULL

Bradley	NULL
,	NULL
M.	NULL
Croft	NULL
,	NULL
S.	NULL
Tonkowagy	NULL
,	NULL
G.	NULL
At-kins	NULL
,	NULL
A.D.	NULL
Weinberg	NULL
,	NULL
D.D	NULL
.	NULL

Duncan	NULL
,	NULL
S.M	NULL
.	NULL

Hedrick	NULL
,	NULL
R.W	NULL
.	NULL

Dutton	NULL
,	NULL
and	NULL
G.	NULL
Huston	NULL
.	NULL

1991	NULL
.	NULL

Helper	NULL
T-cell	NULL
subsets	NULL
:	NULL
pheno-type	NULL
,	NULL
function	NULL
and	NULL
the	NULL
role	NULL
lymphokines	NULL
in	NULL
regulating	NULL
their	NULL
development	NULL
.	NULL

Immunol	NULL
.	NULL

Rev	NULL
.	NULL

123:115-144	NULL
.	NULL

Seder	NULL
,	NULL
R.A.	NULL
,	NULL
R.N	NULL
.	NULL

Germain	NULL
,	NULL
P.S	NULL
.	NULL

Linsley	NULL
,	NULL
and	NULL
WE	NULL
.	NULL

Paul	NULL
.	NULL

1994	NULL
.	NULL

CD28-mediated	NULL
costimulation	NULL
of	NULL
interleukin	NULL
2	NULL
(	NULL
IL-2	NULL
)	NULL
production	NULL
plays	NULL
a	NULL
critical	NULL
role	NULL
in	NULL
T	NULL
cell	NULL
priming	NULL
for	NULL
IL-4	NULL
and	NULL
interferon	NULL
y	NULL
production	NULL
.	NULL

J	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

179:299-304	NULL
.	NULL

Cua	NULL
,	NULL
D.J	NULL
.	NULL

,	NULL
RL	NULL
.	NULL

Coffman	NULL
,	NULL
and	NULL
S.A.	NULL
Stohlman	NULL
.	NULL

1996	NULL
.	NULL

Exposure	NULL
to	NULL
T	NULL
helper	NULL
2	NULL
cytokines	NULL
in	NULL
vivo	NULL
before	NULL
encounter	NULL
with	NULL
antigen	NULL
selects	NULL
for	NULL
T	NULL
helper	NULL
subsets	NULL
via	NULL
alterations	NULL
in	NULL
antigen-presenting	NULL
cell	NULL
function	NULL
.	NULL

J	NULL
Immunol	NULL
.	NULL

157:2830-2836	NULL
.	NULL

R	NULL
ulifson	NULL
,	NULL
IC	NULL
.	NULL

,	NULL
A.I	NULL
.	NULL

Sperling	NULL
,	NULL
P.E	NULL
.	NULL

Fields	NULL
,	NULL
FW	NULL
.	NULL

Fitch	NULL
,	NULL
and	NULL
J.A	NULL
.	NULL

Bluestone	NULL
.	NULL

1997	NULL
.	NULL

CD28	NULL
costimulation	NULL
promotes	NULL
the	NULL
production	NULL
of	NULL
Th2	NULL
cytokines	NULL
.	NULL

J	NULL
Immunol	NULL
.	NULL

158:658-665	NULL
.	NULL

Fowell	NULL
,	NULL
D.J	NULL
.	NULL

,	NULL
J.	NULL
Magram	NULL
,	NULL
C.W	NULL
.	NULL

Turck	NULL
,	NULL
N.	NULL
Killeen	NULL
,	NULL
and	NULL
R	NULL
.M	NULL
.	NULL

Locksley	NULL
.	NULL

1997	NULL
.	NULL

Impaired	NULL
Th2	NULL
subset	NULL
development	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
CD4	NULL
.	NULL

Immunity	NULL
.	NULL

6:559-569	NULL
.	NULL

1814	NULL
18	NULL
.	NULL

19	NULL
.	NULL

20	NULL
.	NULL

21	NULL
.	NULL

22	NULL
.	NULL

23	NULL
.	NULL

24	NULL
.	NULL

25	NULL
.	NULL

26	NULL
.	NULL

27	NULL
.	NULL

28	NULL
.	NULL

29	NULL
.	NULL

30	NULL
.	NULL

31	NULL
.	NULL

32	NULL
.	NULL

33	NULL
.	NULL

34	NULL
.	NULL

Constant	NULL
,	NULL
SL	NULL
.	NULL

,	NULL
and	NULL
K.	NULL
Bottomly	NULL
.	NULL

1997	NULL
.	NULL

Induction	NULL
of	NULL
Th1	NULL
and	NULL
Th2	NULL
CD4+	NULL
T	NULL
cell	NULL
responses	NULL
:	NULL
the	NULL
alternative	NULL
approaches	NULL
.	NULL

Annu	NULL
.	NULL

Rev	NULL
.	NULL

Immunol	NULL
.	NULL

15:297-322	NULL
.	NULL

Magram	NULL
,	NULL
J.	NULL
,	NULL
S.E	NULL
.	NULL

Connaughton	NULL
,	NULL
R.R	NULL
.	NULL

Warrier	NULL
,	NULL
D.M	NULL
.	NULL

Carva-jal	NULL
,	NULL
C.-Y	NULL
.	NULL

Wu	NULL
,	NULL
J.	NULL
Ferrante	NULL
,	NULL
C.	NULL
Stewart	NULL
,	NULL
U.	NULL
Sarmiento	NULL
,	NULL
D.A	NULL
.	NULL

Faherty	NULL
,	NULL
and	NULL
MK	NULL
.	NULL

Gately	NULL
.	NULL

1996	NULL
.	NULL

IL-12-deficient	NULL
mice	NULL
are	NULL
defective	NULL
in	NULL
IFNy	NULL
production	NULL
and	NULL
type	NULL
1	NULL
cytokine	NULL
responses	NULL
.	NULL

Immunity	NULL
.	NULL

4:471-481	NULL
.	NULL

Wenner	NULL
,	NULL
C.A	NULL
.	NULL

,	NULL
M.L	NULL
.	NULL

Guler	NULL
,	NULL
S.E	NULL
.	NULL

Macatonia	NULL
,	NULL
A.	NULL
O	NULL
'Garra	NULL
,	NULL
and	NULL
K.M	NULL
.	NULL

Murphy	NULL
.	NULL

1996	NULL
.	NULL

R	NULL
oles	NULL
of	NULL
IFN-y	NULL
and	NULL
IFN	NULL
-a	NULL
in	NULL
IL-12-induced	NULL
T	NULL
helper	NULL
cell-1	NULL
development	NULL
.	NULL

J	NULL
Immunol	NULL
.	NULL

156:1442-1447	NULL
.	NULL

Seder	NULL
,	NULL
R.A.	NULL
,	NULL
R.	NULL
Gazzinelli	NULL
,	NULL
A.	NULL
Sher	NULL
,	NULL
and	NULL
W.E	NULL
.	NULL

Paul	NULL
.	NULL

1993	NULL
.	NULL

IL-12	NULL
acts	NULL
directly	NULL
on	NULL
CD4*	NULL
T	NULL
cells	NULL
to	NULL
enhance	NULL
priming	NULL
for	NULL
IFNy	NULL
production	NULL
and	NULL
diminishes	NULL
IL-4	NULL
inhibition	NULL
of	NULL
such	NULL
priming	NULL
.	NULL

Proc	NULL
Natl	NULL
.	NULL

Aad	NULL
.	NULL

Sa	NULL
.	NULL

USA	NULL
.	NULL

90:10188-10192	NULL
.	NULL

Kopf	NULL
,	NULL
M.	NULL
,	NULL
G.	NULL
Le	NULL
Gros	NULL
,	NULL
M.	NULL
Bachmann	NULL
,	NULL
M.C	NULL
.	NULL

Lamers	NULL
,	NULL
H.	NULL
Bluethmann	NULL
,	NULL
and	NULL
G.	NULL
Kohler	NULL
.	NULL

1993	NULL
.	NULL

Disruption	NULL
of	NULL
the	NULL
murine	NULL
IL-4	NULL
gene	NULL
blocks	NULL
Th2	NULL
cytokine	NULL
responses	NULL
.	NULL

Natwre	NULL
.	NULL

362:245-248	NULL
.	NULL

Burstein	NULL
,	NULL
H.J	NULL
.	NULL

,	NULL
R	NULL
.I	NULL
.	NULL

Tepper	NULL
,	NULL
P.	NULL
Leder	NULL
,	NULL
and	NULL
A.K	NULL
.	NULL

Abbas	NULL
.	NULL

1991	NULL
.	NULL

Humoral	NULL
immune	NULL
functions	NULL
in	NULL
IL-4	NULL
transgenic	NULL
mice	NULL
.	NULL

J	NULL
Immunol	NULL
.	NULL

147:2950-2956	NULL
.	NULL

Yoshimoto	NULL
,	NULL
K.	NULL
,	NULL
SL	NULL
.	NULL

Swain	NULL
,	NULL
and	NULL
LM	NULL
.	NULL

Bradley	NULL
.	NULL

1996	NULL
.	NULL

Enhanced	NULL
development	NULL
of	NULL
Th2-like	NULL
primary	NULL
CD4	NULL
effectors	NULL
in	NULL
response	NULL
to	NULL
sustained	NULL
exposure	NULL
to	NULL
limited	NULL
rIL-4	NULL
in	NULL
vivo	NULL
.	NULL

J	NULL
Immunol	NULL
.	NULL

156:3267-3274	NULL
.	NULL

Bradley	NULL
,	NULL
LM	NULL
.	NULL

,	NULL
D.K	NULL
.	NULL

Dalton	NULL
,	NULL
and	NULL
M.	NULL
Croft	NULL
.	NULL

1996	NULL
.	NULL

A	NULL
direct	NULL
role	NULL
for	NULL
IFN-7y	NULL
in	NULL
regulation	NULL
of	NULL
Th1	NULL
cell	NULL
development	NULL
.	NULL

J	NULL
Immunol	NULL
.	NULL

157:1350-1358	NULL
.	NULL

Dighe	NULL
,	NULL
A.S.	NULL
,	NULL
D.	NULL
Campbell	NULL
,	NULL
C.-S.	NULL
Hsieh	NULL
,	NULL
S.	NULL
Clarke	NULL
,	NULL
D.R	NULL
.	NULL

Greaves	NULL
,	NULL
S.	NULL
Gordon	NULL
,	NULL
K.M	NULL
.	NULL

Murphy	NULL
,	NULL
and	NULL
R.D	NULL
.	NULL

Schreiber	NULL
.	NULL

1995	NULL
.	NULL

Tissue-specific	NULL
targeting	NULL
of	NULL
cytokine	NULL
unresponsiveness	NULL
in	NULL
transgenic	NULL
mice	NULL
.	NULL

Immunity	NULL
.	NULL

3:657-666	NULL
.	NULL

Lohoff	NULL
,	NULL
M.	NULL
,	NULL
D.	NULL
Ferrick	NULL
,	NULL
H.-W.	NULL
Mittrucker	NULL
,	NULL
G.S	NULL
.	NULL

Duncan	NULL
,	NULL
S.	NULL
Bischof	NULL
,	NULL
M.	NULL
Rollinghoff	NULL
,	NULL
and	NULL
T.W	NULL
.	NULL

Mak	NULL
.	NULL

1997	NULL
.	NULL

Interferon	NULL
regulatory	NULL
factor-1	NULL
is	NULL
required	NULL
for	NULL
a	NULL
T	NULL
helper	NULL
1	NULL
immune	NULL
response	NULL
in	NULL
vivo	NULL
.	NULL

Immunity	NULL
.	NULL

6:681-689	NULL
.	NULL

Taki	NULL
,	NULL
S.	NULL
,	NULL
T.	NULL
Sato	NULL
,	NULL
K.	NULL
Ogasawara	NULL
,	NULL
T.	NULL
Fukuda	NULL
,	NULL
M.	NULL
Sato	NULL
,	NULL
S.	NULL
Hida	NULL
,	NULL
G.	NULL
Suzuki	NULL
,	NULL
M.	NULL
Mitsuyama	NULL
,	NULL
E.-H.	NULL
Shin	NULL
,	NULL
S.	NULL
Kojima	NULL
,	NULL
et	NULL
al	NULL
.	NULL

1997	NULL
.	NULL

Multistage	NULL
regulation	NULL
of	NULL
Th-1	NULL
type	NULL
immune	NULL
responses	NULL
by	NULL
the	NULL
transcription	NULL
factor	NULL
IRF-1	NULL
.	NULL

Immunity	NULL
.	NULL

6:673-679	NULL
.	NULL

Stack	NULL
,	NULL
R.M	NULL
.	NULL

,	NULL
D.J	NULL
.	NULL

Lenschow	NULL
,	NULL
G.S	NULL
.	NULL

Gray	NULL
,	NULL
J.A	NULL
.	NULL

Bluestone	NULL
,	NULL
and	NULL
FEW	NULL
.	NULL

Fitch	NULL
.	NULL

1994	NULL
.	NULL

IL-4	NULL
treatment	NULL
of	NULL
small	NULL
splenic	NULL
B	NULL
cells	NULL
induces	NULL
the	NULL
costimulatory	NULL
molecules	NULL
B7-1	NULL
and	NULL
B7-2	NULL
.	NULL

J	NULL
Immunol	NULL
.	NULL

152:5723-5733	NULL
.	NULL

Mond	NULL
,	NULL
J.J.	NULL
,	NULL
J.	NULL
Carman	NULL
,	NULL
C.	NULL
Sarma	NULL
,	NULL
J.	NULL
Ohara	NULL
,	NULL
and	NULL
F.D	NULL
.	NULL

Finkel-man	NULL
.	NULL

1986	NULL
.	NULL

Interferon-y	NULL
suppresses	NULL
B	NULL
cell	NULL
stimulation	NULL
factor	NULL
(	NULL
BSF-1	NULL
)	NULL
induction	NULL
of	NULL
class	NULL
II	NULL
MHC	NULL
determinants	NULL
on	NULL
B	NULL
cells	NULL
.	NULL

J	NULL
Immunol	NULL
.	NULL

137:3534-3537	NULL
.	NULL

Boothby	NULL
,	NULL
M.	NULL
,	NULL
E.	NULL
Gravallese	NULL
,	NULL
H.-C.	NULL
Liou	NULL
,	NULL
and	NULL
LH	NULL
.	NULL

Glimcher	NULL
.	NULL

1988	NULL
.	NULL

A	NULL
DNA	NULL
binding	NULL
protein	NULL
regulated	NULL
by	NULL
IL-4	NULL
and	NULL
by	NULL
dif	NULL
ferentiation	NULL
in	NULL
B	NULL
cells	NULL
Sdene	NULL
.	NULL

242:1559-1562	NULL
.	NULL

Noben-Trauth	NULL
,	NULL
N.	NULL
,	NULL
P.	NULL
Kropf	NULL
,	NULL
and	NULL
I.	NULL
Muller	NULL
.	NULL

1996	NULL
.	NULL

Susceptibility	NULL
to	NULL
Leishmania	NULL
major	NULL
infection	NULL
in	NULL
interleukin-4-deficient	NULL
mice	NULL
.	NULL

Sdene	NULL
.	NULL

271:987-990	NULL
.	NULL

Kropf	NULL
,	NULL
P.	NULL
,	NULL
R.	NULL
Etges	NULL
,	NULL
L.	NULL
Schopf	NULL
,	NULL
C.	NULL
Chung	NULL
,	NULL
J.	NULL
Sypek	NULL
,	NULL
and	NULL
I.	NULL
Muller	NULL
.	NULL

1997	NULL
.	NULL

Characterization	NULL
of	NULL
T	NULL
cell-mediated	NULL
responses	NULL
in	NULL
nonhealing	NULL
and	NULL
healing	NULL
Leishmania	NULL
major	NULL
infections	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
endogenous	NULL
IL-4	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

159:3434-3443	NULL
.	NULL

Hershey	NULL
,	NULL
G.KK	NULL
.	NULL

,	NULL
M.F	NULL
.	NULL

Friedrich	NULL
,	NULL
L.A.	NULL
Esswein	NULL
,	NULL
M.L.Tho-mas	NULL
,	NULL
and	NULL
T.A	NULL
.	NULL

Chatila	NULL
.	NULL

1997	NULL
.	NULL

The	NULL
association	NULL
of	NULL
atopy	NULL
with	NULL
a	NULL
gain-of-function	NULL
mutation	NULL
in	NULL
the	NULL
alpha	NULL
subunit	NULL
of	NULL
the	NULL
inter	NULL
In	NULL
Vivo	NULL
Function	NULL
of	NULL
an	NULL
IL-2R/IL-4R	NULL
Chimera	NULL
35	NULL
.	NULL

36	NULL
.	NULL

37	NULL
.	NULL

38	NULL
.	NULL

39	NULL
.	NULL

40	NULL
.	NULL

41	NULL
.	NULL

42	NULL
.	NULL

43	NULL
.	NULL

44	NULL
.	NULL

45	NULL
.	NULL

46	NULL
.	NULL

47	NULL
.	NULL

48	NULL
.	NULL

49	NULL
.	NULL

50.	NULL
leukin-4	NULL
receptor	NULL
.	NULL

N.	NULL
Engl	NULL
.	NULL

J.	NULL
Med	NULL
.	NULL

337:1720-1725	NULL
.	NULL

Wang	NULL
,	NULL
H.Y	NULL
.	NULL

,	NULL
W.E	NULL
.	NULL

Paul	NULL
,	NULL
and	NULL
A.D.	NULL
Keegan	NULL
.	NULL

1996	NULL
.	NULL

IL-4	NULL
function	NULL
can	NULL
be	NULL
transferred	NULL
to	NULL
the	NULL
IL-2	NULL
receptor	NULL
by	NULL
tyrosine	NULL
containing	NULL
sequences	NULL
found	NULL
in	NULL
the	NULL
IL-4	NULL
receptor	NULL
«	NULL
chain	NULL
.	NULL

Immunity	NULL
.	NULL

4:113-121	NULL
.	NULL

Nemoto	NULL
,	NULL
T.	NULL
,	NULL
T.	NULL
Takeshita	NULL
,	NULL
N.	NULL
Ishii	NULL
,	NULL
M.	NULL
Kondo	NULL
,	NULL
M.	NULL
Higuchi	NULL
,	NULL
S.	NULL
Satomi	NULL
,	NULL
M.	NULL
Nakamura	NULL
,	NULL
S.	NULL
Mori	NULL
,	NULL
and	NULL
K.	NULL
Sugamura	NULL
.	NULL

1995	NULL
.	NULL

Differences	NULL
in	NULL
the	NULL
interleukin-2	NULL
(	NULL
IL-2	NULL
)	NULL
receptor	NULL
system	NULL
in	NULL
human	NULL
and	NULL
mouse	NULL
:	NULL
«	NULL
chain	NULL
is	NULL
required	NULL
for	NULL
formation	NULL
of	NULL
the	NULL
functional	NULL
mouse	NULL
IL-2	NULL
receptor	NULL
.	NULL

Eur	NULL
J	NULL
Immunol	NULL
.	NULL

25:3001-3005	NULL
.	NULL

Hattori	NULL
,	NULL
M.	NULL
,	NULL
H.	NULL
Okazaki	NULL
,	NULL
Y.	NULL
Ishida	NULL
,	NULL
M.	NULL
Onuma	NULL
,	NULL
S.	NULL
Kano	NULL
,	NULL
T.	NULL
Honjo	NULL
,	NULL
and	NULL
N.	NULL
Minato	NULL
.	NULL

1990	NULL
.	NULL

Expression	NULL
of	NULL
murine	NULL
IL-2	NULL
receptor	NULL
B-chain	NULL
on	NULL
thymic	NULL
and	NULL
splenic	NULL
lymphocyte	NULL
subpopu-lations	NULL
as	NULL
revealed	NULL
by	NULL
the	NULL
IL-2-induced	NULL
proliferative	NULL
response	NULL
in	NULL
human	NULL
IL-2	NULL
receptor	NULL
«	NULL
-chain	NULL
transgenic	NULL
mice	NULL
.	NULL

J	NULL
Immunol	NULL
.	NULL

144:3809-3815	NULL
.	NULL

Asano	NULL
,	NULL
M.	NULL
,	NULL
Y.	NULL
Ishida	NULL
,	NULL
H.	NULL
Sabe	NULL
,	NULL
M.	NULL
Kondo	NULL
,	NULL
K.	NULL
Sugamura	NULL
,	NULL
and	NULL
T.	NULL
Honjo	NULL
.	NULL

1994	NULL
.	NULL

IL-2	NULL
can	NULL
support	NULL
growth	NULL
of	NULL
CD8+	NULL
T	NULL
cells	NULL
but	NULL
not	NULL
CD4+	NULL
T	NULL
cells	NULL
of	NULL
human	NULL
IL-2	NULL
receptor	NULL
B-chain	NULL
transgenic	NULL
mice	NULL
.	NULL

J	NULL
Immunol	NULL
.	NULL

153:5373-5381	NULL
.	NULL

Boothby	NULL
,	NULL
M.	NULL
,	NULL
A.L	NULL
.	NULL

Mora	NULL
,	NULL
D.C.	NULL
Scherer	NULL
,	NULL
J.	NULL
Brockman	NULL
,	NULL
and	NULL
D.W.	NULL
Ballard	NULL
.	NULL

1997	NULL
.	NULL

Perturbation	NULL
of	NULL
the	NULL
T	NULL
lymphocyte	NULL
lineage	NULL
in	NULL
transgenic	NULL
mice	NULL
expressing	NULL
a	NULL
constitutive	NULL
repressor	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
.	NULL

J	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

185:1897-1907	NULL
.	NULL

Kono	NULL
,	NULL
T.	NULL
,	NULL
T.	NULL
Doi	NULL
,	NULL
G.	NULL
Yamada	NULL
,	NULL
M.	NULL
Hatakeyama	NULL
,	NULL
S.	NULL
Mina	NULL
moto	NULL
,	NULL
M.	NULL
T	NULL
sudo	NULL
,	NULL
M.	NULL
Miyasaka	NULL
,	NULL
T.	NULL
Miyata	NULL
,	NULL
and	NULL
T.	NULL
Taniguchi	NULL
.	NULL

1990	NULL
.	NULL

Murine	NULL
interleukin	NULL
2	NULL
receptor	NULL
B	NULL
chain	NULL
:	NULL
dysregulated	NULL
gene	NULL
expression	NULL
in	NULL
lymphoma	NULL
line	NULL
EL-4	NULL
caused	NULL
by	NULL
a	NULL
promoter	NULL
insertion	NULL
.	NULL

Proc	NULL
Natl	NULL
.	NULL

Aad	NULL
.	NULL

Sa	NULL
.	NULL

USA	NULL
.	NULL

87:1806-1810	NULL
.	NULL

Mosley	NULL
,	NULL
B.	NULL
,	NULL
M.P	NULL
.	NULL

Beckmann	NULL
,	NULL
C.J	NULL
.	NULL

March	NULL
,	NULL
R	NULL
.L	NULL
.	NULL

Idzerda	NULL
,	NULL
S.D	NULL
.	NULL

Gimpel	NULL
,	NULL
T.	NULL
VandenBos	NULL
,	NULL
D.	NULL
Friend	NULL
,	NULL
A.	NULL
Alpert	NULL
,	NULL
D.	NULL
Anderson	NULL
,	NULL
J.	NULL
Jackson	NULL
,	NULL
et	NULL
al	NULL
.	NULL

1989	NULL
.	NULL

The	NULL
murine	NULL
interleukin	NULL
4	NULL
receptor	NULL
:	NULL
molecular	NULL
cloning	NULL
and	NULL
characterization	NULL
of	NULL
secreted	NULL
and	NULL
membrane	NULL
bound	NULL
forms	NULL
.	NULL

Cell	NULL
.	NULL

59:335-348	NULL
.	NULL

Lewis	NULL
,	NULL
D.B	NULL
.	NULL

,	NULL
C.C	NULL
.	NULL

Yu	NULL
,	NULL
K.A	NULL
.	NULL

Forbush	NULL
,	NULL
J.	NULL
Carpenter	NULL
,	NULL
T.A	NULL
.	NULL

Sato	NULL
,	NULL
A.	NULL
Grossman	NULL
,	NULL
D.H.	NULL
Liggitt	NULL
,	NULL
and	NULL
R.M	NULL
.	NULL

Perlmutter	NULL
.	NULL

1989	NULL
.	NULL

Interleukin	NULL
4	NULL
expressed	NULL
in	NULL
situ	NULL
selectively	NULL
alters	NULL
thymocyte	NULL
development	NULL
.	NULL

J	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

173:89-100	NULL
.	NULL

Ryan	NULL
,	NULL
J.J.	NULL
,	NULL
LJ	NULL
.	NULL

McReynolds	NULL
,	NULL
A.	NULL
Keegan	NULL
,	NULL
L.-H.	NULL
Wang	NULL
,	NULL
E.	NULL
Garfein	NULL
,	NULL
P.	NULL
Rothman	NULL
,	NULL
K.	NULL
Nelms	NULL
,	NULL
and	NULL
W.E	NULL
.	NULL

Paul	NULL
.	NULL

1996	NULL
.	NULL

Growth	NULL
and	NULL
gene	NULL
expression	NULL
are	NULL
predominantly	NULL
controlled	NULL
by	NULL
distinct	NULL
regions	NULL
of	NULL
the	NULL
human	NULL
IL-4	NULL
receptor	NULL
.	NULL

Immunity	NULL
.	NULL

4:123-132	NULL
.	NULL

Wang	NULL
,	NULL
D.-Z	NULL
.	NULL

,	NULL
A.L	NULL
.	NULL

Cherrington	NULL
,	NULL
B.M	NULL
.	NULL

Famakin-Mosuro	NULL
,	NULL
and	NULL
M.	NULL
Boothby	NULL
.	NULL

1996	NULL
.	NULL

Independent	NULL
pathways	NULL
to	NULL
de-repression	NULL
of	NULL
the	NULL
mouse	NULL
immunoglobulin	NULL
heavy	NULL
chain	NULL
epsilon	NULL
germ-line	NULL
promoter	NULL
.	NULL

Int	NULL
.	NULL

Immunol	NULL
.	NULL

8:977-989	NULL
.	NULL

Schindler	NULL
,	NULL
C.	NULL
,	NULL
K.	NULL
Shuai	NULL
,	NULL
V.R	NULL
.	NULL

Prezioso	NULL
,	NULL
and	NULL
J.E	NULL
.	NULL

Darnell	NULL
,	NULL
Jr.	NULL
1992	NULL
.	NULL

Interferon-dependent	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
a	NULL
latent	NULL
cytoplasmic	NULL
transcription	NULL
factor	NULL
.	NULL

Sdere	NULL
.	NULL

257:809-813	NULL
.	NULL

Tu	NULL
,	NULL
Y.-P	NULL
,	NULL
G.L	NULL
.	NULL

Larsen	NULL
,	NULL
and	NULL
G.L	NULL
.	NULL

Irvin	NULL
.	NULL

1995	NULL
.	NULL

Utility	NULL
of	NULL
murine	NULL
systems	NULL
to	NULL
study	NULL
asthma	NULL
pathogenesis	NULL
.	NULL

Eur	NULL
.	NULL

Respir	NULL
Rev	NULL
.	NULL

5:224-230	NULL
.	NULL

Irvin	NULL
,	NULL
C.G	NULL
.	NULL

,	NULL
Y.-P.	NULL
Tu	NULL
,	NULL
JR.	NULL
Sheller	NULL
,	NULL
and	NULL
C.D	NULL
.	NULL

Funk	NULL
.	NULL

1997	NULL
.	NULL

5-Lipoxygenase	NULL
products	NULL
are	NULL
necessary	NULL
for	NULL
ovalbumin-induced	NULL
airway	NULL
responsiveness	NULL
in	NULL
mice	NULL
.	NULL

Am	NULL
.	NULL

J	NULL
Physiol	NULL
.	NULL

272	NULL
:	NULL
L1053-11058	NULL
.	NULL

Swain	NULL
,	NULL
SL	NULL
.	NULL

1994	NULL
.	NULL

Generation	NULL
and	NULL
in	NULL
vivo	NULL
persistence	NULL
of	NULL
polarized	NULL
Th1	NULL
and	NULL
Th2	NULL
memory	NULL
cells	NULL
.	NULL

Immunity	NULL
.	NULL

1:543-552	NULL
.	NULL

O'Shea	NULL
,	NULL
J.J.	NULL
1997	NULL
.	NULL

Jaks	NULL
,	NULL
ST	NULL
AT	NULL
's	NULL
,	NULL
cytokine	NULL
signal	NULL
transduction	NULL
,	NULL
and	NULL
immunoregulation	NULL
:	NULL
are	NULL
we	NULL
there	NULL
yet	NULL
?	NULL

Immunity	NULL
.	NULL

7:1-11	NULL
.	NULL

Keegan	NULL
,	NULL
A.D.	NULL
,	NULL
K.	NULL
Nelms	NULL
,	NULL
M.	NULL
White	NULL
,	NULL
L.-M.	NULL
Wang	NULL
,	NULL
JH	NULL
.	NULL

1815	NULL
Youn	NULL
et	NULL
al	NULL
.	NULL

51	NULL
.	NULL

52	NULL
.	NULL

53	NULL
.	NULL

54	NULL
.	NULL

55	NULL
.	NULL

56	NULL
.	NULL

57	NULL
.	NULL

58	NULL
.	NULL

59	NULL
.	NULL

60	NULL
.	NULL

61	NULL
.	NULL

62	NULL
.	NULL

63	NULL
.	NULL

64	NULL
.	NULL

65	NULL
.	NULL

66	NULL
.	NULL

Pierce	NULL
,	NULL
and	NULL
W.E	NULL
.	NULL

Paul	NULL
.	NULL

1994	NULL
.	NULL

An	NULL
IL-4	NULL
receptor	NULL
region	NULL
containing	NULL
an	NULL
insulin	NULL
receptor	NULL
motif	NULL
is	NULL
important	NULL
for	NULL
IL-4-mediated	NULL
IR	NULL
S-	NULL
1	NULL
phosphorylation	NULL
and	NULL
cell	NULL
growth	NULL
.	NULL

Cell	NULL
.	NULL

76:811-820	NULL
.	NULL

Welham	NULL
,	NULL
M.J.	NULL
,	NULL
V.	NULL
Duronio	NULL
,	NULL
and	NULL
J.W	NULL
.	NULL

Schrader	NULL
.	NULL

1994	NULL
.	NULL

Inter-leukin-4-dependent	NULL
proliferation	NULL
dissociates	NULL
p44~	NULL
!	NULL

,	NULL
and	NULL
p21	NULL
``	NULL
activation	NULL
from	NULL
cell	NULL
growth	NULL
.	NULL

J	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

269	NULL
:	NULL
5865-5873	NULL
.	NULL

Bendelac	NULL
,	NULL
A.	NULL
,	NULL
M.N	NULL
.	NULL

Rivera	NULL
,	NULL
S.-H.	NULL
Park	NULL
,	NULL
and	NULL
J.H	NULL
.	NULL

Roark	NULL
.	NULL

1997	NULL
.	NULL

Mouse	NULL
CD1-specific	NULL
NK1	NULL
T	NULL
cells	NULL
:	NULL
development	NULL
,	NULL
spec-ificity	NULL
,	NULL
and	NULL
function	NULL
.	NULL

Annu	NULL
.	NULL

Rev	NULL
.	NULL

Immunol	NULL
.	NULL

15:535-562	NULL
.	NULL

Zheng	NULL
,	NULL
W.-p.	NULL
,	NULL
and	NULL
R.A.	NULL
Flavell	NULL
.	NULL

1997	NULL
.	NULL

The	NULL
transcription	NULL
factor	NULL
GATA-3	NULL
is	NULL
necessary	NULL
and	NULL
sufficient	NULL
for	NULL
Th2	NULL
cytokine	NULL
gene	NULL
expression	NULL
in	NULL
CD4	NULL
T	NULL
cells	NULL
.	NULL

Cell	NULL
.	NULL

89:587-596	NULL
.	NULL

Bradley	NULL
,	NULL
LM	NULL
.	NULL

,	NULL
D.D	NULL
.	NULL

Duncan	NULL
,	NULL
K.	NULL
Yoshimoto	NULL
,	NULL
and	NULL
S.L	NULL
.	NULL

Swain	NULL
.	NULL

1993	NULL
.	NULL

Memory	NULL
effectors	NULL
:	NULL
a	NULL
potent	NULL
,	NULL
IL-4-secreting	NULL
helper	NULL
T	NULL
cell	NULL
population	NULL
that	NULL
develops	NULL
in	NULL
vivo	NULL
after	NULL
restimulation	NULL
with	NULL
antigen	NULL
.	NULL

J	NULL
Immunol	NULL
.	NULL

150:3119-3130	NULL
.	NULL

Natesan	NULL
,	NULL
M.	NULL
,	NULL
Z.	NULL
R	NULL
azi-	NULL
Wolf	NULL
,	NULL
and	NULL
H.	NULL
Reiser	NULL
.	NULL

1996	NULL
.	NULL

Costimulation	NULL
of	NULL
IL-4	NULL
production	NULL
by	NULL
murine	NULL
B7-1	NULL
and	NULL
B7-2	NULL
molecules	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

156:2783-2791	NULL
.	NULL

Seder	NULL
,	NULL
R.A.	NULL
,	NULL
and	NULL
W	NULL
.E	NULL
.	NULL

Paul	NULL
.	NULL

Acquisition	NULL
of	NULL
lymphokine-pro-ducing	NULL
phenotype	NULL
by	NULL
CD4*	NULL
T	NULL
cells	NULL
.	NULL

Annu	NULL
.	NULL

Rev	NULL
.	NULL

Immunol	NULL
.	NULL

12	NULL
:	NULL
635-673	NULL
.	NULL

Finkelman	NULL
,	NULL
F.D	NULL
.	NULL

,	NULL
J.	NULL
Holmes	NULL
,	NULL
LM	NULL
.	NULL

Katona	NULL
,	NULL
J.F	NULL
.	NULL

Urban	NULL
,	NULL
Jr.	NULL
,	NULL
M.P	NULL
.	NULL

Beckmann	NULL
,	NULL
LS	NULL
.	NULL

Park	NULL
,	NULL
K.A	NULL
.	NULL

Schooley	NULL
,	NULL
RL	NULL
.	NULL

Coffman	NULL
,	NULL
TR	NULL
.	NULL

Mosmann	NULL
,	NULL
and	NULL
W.E	NULL
.	NULL

Paul	NULL
.	NULL

1990	NULL
.	NULL

Lymphokine	NULL
control	NULL
of	NULL
in	NULL
vivo	NULL
immunoglobulin	NULL
isotype	NULL
selection	NULL
.	NULL

Annu	NULL
.	NULL

Rev	NULL
.	NULL

Immunol	NULL
.	NULL

$	NULL
:303-333	NULL
.	NULL

Mandler	NULL
,	NULL
R.	NULL
,	NULL
F.D	NULL
.	NULL

Finkelman	NULL
,	NULL
A.D.	NULL
Levine	NULL
,	NULL
and	NULL
C.M	NULL
.	NULL

Snap-per	NULL
.	NULL

1993	NULL
.	NULL

IL-4	NULL
induction	NULL
of	NULL
IgE	NULL
class	NULL
switching	NULL
by	NULL
li-popolysaccharide-activated	NULL
murine	NULL
B	NULL
cells	NULL
occurs	NULL
predominantly	NULL
through	NULL
sequential	NULL
switching	NULL
.	NULL

J	NULL
Immunol	NULL
.	NULL

150:407-418	NULL
.	NULL

Snapper	NULL
,	NULL
C.M	NULL
.	NULL

,	NULL
K.B	NULL
.	NULL

Marcu	NULL
,	NULL
and	NULL
P.	NULL
Zelazowski	NULL
.	NULL

1997	NULL
.	NULL

The	NULL
immunoglobulin	NULL
class	NULL
switch	NULL
:	NULL
beyond	NULL
``	NULL
accessibility	NULL
.	NULL
``	NULL

Immunity	NULL
.	NULL

6:217-223	NULL
.	NULL

Drazen	NULL
,	NULL
J.M	NULL
.	NULL

,	NULL
J.P	NULL
.	NULL

Arm	NULL
,	NULL
and	NULL
K.F	NULL
.	NULL

Austen	NULL
.	NULL

1996	NULL
.	NULL

Sorting	NULL
out	NULL
the	NULL
cytokines	NULL
of	NULL
asthma	NULL
.	NULL

J	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

183:1-5	NULL
.	NULL

Zhang	NULL
,	NULL
Y.	NULL
,	NULL
W.J.E	NULL
.	NULL

Lamm	NULL
,	NULL
RK	NULL
.	NULL

Albert	NULL
,	NULL
EY	NULL
.	NULL

Chi	NULL
,	NULL
WR	NULL
.	NULL

Henderson	NULL
,	NULL
and	NULL
D.B	NULL
.	NULL

Lewis	NULL
.	NULL

1997	NULL
.	NULL

Influence	NULL
of	NULL
the	NULL
route	NULL
of	NULL
allergen	NULL
administration	NULL
and	NULL
genetic	NULL
background	NULL
on	NULL
the	NULL
murine	NULL
allergic	NULL
pulmonary	NULL
response	NULL
.	NULL

Am	NULL
.	NULL

J	NULL
Respir	NULL
Cnt	NULL
Care	NULL
Med	NULL
.	NULL

155:661-669	NULL
.	NULL

Corry	NULL
,	NULL
D.B	NULL
.	NULL

,	NULL
H.G	NULL
.	NULL

Folkesson	NULL
,	NULL
M.L	NULL
.	NULL

Warnock	NULL
,	NULL
D.J	NULL
.	NULL

Erle	NULL
,	NULL
M.A	NULL
.	NULL

Matthay	NULL
,	NULL
J.P.	NULL
Wiener-Kronish	NULL
,	NULL
and	NULL
R.M	NULL
.	NULL

Locksley	NULL
.	NULL

1996	NULL
.	NULL

Interleukin	NULL
4	NULL
,	NULL
but	NULL
not	NULL
interleukin	NULL
5	NULL
or	NULL
eosinophils	NULL
,	NULL
is	NULL
required	NULL
in	NULL
a	NULL
mouse	NULL
model	NULL
of	NULL
acute	NULL
airway	NULL
hyperreactivity	NULL
.	NULL

J	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

183:109-117	NULL
.	NULL

Hsieh	NULL
,	NULL
C.S	NULL
.	NULL

,	NULL
S.E	NULL
.	NULL

Macatonia	NULL
,	NULL
A.	NULL
O	NULL
'Garra	NULL
,	NULL
and	NULL
K.M	NULL
.	NULL

Murphy	NULL
.	NULL

1995	NULL
.	NULL

T	NULL
cell	NULL
genetic	NULL
background	NULL
determines	NULL
default	NULL
T	NULL
helper	NULL
phenotype	NULL
development	NULL
in	NULL
vitro	NULL
.	NULL

J	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

181:713-721	NULL
.	NULL

Nakamura	NULL
,	NULL
T.	NULL
,	NULL
Y.	NULL
Kamogawa	NULL
,	NULL
K.	NULL
Bottomly	NULL
,	NULL
and	NULL
R.A.	NULL
Flavell	NULL
.	NULL

1997	NULL
.	NULL

Polarization	NULL
of	NULL
IL-4-	NULL
and	NULL
IFN-y-producing	NULL
CD4*	NULL
T	NULL
cells	NULL
following	NULL
activation	NULL
of	NULL
naive	NULL
CD4*	NULL
T	NULL
cells	NULL
.	NULL

J	NULL
Immunol	NULL
.	NULL

158:1085-1094	NULL
.	NULL

Murphy	NULL
,	NULL
KM	NULL
.	NULL

,	NULL
TL	NULL
.	NULL

Murphy	NULL
,	NULL
SJ	NULL
.	NULL

Szabo	NULL
,	NULL
N.G	NULL
.	NULL

Jacobson	NULL
,	NULL
ML	NULL
.	NULL

Guler	NULL
,	NULL
J.D	NULL
.	NULL

Gorham	NULL
,	NULL
and	NULL
U.	NULL
Gubler	NULL
.	NULL

1997	NULL
.	NULL

Regulation	NULL
of	NULL
IL-	NULL
12	NULL
receptor	NULL
expression	NULL
in	NULL
early	NULL
T-helper	NULL
responses	NULL
implies	NULL
two	NULL
phases	NULL
of	NULL
Th1	NULL
differentiation	NULL
:	NULL
capacitance	NULL
and	NULL
development	NULL
.	NULL

Chem	NULL
.	NULL

Immunol	NULL
.	NULL

68:54-69	NULL
.	NULL

Takeda	NULL
,	NULL
K.	NULL
,	NULL
T.	NULL
Tanaka	NULL
,	NULL
W.	NULL
Shi	NULL
,	NULL
M.	NULL
Matsumoto	NULL
,	NULL
M.	NULL
Minami	NULL
,	NULL
S.-i	NULL
.	NULL

Kashiwamura	NULL
,	NULL
K.	NULL
Nakanishi	NULL
,	NULL
N.	NULL
Yoshida	NULL
,	NULL
T.	NULL
Kishimoto	NULL
,	NULL
and	NULL
S.	NULL
Kira	NULL
.	NULL

1996	NULL
.	NULL

Essential	NULL
role	NULL
of	NULL
Stat6	NULL
in	NULL
IL-4	NULL
signaling	NULL
.	NULL

Nature	NULL
.	NULL

380:627-630	NULL
.	NULL

67	NULL
.	NULL

68	NULL
.	NULL

69	NULL
.	NULL

70	NULL
.	NULL

71	NULL
.	NULL

72	NULL
.	NULL

73	NULL
.	NULL

74	NULL
.	NULL

Shimoda	NULL
,	NULL
K.	NULL
,	NULL
J.	NULL
van	NULL
Deursen	NULL
,	NULL
M.Y	NULL
.	NULL

Sangster	NULL
,	NULL
S.R	NULL
.	NULL

Sarawar	NULL
,	NULL
R.T.	NULL
Carson	NULL
,	NULL
R.A.	NULL
Tripp	NULL
,	NULL
C.	NULL
Chu	NULL
,	NULL
FW	NULL
.	NULL

Quelle	NULL
,	NULL
T.	NULL
Nosaka	NULL
,	NULL
D.A.A	NULL
.	NULL

Vignali	NULL
,	NULL
et	NULL
.	NULL

al	NULL
.	NULL

1996	NULL
.	NULL

Lack	NULL
of	NULL
IL-4-induced	NULL
Th2	NULL
response	NULL
and	NULL
IgE	NULL
class	NULL
switching	NULL
in	NULL
mice	NULL
with	NULL
a	NULL
disrupted	NULL
Stat6	NULL
gene	NULL
.	NULL

Nature	NULL
.	NULL

380:630-633	NULL
.	NULL

Boehm	NULL
,	NULL
U.	NULL
,	NULL
T.	NULL
Klamp	NULL
,	NULL
M.	NULL
Groot	NULL
,	NULL
and	NULL
J.C.	NULL
Howard	NULL
.	NULL

1997	NULL
.	NULL

Cellular	NULL
responses	NULL
to	NULL
interferon-y	NULL
.	NULL

Annu	NULL
.	NULL

Rev	NULL
.	NULL

Immunol	NULL
.	NULL

15	NULL
:	NULL
749-1795	NULL
.	NULL

Ohmori	NULL
,	NULL
Y.	NULL
,	NULL
and	NULL
TA	NULL
.	NULL

Hamilton	NULL
.	NULL

1997	NULL
.	NULL

IL-4-induced	NULL
Stat6	NULL
suppresses	NULL
IFN	NULL
-y-stimulated	NULL
Stat	NULL
1-dependent	NULL
transcription	NULL
in	NULL
mouse	NULL
macrophages	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

159:5474-5482	NULL
.	NULL

Szabo	NULL
,	NULL
S.J	NULL
.	NULL

,	NULL
A.S.	NULL
Dighe	NULL
,	NULL
U.	NULL
Gubler	NULL
,	NULL
and	NULL
K.M	NULL
.	NULL

Murphy	NULL
.	NULL

1997	NULL
.	NULL

Regulation	NULL
of	NULL
the	NULL
interleukin	NULL
(	NULL
IL	NULL
)	NULL
-12R	NULL
B2	NULL
subunit	NULL
expression	NULL
in	NULL
developing	NULL
T	NULL
helper	NULL
1	NULL
(	NULL
Th1	NULL
)	NULL
and	NULL
Th2	NULL
cells	NULL
J	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

185:817-824	NULL
.	NULL

Postma	NULL
,	NULL
D.S	NULL
.	NULL

,	NULL
ER	NULL
.	NULL

Bleecker	NULL
,	NULL
P.J	NULL
.	NULL

Amelung	NULL
,	NULL
K.J	NULL
.	NULL

Holroyd	NULL
,	NULL
J.	NULL
Xu	NULL
,	NULL
C.LM	NULL
.	NULL

Panhuysen	NULL
,	NULL
D.A	NULL
.	NULL

Meyers	NULL
,	NULL
and	NULL
R.C	NULL
.	NULL

Levitt	NULL
.	NULL

1995	NULL
.	NULL

Genetic	NULL
susceptibility	NULL
to	NULL
asthma-bronchial	NULL
hyperresponsiveness	NULL
coinherited	NULL
with	NULL
a	NULL
major	NULL
gene	NULL
for	NULL
atopy	NULL
.	NULL

N.	NULL
Engl	NULL
J	NULL
Med	NULL
.	NULL

333:894-900	NULL
.	NULL

Scott	NULL
,	NULL
B.	NULL
,	NULL
R.	NULL
Liblau	NULL
,	NULL
S.	NULL
Degermann	NULL
,	NULL
L.A.	NULL
Marconi	NULL
,	NULL
L.	NULL
O	NULL
gata	NULL
,	NULL
AJ	NULL
.	NULL

Caton	NULL
,	NULL
H.O0	NULL
.	NULL

McDevitt	NULL
,	NULL
and	NULL
D.	NULL
Lo	NULL
.	NULL

1994	NULL
.	NULL

A	NULL
role	NULL
for	NULL
non-MHC	NULL
genetic	NULL
polymorphism	NULL
in	NULL
susceptibility	NULL
to	NULL
spontaneous	NULL
autoimmunity	NULL
.	NULL

Immunity	NULL
.	NULL

1:73-82	NULL
.	NULL

Reiner	NULL
,	NULL
SL	NULL
.	NULL

,	NULL
and	NULL
R.M	NULL
.	NULL

Locksley	NULL
.	NULL

1995	NULL
.	NULL

The	NULL
regulation	NULL
of	NULL
immunity	NULL
to	NULL
Leshmania	NULL
major	NULL
.	NULL

Annu	NULL
.	NULL

Rev	NULL
.	NULL

Immunol	NULL
.	NULL

13:151-177	NULL
.	NULL

DeSanctis	NULL
,	NULL
G.T	NULL
.	NULL

,	NULL
M.	NULL
Merchant	NULL
,	NULL
D.R	NULL
.	NULL

Beier	NULL
,	NULL
R.D	NULL
.	NULL

Dredge	NULL
,	NULL
1816	NULL
75	NULL
.	NULL

76	NULL
.	NULL

77	NULL
.	NULL

78	NULL
.	NULL

79	NULL
.	NULL

80	NULL
.	NULL

J.K.	NULL
Grobholz	NULL
,	NULL
TR	NULL
.	NULL

Martin	NULL
,	NULL
E.S	NULL
.	NULL

Lander	NULL
,	NULL
and	NULL
J.M	NULL
.	NULL

Drazen	NULL
.	NULL

1995	NULL
.	NULL

Quantitative	NULL
locus	NULL
analysis	NULL
of	NULL
airway	NULL
hyper-responsive-ness	NULL
in	NULL
A/	NULL
J	NULL
and	NULL
C57BL/	NULL
6	NULL
mice	NULL
.	NULL

Nat	NULL
.	NULL

Genet	NULL
.	NULL

11:150-154	NULL
.	NULL

DeSanctis	NULL
,	NULL
G.T	NULL
.	NULL

,	NULL
A.	NULL
Itoh	NULL
,	NULL
FH	NULL
.	NULL

Green	NULL
,	NULL
S.	NULL
Qin	NULL
,	NULL
T.	NULL
Kimura	NULL
,	NULL
JK	NULL
.	NULL

Grobholz	NULL
,	NULL
TR	NULL
.	NULL

Martin	NULL
,	NULL
T.	NULL
Maki	NULL
,	NULL
and	NULL
J.M	NULL
.	NULL

Drazen	NULL
.	NULL

1997	NULL
.	NULL

T-lymphocytes	NULL
regulate	NULL
genetically	NULL
determined	NULL
airway	NULL
hyperresponsiveness	NULL
in	NULL
mice	NULL
.	NULL

Nat	NULL
.	NULL

Med	NULL
.	NULL

3:460-462	NULL
.	NULL

Beebe	NULL
,	NULL
A.M.	NULL
,	NULL
S.	NULL
Mauze	NULL
,	NULL
N.J.	NULL
Schork	NULL
,	NULL
and	NULL
R.L	NULL
.	NULL

Coffman	NULL
.	NULL

1997	NULL
.	NULL

Serial	NULL
backcross	NULL
mapping	NULL
of	NULL
multiple	NULL
loci	NULL
associated	NULL
with	NULL
resistance	NULL
to	NULL
Leishmania	NULL
major	NULL
in	NULL
mice	NULL
.	NULL

Immunity	NULL
.	NULL

6:551-557	NULL
.	NULL

Holtzman	NULL
,	NULL
M.J.	NULL
,	NULL
D.	NULL
Sampath	NULL
,	NULL
M.	NULL
Castro	NULL
,	NULL
D.C.	NULL
Look	NULL
,	NULL
and	NULL
S.	NULL
Jayaraman	NULL
.	NULL

1996	NULL
.	NULL

The	NULL
one-two	NULL
of	NULL
T	NULL
helper	NULL
cells	NULL
:	NULL
does	NULL
interferon-y	NULL
knock	NULL
out	NULL
the	NULL
Th2	NULL
hypothesis	NULL
for	NULL
asthma	NULL
?	NULL

Am	NULL
.	NULL

J	NULL
Respir	NULL
.	NULL

Cell	NULL
Mol	NULL
.	NULL

Biol	NULL
.	NULL

14:316-318	NULL
.	NULL

Cohn	NULL
,	NULL
L.	NULL
,	NULL
R.J.	NULL
Homer	NULL
,	NULL
A.	NULL
Marinov	NULL
,	NULL
J.	NULL
Rankin	NULL
,	NULL
and	NULL
K.	NULL
Bottomly	NULL
.	NULL

1997	NULL
.	NULL

Induction	NULL
of	NULL
airway	NULL
mucus	NULL
production	NULL
by	NULL
T	NULL
helper	NULL
2	NULL
(	NULL
Th2	NULL
)	NULL
cells	NULL
:	NULL
a	NULL
critical	NULL
role	NULL
for	NULL
interleukin	NULL
4	NULL
in	NULL
cell	NULL
recruitment	NULL
but	NULL
not	NULL
mucus	NULL
production	NULL
.	NULL

J	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

186:1737-1747	NULL
.	NULL

McHeyzer-	NULL
Williams	NULL
,	NULL
M.G	NULL
.	NULL

,	NULL
and	NULL
M.M	NULL
.	NULL

Davis	NULL
.	NULL

1995	NULL
.	NULL

Antigen-specific	NULL
development	NULL
of	NULL
primary	NULL
and	NULL
memory	NULL
T	NULL
cells	NULL
in	NULL
viva	NULL
.	NULL

Sdence	NULL
.	NULL

268:106-111	NULL
.	NULL

Kurts	NULL
,	NULL
C.	NULL
,	NULL
FR	NULL
.	NULL

Carbone	NULL
,	NULL
M.	NULL
Barnden	NULL
,	NULL
E.	NULL
Blanas	NULL
,	NULL
J.	NULL
Allison	NULL
,	NULL
WR	NULL
.	NULL

Heath	NULL
,	NULL
and	NULL
J.F.A.P	NULL
.	NULL

Miller	NULL
.	NULL

1997	NULL
.	NULL

CD4*	NULL
T	NULL
cell	NULL
help	NULL
impairs	NULL
CD8+*	NULL
T	NULL
cell	NULL
deletion	NULL
induced	NULL
by	NULL
cross-presentation	NULL
of	NULL
self-	NULL
antigens	NULL
and	NULL
favors	NULL
autoimmunity	NULL
.	NULL

J	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

186	NULL
:	NULL
2057-2062	NULL
.	NULL

In	NULL
Vivo	NULL
Function	NULL
of	NULL
an	NULL
IL-2R/IL-4R	NULL
Chimera	NULL

